Difference between revisions of "Follicular lymphoma"
m (Text replacement - "style="background-color:#1a9851" |Phase III" to "style="background-color:#1a9851" |Phase 3") |
|||
Line 90: | Line 90: | ||
|[https://www.thegreenjournal.com/article/S0167-8140(11)00205-2/fulltext Lowry et al. 2011] | |[https://www.thegreenjournal.com/article/S0167-8140(11)00205-2/fulltext Lowry et al. 2011] | ||
|1997-2005 | |1997-2005 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-de-esc) |
|[[#Radiation_therapy|RT]] x 40 to 45 Gy | |[[#Radiation_therapy|RT]] x 40 to 45 Gy | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of ORR | | style="background-color:#ffffbf" |Did not meet primary endpoint of ORR | ||
Line 102: | Line 102: | ||
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70036-1/fulltext Hoskin et al. 2014 (FORT)] | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70036-1/fulltext Hoskin et al. 2014 (FORT)] | ||
|2006-2011 | |2006-2011 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Radiation_therapy|RT]] x 4 Gy | |[[#Radiation_therapy|RT]] x 4 Gy | ||
| style="background-color:#1a9850" |Superior TTP | | style="background-color:#1a9850" |Superior TTP | ||
Line 221: | Line 221: | ||
|[https://www.nejm.org/doi/10.1056/NEJMoa1614598 Marcus et al. 2017 (GALLIUM)] | |[https://www.nejm.org/doi/10.1056/NEJMoa1614598 Marcus et al. 2017 (GALLIUM)] | ||
|2011-2014 | |2011-2014 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-RT-switch-ic) |
|[[Complex_multipart_regimens#GALLIUM|See link]] | |[[Complex_multipart_regimens#GALLIUM|See link]] | ||
| style="background-color:#1a9850" |[[Complex_multipart_regimens#GALLIUM|See link]] | | style="background-color:#1a9850" |[[Complex_multipart_regimens#GALLIUM|See link]] | ||
Line 263: | Line 263: | ||
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2961763-2/fulltext Rummel et al. 2013 (StiL NHL1)] | |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2961763-2/fulltext Rummel et al. 2013 (StiL NHL1)] | ||
|2003-2008 | |2003-2008 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-de-esc) |
|[[#R-CHOP|R-CHOP]] | |[[#R-CHOP|R-CHOP]] | ||
| style="background-color:#1a9850" |Superior PFS | | style="background-color:#1a9850" |Superior PFS | ||
Line 270: | Line 270: | ||
|[https://www.nejm.org/doi/10.1056/NEJMoa1614598 Marcus et al. 2017 (GALLIUM)] | |[https://www.nejm.org/doi/10.1056/NEJMoa1614598 Marcus et al. 2017 (GALLIUM)] | ||
|2011-2014 | |2011-2014 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[Complex_multipart_regimens#GALLIUM|See link]] | |[[Complex_multipart_regimens#GALLIUM|See link]] | ||
| style="background-color:#d73027" |[[Complex_multipart_regimens#GALLIUM|See link]] | | style="background-color:#d73027" |[[Complex_multipart_regimens#GALLIUM|See link]] | ||
Line 277: | Line 277: | ||
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1805104 Morschhauser et al. 2018 (RELEVANCE)] | |[https://www.nejm.org/doi/full/10.1056/NEJMoa1805104 Morschhauser et al. 2018 (RELEVANCE)] | ||
|2011-2014 | |2011-2014 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Lenalidomide_.26_Rituximab_.28R2.29|Lenalidomide & Rituximab]] | |[[#Lenalidomide_.26_Rituximab_.28R2.29|Lenalidomide & Rituximab]] | ||
| style="background-color:#ffffbf" |Did not meet primary endpoints of CR rate/PFS | | style="background-color:#ffffbf" |Did not meet primary endpoints of CR rate/PFS | ||
Line 330: | Line 330: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/ Flinn et al. 2014 (BRIGHT)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/ Flinn et al. 2014 (BRIGHT)] | ||
|2009-2012 | |2009-2012 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-de-esc) |
|1. [[#R-CHOP|R-CHOP]]<br> 2. [[#R-CVP|R-CVP]] | |1. [[#R-CHOP|R-CHOP]]<br> 2. [[#R-CVP|R-CVP]] | ||
| style="background-color:#1a9850" |Superior PFS<sup>1</sup><br>Median PFS: NR vs NR<br>(HR 0.61, 95% CI 0.45-0.85) | | style="background-color:#1a9850" |Superior PFS<sup>1</sup><br>Median PFS: NR vs NR<br>(HR 0.61, 95% CI 0.45-0.85) | ||
Line 381: | Line 381: | ||
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14110-4/abstract Ardeshna et al. 2003] | |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14110-4/abstract Ardeshna et al. 2003] | ||
|1981-1990 | |1981-1990 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Observation_2|Observation]] | |[[#Observation_2|Observation]] | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
Line 413: | Line 413: | ||
|[https://doi.org/10.1200/jco.2003.05.128 Peterson et al. 2003 (CALGB 7951)] | |[https://doi.org/10.1200/jco.2003.05.128 Peterson et al. 2003 (CALGB 7951)] | ||
|1980-1985 | |1980-1985 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-de-esc) |
|[[Follicular_lymphoma_-_historical#CHOP-B|CHOP-B]] | |[[Follicular_lymphoma_-_historical#CHOP-B|CHOP-B]] | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
Line 419: | Line 419: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765852/ Smith et al. 2009 (CALGB 8691)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765852/ Smith et al. 2009 (CALGB 8691)] | ||
|1986-1991 | |1986-1991 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|Cyclophosphamide & Interferon alfa-2a | |Cyclophosphamide & Interferon alfa-2a | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of EFS | | style="background-color:#ffffbf" |Did not meet primary endpoint of EFS | ||
Line 454: | Line 454: | ||
|[https://www.nejm.org/doi/10.1056/NEJMoa1614598 Marcus et al. 2017 (GALLIUM)] | |[https://www.nejm.org/doi/10.1056/NEJMoa1614598 Marcus et al. 2017 (GALLIUM)] | ||
|2011-2014 | |2011-2014 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-RT-switch-ic) |
|[[Complex_multipart_regimens#GALLIUM|See link]] | |[[Complex_multipart_regimens#GALLIUM|See link]] | ||
| style="background-color:#1a9850" |[[Complex_multipart_regimens#GALLIUM|See link]] | | style="background-color:#1a9850" |[[Complex_multipart_regimens#GALLIUM|See link]] | ||
Line 497: | Line 497: | ||
|[https://www.nejm.org/doi/10.1056/NEJMoa1614598 Marcus et al. 2017 (GALLIUM)] | |[https://www.nejm.org/doi/10.1056/NEJMoa1614598 Marcus et al. 2017 (GALLIUM)] | ||
|2011-2014 | |2011-2014 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-RT-switch-ic) |
|[[Complex_multipart_regimens#GALLIUM|See link]] | |[[Complex_multipart_regimens#GALLIUM|See link]] | ||
| style="background-color:#1a9850" |[[Complex_multipart_regimens#GALLIUM|See link]] | | style="background-color:#1a9850" |[[Complex_multipart_regimens#GALLIUM|See link]] | ||
Line 597: | Line 597: | ||
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1805104 Morschhauser et al. 2018 (RELEVANCE)] | |[https://www.nejm.org/doi/full/10.1056/NEJMoa1805104 Morschhauser et al. 2018 (RELEVANCE)] | ||
|2011-2014 | |2011-2014 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-switch-ooc) |
|1. [[#Bendamustine_.26_Rituximab_.28BR.29|R-B]]<br> 2. [[#R-CHOP|R-CHOP]]<br> 3. [[#R-CVP|R-CVP]] | |1. [[#Bendamustine_.26_Rituximab_.28BR.29|R-B]]<br> 2. [[#R-CHOP|R-CHOP]]<br> 3. [[#R-CVP|R-CVP]] | ||
| style="background-color:#ffffbf" |Did not meet primary endpoints of CR rate/PFS | | style="background-color:#ffffbf" |Did not meet primary endpoints of CR rate/PFS | ||
Line 649: | Line 649: | ||
|[https://pubmed.ncbi.nlm.nih.gov/2456618 Young et al. 1988] | |[https://pubmed.ncbi.nlm.nih.gov/2456618 Young et al. 1988] | ||
|NR in abstract | |NR in abstract | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-de-esc) |
|[[Follicular_lymphoma_-_historical#ProMACE-MOPP|ProMACE-MOPP, then TNI]] | |[[Follicular_lymphoma_-_historical#ProMACE-MOPP|ProMACE-MOPP, then TNI]] | ||
| | | | ||
Line 655: | Line 655: | ||
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14110-4/abstract Ardeshna et al. 2003] | |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14110-4/abstract Ardeshna et al. 2003] | ||
|1981-1990 | |1981-1990 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-de-esc) |
|[[#Chlorambucil_monotherapy|Chlorambucil]] | |[[#Chlorambucil_monotherapy|Chlorambucil]] | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
Line 661: | Line 661: | ||
|[https://doi.org/10.1200/jco.1997.15.3.1110 Brice et al. 1997] | |[https://doi.org/10.1200/jco.1997.15.3.1110 Brice et al. 1997] | ||
|1986-1995 | |1986-1995 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-de-esc) |
|1. Interferon alfa<br> 2. Prednimustine | |1. Interferon alfa<br> 2. Prednimustine | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
Line 667: | Line 667: | ||
| rowspan="2" |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70027-0/abstract Ardeshna et al. 2014 (CRUK-2004-001621-16)] | | rowspan="2" |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70027-0/abstract Ardeshna et al. 2014 (CRUK-2004-001621-16)] | ||
|rowspan=2|2004-2009 | |rowspan=2|2004-2009 | ||
− | | rowspan="2" style="background-color:#1a9851" |Phase | + | | rowspan="2" style="background-color:#1a9851" |Phase 3 (C) |
|1. [[#Rituximab_monotherapy_2|Rituximab induction]] | |1. [[#Rituximab_monotherapy_2|Rituximab induction]] | ||
| style="background-color:#d73027" |Inferior TTNT | | style="background-color:#d73027" |Inferior TTNT | ||
Line 771: | Line 771: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/ Flinn et al. 2014 (BRIGHT)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/ Flinn et al. 2014 (BRIGHT)] | ||
|2009-2012 | |2009-2012 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Bendamustine_.26_Rituximab_.28BR.29|BR]] | |[[#Bendamustine_.26_Rituximab_.28BR.29|BR]] | ||
| style="background-color:#eeee01" |Seems to have non-inferior CR rate | | style="background-color:#eeee01" |Seems to have non-inferior CR rate | ||
Line 778: | Line 778: | ||
|[https://www.nejm.org/doi/10.1056/NEJMoa1614598 Marcus et al. 2017 (GALLIUM)] | |[https://www.nejm.org/doi/10.1056/NEJMoa1614598 Marcus et al. 2017 (GALLIUM)] | ||
|2011-2014 | |2011-2014 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[Complex_multipart_regimens#GALLIUM|See link]] | |[[Complex_multipart_regimens#GALLIUM|See link]] | ||
| style="background-color:#d73027" |[[Complex_multipart_regimens#GALLIUM|See link]] | | style="background-color:#d73027" |[[Complex_multipart_regimens#GALLIUM|See link]] | ||
Line 785: | Line 785: | ||
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1805104 Morschhauser et al. 2018 (RELEVANCE)] | |[https://www.nejm.org/doi/full/10.1056/NEJMoa1805104 Morschhauser et al. 2018 (RELEVANCE)] | ||
|2011-2014 | |2011-2014 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Lenalidomide_.26_Rituximab_.28R2.29|Lenalidomide & Rituximab]] | |[[#Lenalidomide_.26_Rituximab_.28R2.29|Lenalidomide & Rituximab]] | ||
| style="background-color:#ffffbf" |Did not meet primary endpoints of CR rate/PFS | | style="background-color:#ffffbf" |Did not meet primary endpoints of CR rate/PFS | ||
Line 823: | Line 823: | ||
|[http://www.bloodjournal.org/content/106/12/3725.long Hiddemann et al. 2005 (GLSG '00)] | |[http://www.bloodjournal.org/content/106/12/3725.long Hiddemann et al. 2005 (GLSG '00)] | ||
|2000-2003 | |2000-2003 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|[[Follicular_lymphoma_-_historical#CHOP|CHOP]] | |[[Follicular_lymphoma_-_historical#CHOP|CHOP]] | ||
| style="background-color:#91cf60" |Seems to have superior OS | | style="background-color:#91cf60" |Seems to have superior OS | ||
Line 830: | Line 830: | ||
| rowspan="2" |[https://doi.org/10.1200/jco.2012.45.0866 Federico et al. 2013 (FOLL05)] | | rowspan="2" |[https://doi.org/10.1200/jco.2012.45.0866 Federico et al. 2013 (FOLL05)] | ||
|rowspan=2|2006-2010 | |rowspan=2|2006-2010 | ||
− | | rowspan="2" style="background-color:#1a9851" |Phase | + | | rowspan="2" style="background-color:#1a9851" |Phase 3 (E-esc) |
|1. [[#R-CVP|R-CVP]] | |1. [[#R-CVP|R-CVP]] | ||
| style="background-color:#91cf60" |Seems to have superior PFS | | style="background-color:#91cf60" |Seems to have superior PFS | ||
Line 867: | Line 867: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732010/ Press et al. 2012 (SWOG S0016)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732010/ Press et al. 2012 (SWOG S0016)] | ||
|2001-2008 | |2001-2008 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
| CHOP.2C_then_131Iodine-Tositumomab_.28Bexxar.29 |CHOP, then <sup>131</sup>Iodine-Tositumomab | | CHOP.2C_then_131Iodine-Tositumomab_.28Bexxar.29 |CHOP, then <sup>131</sup>Iodine-Tositumomab | ||
| style="background-color:#d73027" |Inferior PFS<sup>1</sup> | | style="background-color:#d73027" |Inferior PFS<sup>1</sup> | ||
Line 897: | Line 897: | ||
|[https://doi.org/10.1200/jco.2011.34.8508 Watanabe et al. 2011 (JCOG 0203)] | |[https://doi.org/10.1200/jco.2011.34.8508 Watanabe et al. 2011 (JCOG 0203)] | ||
|2002-2007 | |2002-2007 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|R-CHOP-14 | |R-CHOP-14 | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | ||
Line 967: | Line 967: | ||
|[http://www.bloodjournal.org/content/112/13/4824.full Salles et al. 2008 (FL2000)] | |[http://www.bloodjournal.org/content/112/13/4824.full Salles et al. 2008 (FL2000)] | ||
|2000-2002 | |2000-2002 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|CHVP+I | |CHVP+I | ||
| style="background-color:#1a9850" |Superior EFS | | style="background-color:#1a9850" |Superior EFS | ||
Line 1,009: | Line 1,009: | ||
|[http://www.bloodjournal.org/content/105/4/1417.full Marcus et al. 2004] | |[http://www.bloodjournal.org/content/105/4/1417.full Marcus et al. 2004] | ||
|2000-2002 | |2000-2002 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-RT-esc) |
|[[Follicular_lymphoma_-_historical#CVP|CVP]] | |[[Follicular_lymphoma_-_historical#CVP|CVP]] | ||
| style="background-color:#1a9850" |Superior TTP | | style="background-color:#1a9850" |Superior TTP | ||
Line 1,023: | Line 1,023: | ||
| rowspan="2" |[https://doi.org/10.1200/jco.2012.45.0866 Federico et al. 2013 (FOLL05)] | | rowspan="2" |[https://doi.org/10.1200/jco.2012.45.0866 Federico et al. 2013 (FOLL05)] | ||
|rowspan=2|2006-2010 | |rowspan=2|2006-2010 | ||
− | | rowspan="2" style="background-color:#1a9851" |Phase | + | | rowspan="2" style="background-color:#1a9851" |Phase 3 (E-de-esc) |
|1. [[#R-CHOP|R-CHOP]] | |1. [[#R-CHOP|R-CHOP]] | ||
| style="background-color:#fc8d59" |Seems to have inferior PFS | | style="background-color:#fc8d59" |Seems to have inferior PFS | ||
Line 1,034: | Line 1,034: | ||
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1805104 Morschhauser et al. 2018 (RELEVANCE)] | |[https://www.nejm.org/doi/full/10.1056/NEJMoa1805104 Morschhauser et al. 2018 (RELEVANCE)] | ||
|2011-2014 | |2011-2014 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Lenalidomide_.26_Rituximab_.28R2.29|Lenalidomide & Rituximab]] | |[[#Lenalidomide_.26_Rituximab_.28R2.29|Lenalidomide & Rituximab]] | ||
| style="background-color:#ffffbf" |Did not meet primary endpoints of CR rate/PFS | | style="background-color:#ffffbf" |Did not meet primary endpoints of CR rate/PFS | ||
Line 1,066: | Line 1,066: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/ Flinn et al. 2014 (BRIGHT)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/ Flinn et al. 2014 (BRIGHT)] | ||
|2009-2012 | |2009-2012 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Bendamustine_.26_Rituximab_.28BR.29|BR]] | |[[#Bendamustine_.26_Rituximab_.28BR.29|BR]] | ||
| style="background-color:#eeee01" |Seems to have non-inferior CR rate | | style="background-color:#eeee01" |Seems to have non-inferior CR rate | ||
Line 1,073: | Line 1,073: | ||
|[https://www.nejm.org/doi/10.1056/NEJMoa1614598 Marcus et al. 2017 (GALLIUM)] | |[https://www.nejm.org/doi/10.1056/NEJMoa1614598 Marcus et al. 2017 (GALLIUM)] | ||
|2011-2014 | |2011-2014 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[Complex_multipart_regimens#GALLIUM|See link]] | |[[Complex_multipart_regimens#GALLIUM|See link]] | ||
| style="background-color:#d73027" |[[Complex_multipart_regimens#GALLIUM|See link]] | | style="background-color:#d73027" |[[Complex_multipart_regimens#GALLIUM|See link]] | ||
Line 1,190: | Line 1,190: | ||
| rowspan="2" |[https://doi.org/10.1200/jco.2012.45.0866 Federico et al. 2013 (FOLL05)] | | rowspan="2" |[https://doi.org/10.1200/jco.2012.45.0866 Federico et al. 2013 (FOLL05)] | ||
|rowspan=2|2006-2010 | |rowspan=2|2006-2010 | ||
− | | rowspan="2" style="background-color:#1a9851" |Phase | + | | rowspan="2" style="background-color:#1a9851" |Phase 3 (E-switch-ic) |
|1. [[#R-CHOP|R-CHOP]] | |1. [[#R-CHOP|R-CHOP]] | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of TTF | | style="background-color:#ffffbf" |Did not meet primary endpoint of TTF | ||
Line 1,272: | Line 1,272: | ||
|[https://doi.org/10.1200/jco.2006.06.4618 Herold et al. 2007 (OSHO-39)] | |[https://doi.org/10.1200/jco.2006.06.4618 Herold et al. 2007 (OSHO-39)] | ||
|1998-2003 | |1998-2003 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|[[Follicular_lymphoma_-_historical#MCP_.28Prednisolone.29|MCP]] | |[[Follicular_lymphoma_-_historical#MCP_.28Prednisolone.29|MCP]] | ||
| style="background-color:#1a9850" |Superior OS | | style="background-color:#1a9850" |Superior OS | ||
Line 1,348: | Line 1,348: | ||
| rowspan="2" |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70027-0/abstract Ardeshna et al. 2014 (CRUK-2004-001621-16)] | | rowspan="2" |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70027-0/abstract Ardeshna et al. 2014 (CRUK-2004-001621-16)] | ||
|rowspan=2|2004-2009 | |rowspan=2|2004-2009 | ||
− | | rowspan="2" style="background-color:#1a9851" |Phase | + | | rowspan="2" style="background-color:#1a9851" |Phase 3 (E-esc) |
|1. [[#Observation_2|Observation]] | |1. [[#Observation_2|Observation]] | ||
| style="background-color:#1a9850" |Superior TTNT | | style="background-color:#1a9850" |Superior TTNT | ||
Line 1,357: | Line 1,357: | ||
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30157-1/fulltext Ogura et al. 2018 (CT-P10 3.4)] | |[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30157-1/fulltext Ogura et al. 2018 (CT-P10 3.4)] | ||
|2015-2018 | |2015-2018 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|CT-P10 | |CT-P10 | ||
| style="background-color:#eeee01" |Equivalent ORR | | style="background-color:#eeee01" |Equivalent ORR | ||
Line 1,389: | Line 1,389: | ||
|[http://www.tandfonline.com/doi/full/10.3109/10428194.2015.1014363 Kimby et al. 2015 (NLG ML16865)] | |[http://www.tandfonline.com/doi/full/10.3109/10428194.2015.1014363 Kimby et al. 2015 (NLG ML16865)] | ||
|2002-2008 | |2002-2008 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|Rituximab & IFN-α2a | |Rituximab & IFN-α2a | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of TTF | | style="background-color:#ffffbf" |Did not meet primary endpoint of TTF | ||
Line 1,787: | Line 1,787: | ||
|[https://doi.org/10.1200/jco.2008.17.2015 Morschhauser et al. 2008 (FIT)] | |[https://doi.org/10.1200/jco.2008.17.2015 Morschhauser et al. 2008 (FIT)] | ||
|2001-2005 | |2001-2005 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-RT-esc) |
|[[#Observation_3|Observation]] | |[[#Observation_3|Observation]] | ||
| style="background-color:#1a9850" |Superior PFS | | style="background-color:#1a9850" |Superior PFS | ||
Line 1,950: | Line 1,950: | ||
|[https://doi.org/10.1200/JCO.1998.16.1.41 Hagenbeek et al. 1998] | |[https://doi.org/10.1200/JCO.1998.16.1.41 Hagenbeek et al. 1998] | ||
|1985-1992 | |1985-1992 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|Interferon alfa | |Interferon alfa | ||
| style="background-color:#fee08b" |Might have inferior TTP | | style="background-color:#fee08b" |Might have inferior TTP | ||
Line 1,956: | Line 1,956: | ||
|[https://doi.org/10.1200/JCO.2000.18.10.2010 Fisher et al. 2000 (SWOG S8809)] | |[https://doi.org/10.1200/JCO.2000.18.10.2010 Fisher et al. 2000 (SWOG S8809)] | ||
|1988-1994 | |1988-1994 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|Interferon alfa | |Interferon alfa | ||
| style="background-color:#ffffbf" |Did not meet primary endpoints of PFS/OS | | style="background-color:#ffffbf" |Did not meet primary endpoints of PFS/OS | ||
Line 1,962: | Line 1,962: | ||
|[http://www.bloodjournal.org/content/103/12/4416.full Ghielmini et al. 2004 (SAKK 35/98)] | |[http://www.bloodjournal.org/content/103/12/4416.full Ghielmini et al. 2004 (SAKK 35/98)] | ||
|1998-2001 | |1998-2001 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Rituximab_monotherapy.2C_abbreviated_course|Rituximab]] | |[[#Rituximab_monotherapy.2C_abbreviated_course|Rituximab]] | ||
| style="background-color:#fc8d59" |Seems to have inferior EFS | | style="background-color:#fc8d59" |Seems to have inferior EFS | ||
Line 1,968: | Line 1,968: | ||
|[https://doi.org/10.1200/jco.2008.17.2015 Morschhauser et al. 2008 (FIT)] | |[https://doi.org/10.1200/jco.2008.17.2015 Morschhauser et al. 2008 (FIT)] | ||
|2001-2005 | |2001-2005 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Ibritumomab_tiuxetan_protocol_3|Ibritumomab tiuxetan]] | |[[#Ibritumomab_tiuxetan_protocol_3|Ibritumomab tiuxetan]] | ||
| style="background-color:#d73027" |Inferior PFS | | style="background-color:#d73027" |Inferior PFS | ||
Line 1,974: | Line 1,974: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668968/ Hochster et al. 2009 (ECOG E1496)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668968/ Hochster et al. 2009 (ECOG E1496)] | ||
|NR | |NR | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Rituximab_monotherapy.2C_extended_course|Rituximab]] | |[[#Rituximab_monotherapy.2C_extended_course|Rituximab]] | ||
| style="background-color:#d73027" |Inferior PFS | | style="background-color:#d73027" |Inferior PFS | ||
Line 1,980: | Line 1,980: | ||
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2962175-7/fulltext Salles et al. 2010 (PRIMA<sub>FL</sub>)] | |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2962175-7/fulltext Salles et al. 2010 (PRIMA<sub>FL</sub>)] | ||
|2004-2007 | |2004-2007 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Rituximab_monotherapy.2C_extended_course|Rituximab]] | |[[#Rituximab_monotherapy.2C_extended_course|Rituximab]] | ||
| style="background-color:#d73027" |Inferior PFS | | style="background-color:#d73027" |Inferior PFS | ||
Line 1,986: | Line 1,986: | ||
|[https://doi.org/10.1200/jco.2012.44.8290 Vitolo et al. 2013 (ML17638)] | |[https://doi.org/10.1200/jco.2012.44.8290 Vitolo et al. 2013 (ML17638)] | ||
|2004-2007 | |2004-2007 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Rituximab_monotherapy.2C_abbreviated_course|Rituximab]] | |[[#Rituximab_monotherapy.2C_abbreviated_course|Rituximab]] | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | ||
Line 2,113: | Line 2,113: | ||
|[https://doi.org/10.1200/jco.2012.44.8290 Vitolo et al. 2013 (ML17638)] | |[https://doi.org/10.1200/jco.2012.44.8290 Vitolo et al. 2013 (ML17638)] | ||
|2004-2007 | |2004-2007 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|[[#Observation_3|Observation]] | |[[#Observation_3|Observation]] | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | ||
Line 2,138: | Line 2,138: | ||
|[http://www.bloodjournal.org/content/103/12/4416.full Ghielmini et al. 2004 (SAKK 35/98)] | |[http://www.bloodjournal.org/content/103/12/4416.full Ghielmini et al. 2004 (SAKK 35/98)] | ||
|1998-2001 | |1998-2001 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|[[#Observation_3|Observation]] | |[[#Observation_3|Observation]] | ||
| style="background-color:#91cf60" |Seems to have superior EFS | | style="background-color:#91cf60" |Seems to have superior EFS | ||
Line 2,144: | Line 2,144: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872010/ Taverna et al. 2015 (SAKK 35/03)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872010/ Taverna et al. 2015 (SAKK 35/03)] | ||
|2004-2007 | |2004-2007 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Rituximab_monotherapy.2C_very_extended_course|Rituximab]] x 5 y | |[[#Rituximab_monotherapy.2C_very_extended_course|Rituximab]] x 5 y | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of EFS | | style="background-color:#ffffbf" |Did not meet primary endpoint of EFS | ||
Line 2,253: | Line 2,253: | ||
|[https://www.nejm.org/doi/10.1056/NEJMoa1614598 Marcus et al. 2017 (GALLIUM)] | |[https://www.nejm.org/doi/10.1056/NEJMoa1614598 Marcus et al. 2017 (GALLIUM)] | ||
|2011-2014 | |2011-2014 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-RT-switch-ic) |
|[[Complex_multipart_regimens#GALLIUM|See link]] | |[[Complex_multipart_regimens#GALLIUM|See link]] | ||
| style="background-color:#1a9850" |[[Complex_multipart_regimens#GALLIUM|See link]] | | style="background-color:#1a9850" |[[Complex_multipart_regimens#GALLIUM|See link]] | ||
Line 2,288: | Line 2,288: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646306/ Freedman et al. 2009] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646306/ Freedman et al. 2009] | ||
|2004-2006 | |2004-2006 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|Mitumprotimut-T & GM-CSF | |Mitumprotimut-T & GM-CSF | ||
| style="background-color:#91cf60" |Seems to have superior TTP | | style="background-color:#91cf60" |Seems to have superior TTP | ||
Line 2,318: | Line 2,318: | ||
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2962175-7/fulltext Salles et al. 2010 (PRIMA<sub>FL</sub>)] | |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2962175-7/fulltext Salles et al. 2010 (PRIMA<sub>FL</sub>)] | ||
|2004-2007 | |2004-2007 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-RT-esc) |
|[[#Observation_3|Observation]] | |[[#Observation_3|Observation]] | ||
| style="background-color:#1a9850" |Superior PFS | | style="background-color:#1a9850" |Superior PFS | ||
Line 2,324: | Line 2,324: | ||
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30078-9/fulltext Davies et al. 2017 (SABRINA)] | |[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30078-9/fulltext Davies et al. 2017 (SABRINA)] | ||
|2011-2013 | |2011-2013 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Rituximab_monotherapy.2C_extended_course|SC Rituximab]] | |[[#Rituximab_monotherapy.2C_extended_course|SC Rituximab]] | ||
| style="background-color:#ffffbf" |Similar efficacy | | style="background-color:#ffffbf" |Similar efficacy | ||
Line 2,351: | Line 2,351: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668968/ Hochster et al. 2009 (ECOG E1496)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668968/ Hochster et al. 2009 (ECOG E1496)] | ||
|NR | |NR | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-RT-esc) |
|[[#Observation_3|Observation]] | |[[#Observation_3|Observation]] | ||
| style="background-color:#1a9850" |Superior PFS | | style="background-color:#1a9850" |Superior PFS | ||
Line 2,376: | Line 2,376: | ||
| rowspan="2" |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70027-0/abstract Ardeshna et al. 2014 (CRUK-2004-001621-16)] | | rowspan="2" |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70027-0/abstract Ardeshna et al. 2014 (CRUK-2004-001621-16)] | ||
|rowspan=2|2004-2009 | |rowspan=2|2004-2009 | ||
− | | rowspan="2" style="background-color:#1a9851" |Phase | + | | rowspan="2" style="background-color:#1a9851" |Phase 3 (E-esc) |
|1. [[#Observation_2|Observation]] | |1. [[#Observation_2|Observation]] | ||
| style="background-color:#1a9850" |Superior TTNT | | style="background-color:#1a9850" |Superior TTNT | ||
Line 2,407: | Line 2,407: | ||
|[http://www.bloodjournal.org/content/124/21/3052 Rummel et al. 2014 (MAINTAIN)] | |[http://www.bloodjournal.org/content/124/21/3052 Rummel et al. 2014 (MAINTAIN)] | ||
|2009-2012 | |2009-2012 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Rituximab_monotherapy.2C_very_extended_course|Rituximab x 4y]] | |[[#Rituximab_monotherapy.2C_very_extended_course|Rituximab x 4y]] | ||
|TBD | |TBD | ||
Line 2,421: | Line 2,421: | ||
|[https://www.nejm.org/doi/10.1056/NEJMoa1614598 Marcus et al. 2017 (GALLIUM)] | |[https://www.nejm.org/doi/10.1056/NEJMoa1614598 Marcus et al. 2017 (GALLIUM)] | ||
|2011-2014 | |2011-2014 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[Complex_multipart_regimens#GALLIUM|See link]] | |[[Complex_multipart_regimens#GALLIUM|See link]] | ||
| style="background-color:#d73027" |[[Complex_multipart_regimens#GALLIUM|See link]] | | style="background-color:#d73027" |[[Complex_multipart_regimens#GALLIUM|See link]] | ||
Line 2,471: | Line 2,471: | ||
|[http://www.bloodjournal.org/content/124/21/3052 Rummel et al. 2014 (MAINTAIN)] | |[http://www.bloodjournal.org/content/124/21/3052 Rummel et al. 2014 (MAINTAIN)] | ||
|2009-2012 | |2009-2012 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|[[#Rituximab_monotherapy.2C_extended_course|Rituximab x 2 y]] | |[[#Rituximab_monotherapy.2C_extended_course|Rituximab x 2 y]] | ||
|TBD | |TBD | ||
Line 2,496: | Line 2,496: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872010/ Taverna et al. 2015 (SAKK 35/03)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872010/ Taverna et al. 2015 (SAKK 35/03)] | ||
|2004-2007 | |2004-2007 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|[[#Rituximab_monotherapy.2C_abbreviated_course|Rituximab]] x 9 mo | |[[#Rituximab_monotherapy.2C_abbreviated_course|Rituximab]] x 9 mo | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of EFS | | style="background-color:#ffffbf" |Did not meet primary endpoint of EFS | ||
Line 2,523: | Line 2,523: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171355/ Kahl et al. 2014 (RESORT)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171355/ Kahl et al. 2014 (RESORT)] | ||
|2003-2008 | |2003-2008 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|[[#Rituximab_monotherapy_3|Rituximab]]; salvage | |[[#Rituximab_monotherapy_3|Rituximab]]; salvage | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of TTF | | style="background-color:#ffffbf" |Did not meet primary endpoint of TTF | ||
Line 2,562: | Line 2,562: | ||
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30078-9/fulltext Davies et al. 2017 (SABRINA)] | |[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30078-9/fulltext Davies et al. 2017 (SABRINA)] | ||
|2011-2013 | |2011-2013 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-RT-switch-ic) |
|[[#Rituximab_monotherapy.2C_extended_course|IV Rituximab]] | |[[#Rituximab_monotherapy.2C_extended_course|IV Rituximab]] | ||
| style="background-color:#ffffbf" |Similar efficacy | | style="background-color:#ffffbf" |Similar efficacy | ||
Line 2,642: | Line 2,642: | ||
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30097-3/fulltext Sehn et al. 2016 (GADOLIN)] | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30097-3/fulltext Sehn et al. 2016 (GADOLIN)] | ||
|2010-2014 | |2010-2014 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Bendamustine_.26_Obinutuzumab_2|Bendamustine & Obinutuzumab]] | |[[#Bendamustine_.26_Obinutuzumab_2|Bendamustine & Obinutuzumab]] | ||
| style="background-color:#fc8d59" |Seems to have inferior OS<sup>1</sup> | | style="background-color:#fc8d59" |Seems to have inferior OS<sup>1</sup> | ||
Line 2,648: | Line 2,648: | ||
|[https://doi.org/10.1111/bjh.17420 Rummel et al. 2021 (COMPLEMENT A + B)] | |[https://doi.org/10.1111/bjh.17420 Rummel et al. 2021 (COMPLEMENT A + B)] | ||
|2010-2016 | |2010-2016 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|Bendamustine & Ofatumumab | |Bendamustine & Ofatumumab | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | ||
Line 2,687: | Line 2,687: | ||
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30097-3/fulltext Sehn et al. 2016 (GADOLIN)] | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30097-3/fulltext Sehn et al. 2016 (GADOLIN)] | ||
|2010-2014 | |2010-2014 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-RT-esc) |
|[[#Bendamustine_monotherapy|Bendamustine]] | |[[#Bendamustine_monotherapy|Bendamustine]] | ||
| style="background-color:#91cf60" |Seems to have superior OS | | style="background-color:#91cf60" |Seems to have superior OS | ||
Line 2,770: | Line 2,770: | ||
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00447-7/fulltext Rummel et al. 2015 (StiL NHL 2-2003)] | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00447-7/fulltext Rummel et al. 2015 (StiL NHL 2-2003)] | ||
|2003-2010 | |2003-2010 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-switch-ic) |
|[[Follicular_lymphoma_-_historical#FR|FR]] | |[[Follicular_lymphoma_-_historical#FR|FR]] | ||
| style="background-color:#1a9850" |Superior PFS | | style="background-color:#1a9850" |Superior PFS | ||
Line 2,899: | Line 2,899: | ||
|[https://doi.org/10.1200/jco.2002.11.076 Witzig et al. 2002a] | |[https://doi.org/10.1200/jco.2002.11.076 Witzig et al. 2002a] | ||
|NR | |NR | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-RT-switch-ic) |
|[[#Rituximab_monotherapy_3|Rituximab]] | |[[#Rituximab_monotherapy_3|Rituximab]] | ||
| style="background-color:#1a9850" |Superior ORR | | style="background-color:#1a9850" |Superior ORR | ||
Line 3,080: | Line 3,080: | ||
|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7035866/ Leonard et al. 2019 (AUGMENT)] | |[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7035866/ Leonard et al. 2019 (AUGMENT)] | ||
|2014-2017 | |2014-2017 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-RT-esc) |
|[[#Rituximab_monotherapy_3|Rituximab]] | |[[#Rituximab_monotherapy_3|Rituximab]] | ||
| style="background-color:#1a9850" |Superior PFS <br>Median PFS: 39.4 mo vs 14.1 mo <br>(HR 0.46, 95% CI 0.34-0.62) | | style="background-color:#1a9850" |Superior PFS <br>Median PFS: 39.4 mo vs 14.1 mo <br>(HR 0.46, 95% CI 0.34-0.62) | ||
Line 3,104: | Line 3,104: | ||
|Awaiting publication (MAGNIFY) | |Awaiting publication (MAGNIFY) | ||
|2014-NR | |2014-NR | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3b (C-RT) |
|[[#Lenalidomide_.26_Rituximab_.28R2.29_3|R<sup>2</sup>]], then Lenalidomide | |[[#Lenalidomide_.26_Rituximab_.28R2.29_3|R<sup>2</sup>]], then Lenalidomide | ||
| style="background-color:#d3d3d3" |Not reported | | style="background-color:#d3d3d3" |Not reported | ||
Line 3,235: | Line 3,235: | ||
|[http://www.bloodjournal.org/content/108/10/3295.long Van Oers et al. 2006 (EORTC 20981)] | |[http://www.bloodjournal.org/content/108/10/3295.long Van Oers et al. 2006 (EORTC 20981)] | ||
|1998-2004 | |1998-2004 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|[[Follicular_lymphoma_-_historical#CHOP_2|CHOP]] | |[[Follicular_lymphoma_-_historical#CHOP_2|CHOP]] | ||
| style="background-color:#1a9850" |Superior PFS | | style="background-color:#1a9850" |Superior PFS | ||
Line 3,302: | Line 3,302: | ||
|[http://www.bloodjournal.org/content/104/10/3064.long Forstpointner et al. 2004] | |[http://www.bloodjournal.org/content/104/10/3064.long Forstpointner et al. 2004] | ||
|1998-2001 | |1998-2001 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|[[Follicular_lymphoma_-_historical#FCM|FCM]] | |[[Follicular_lymphoma_-_historical#FCM|FCM]] | ||
| style="background-color:#91cf60" |Seems to have superior PFS | | style="background-color:#91cf60" |Seems to have superior PFS | ||
Line 3,347: | Line 3,347: | ||
|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7448588/ Maloney et al. 2020 (HOMER)] | |[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7448588/ Maloney et al. 2020 (HOMER)] | ||
|2010-2016 | |2010-2016 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[Follicular_lymphoma_-_historical#Ofatumumab_monotherapy|Ofatumumab]] | |[[Follicular_lymphoma_-_historical#Ofatumumab_monotherapy|Ofatumumab]] | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | ||
Line 3,394: | Line 3,394: | ||
|[https://doi.org/10.1200/jco.2002.11.076 Witzig et al. 2002a] | |[https://doi.org/10.1200/jco.2002.11.076 Witzig et al. 2002a] | ||
|NR | |NR | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Ibritumomab_tiuxetan_protocol_4|Ibritumomab tiuxetan]] | |[[#Ibritumomab_tiuxetan_protocol_4|Ibritumomab tiuxetan]] | ||
| style="background-color:#d73027" |Inferior ORR | | style="background-color:#d73027" |Inferior ORR | ||
Line 3,445: | Line 3,445: | ||
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70150-4/abstract Coiffier et al. 2011 (LYM-3001)] | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70150-4/abstract Coiffier et al. 2011 (LYM-3001)] | ||
|2006-2008 | |2006-2008 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#VR|VR]] | |[[#VR|VR]] | ||
| style="background-color:#fc8d59" |Seems to have inferior PFS | | style="background-color:#fc8d59" |Seems to have inferior PFS | ||
Line 3,473: | Line 3,473: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171355/ Kahl et al. 2014 (RESORT)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171355/ Kahl et al. 2014 (RESORT)] | ||
|2003-2008 | |2003-2008 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Rituximab_monotherapy.2C_very_extended_course|Rituximab]]; indefinite | |[[#Rituximab_monotherapy.2C_very_extended_course|Rituximab]]; indefinite | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of TTF | | style="background-color:#ffffbf" |Did not meet primary endpoint of TTF | ||
Line 3,524: | Line 3,524: | ||
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70150-4/abstract Coiffier et al. 2011 (LYM-3001)] | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70150-4/abstract Coiffier et al. 2011 (LYM-3001)] | ||
|2006-2008 | |2006-2008 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|[[#Rituximab_monotherapy_3|Rituximab]] | |[[#Rituximab_monotherapy_3|Rituximab]] | ||
| style="background-color:#91cf60" |Seems to have superior PFS | | style="background-color:#91cf60" |Seems to have superior PFS | ||
Line 4,372: | Line 4,372: | ||
|[http://www.bloodjournal.org/content/103/12/4416.full Ghielmini et al. 2004 (SAKK 35/98)] | |[http://www.bloodjournal.org/content/103/12/4416.full Ghielmini et al. 2004 (SAKK 35/98)] | ||
|1998-2001 | |1998-2001 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Rituximab_monotherapy.2C_abbreviated_course_2|Rituximab]] | |[[#Rituximab_monotherapy.2C_abbreviated_course_2|Rituximab]] | ||
| style="background-color:#fc8d59" |Seems to have inferior EFS | | style="background-color:#fc8d59" |Seems to have inferior EFS | ||
Line 4,378: | Line 4,378: | ||
|[http://www.bloodjournal.org/content/104/10/3064.long Forstpointner et al. 2004] | |[http://www.bloodjournal.org/content/104/10/3064.long Forstpointner et al. 2004] | ||
|1998-2001 | |1998-2001 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Rituximab_monotherapy.2C_abbreviated_course_2|Rituximab]] | |[[#Rituximab_monotherapy.2C_abbreviated_course_2|Rituximab]] | ||
| style="background-color:#fc8d59" |Seems to have inferior PFS | | style="background-color:#fc8d59" |Seems to have inferior PFS | ||
Line 4,384: | Line 4,384: | ||
|[http://www.bloodjournal.org/content/108/10/3295.long Van Oers et al. 2006 (EORTC 20981)] | |[http://www.bloodjournal.org/content/108/10/3295.long Van Oers et al. 2006 (EORTC 20981)] | ||
|1998-2004 | |1998-2004 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Rituximab_monotherapy.2C_extended_course_2|Rituximab]] | |[[#Rituximab_monotherapy.2C_extended_course_2|Rituximab]] | ||
| style="background-color:#fc8d59" |Seems to have inferior OS | | style="background-color:#fc8d59" |Seems to have inferior OS | ||
Line 4,390: | Line 4,390: | ||
|[https://doi.org/10.1200/JCO.2012.47.1862 Pettengell et al. 2013 (EBMT Lym-1)] | |[https://doi.org/10.1200/JCO.2012.47.1862 Pettengell et al. 2013 (EBMT Lym-1)] | ||
|1999-2006 | |1999-2006 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Rituximab_monotherapy.2C_abbreviated_course_2|Rituximab]] | |[[#Rituximab_monotherapy.2C_abbreviated_course_2|Rituximab]] | ||
| style="background-color:#fc8d59" |Seems to have inferior PFS | | style="background-color:#fc8d59" |Seems to have inferior PFS | ||
Line 4,429: | Line 4,429: | ||
|[http://www.bloodjournal.org/content/103/12/4416.full Ghielmini et al. 2004 (SAKK 35/98)] | |[http://www.bloodjournal.org/content/103/12/4416.full Ghielmini et al. 2004 (SAKK 35/98)] | ||
|1998-2001 | |1998-2001 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|[[#Observation_4|Observation]] | |[[#Observation_4|Observation]] | ||
| style="background-color:#91cf60" |Seems to have superior EFS | | style="background-color:#91cf60" |Seems to have superior EFS | ||
Line 4,435: | Line 4,435: | ||
|[https://doi.org/10.1200/JCO.2012.47.1862 Pettengell et al. 2013 (EBMT Lym-1)] | |[https://doi.org/10.1200/JCO.2012.47.1862 Pettengell et al. 2013 (EBMT Lym-1)] | ||
|1999-2006 | |1999-2006 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|[[#Observation_4|Observation]] | |[[#Observation_4|Observation]] | ||
| style="background-color:#91cf60" |Seems to have superior EFS | | style="background-color:#91cf60" |Seems to have superior EFS | ||
Line 4,462: | Line 4,462: | ||
|[http://www.bloodjournal.org/content/104/10/3064.long Forstpointner et al. 2004] | |[http://www.bloodjournal.org/content/104/10/3064.long Forstpointner et al. 2004] | ||
|1998-2001 | |1998-2001 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|[[#Observation_4|Observation]] | |[[#Observation_4|Observation]] | ||
| style="background-color:#91cf60" |Seems to have superior PFS | | style="background-color:#91cf60" |Seems to have superior PFS | ||
Line 4,550: | Line 4,550: | ||
|[https://doi.org/10.1200/JCO.2003.10.023 Schouten et al. 2003 (CUP)] | |[https://doi.org/10.1200/JCO.2003.10.023 Schouten et al. 2003 (CUP)] | ||
|1993-1997 | |1993-1997 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|CHOP x 3 | |CHOP x 3 | ||
| style="background-color:#d9ef8b" |Might have superior OS | | style="background-color:#d9ef8b" |Might have superior OS | ||
Line 4,679: | Line 4,679: | ||
|[http://www.bloodjournal.org/content/108/10/3295.long Van Oers et al. 2006 (EORTC 20981)] | |[http://www.bloodjournal.org/content/108/10/3295.long Van Oers et al. 2006 (EORTC 20981)] | ||
|1998-2004 | |1998-2004 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|[[#Observation_4|Observation]] | |[[#Observation_4|Observation]] | ||
| style="background-color:#91cf60" |Seems to have superior OS | | style="background-color:#91cf60" |Seems to have superior OS |
Revision as of 02:10, 16 December 2021
Section editor | |
---|---|
Sanjai Sharma, MD Sequoia Regional Cancer Center Visalia, CA |
Are you looking for a regimen but can't find it here? It is possible that we've moved it to the historical regimens page. If you still can't find it, please let us know so we can add it!
85 regimens on this page
140 variants on this page
|
Guidelines
BSH
- 2020: McNamara et al. The investigation and management of follicular lymphoma
ESMO
- 2020: Dreyling et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Older
- 2016: Dreyling et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- 2014: Dreyling et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2013: Ghielmini et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) PubMed
"How I Treat"
- 2019: Casulo C, Barr PM. How I treat early-relapsing follicular lymphoma. Blood. 2019 Apr 4;133(14):1540-1547. link to original article PubMed
NCCN
Early disease, definitive therapy
Ibritumomab tiuxetan protocol
back to top |
Regimen
Study | Evidence |
---|---|
Samaniego et al. 2014 (MDACC 2005-0512) | Phase II |
Targeted therapy
- Rituximab (Rituxan) 250 mg/m2 IV once per day on days 1 & 8, given first on day 8
Radioconjugate therapy
- Ibritumomab tiuxetan & Yttrium-90 (Zevalin) given second, as follows:
- Platelet count greater than 150 x 109/L: 14.8 MBq/kg (maximum dose of 1184 MBq) IV once on day 8
- Platelet count between 100 and 149 x 109/L: 11.1 MBq/kg (maximum dose of 1184 MBq) IV once on day 8
References
- MDACC 2005-0512: Samaniego F, Berkova Z, Romaguera JE, Fowler N, Fanale MA, Pro B, Shah JJ, McLaughlin P, Sehgal L, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu SS, Kwak LW. 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. Br J Haematol. 2014 Oct;167(2):207-13. Epub 2014 Jul 8. link to original article contains verified protocol PubMed NCT00493467
Radiation therapy
back to top |
RT: Radiation Therapy
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kelsey et al. 1994 | 1974-1981 | Non-randomized portion of RCT | ||
Yahalom et al. 1993 | 1980-1988 | Non-randomized portion of RCT | ||
Lowry et al. 2011 | 1997-2005 | Phase 3 (E-de-esc) | RT x 40 to 45 Gy | Did not meet primary endpoint of ORR |
MacManus et al. 2018 (TROG 99.03) | 2000-2012 | Non-randomized portion of RCT | ||
Hoskin et al. 2014 (FORT) | 2006-2011 | Phase 3 (C) | RT x 4 Gy | Superior TTP |
This is the current "standard dose" radiotherapy - dose varies per protocol and location radiated.
Radiotherapy
- External beam radiotherapy 24 to 36 Gy
Subsequent treatment
- Yahalom et al. 1993: CHOP versus no further treatment
- Kelsey et al. 1994: Chlorambucil versus no further treatment
- TROG 99.03: CVP or R-CVP versus no further treatment
References
- Yahalom J, Varsos G, Fuks Z, Myers J, Clarkson BD, Straus DJ. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma: results of a prospective randomized study. Cancer. 1993 Apr 1;71(7):2342-50. link to original article PubMed
- Kelsey SM, Newland AC, Hudson GV, Jelliffe AM. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Med Oncol. 1994;11(1):19-25. link to original article PubMed
- Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, Linch D, Robinson M, Jack A, Hoskin P. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011 Jul;100(1):86-92. Epub 2011 Jun 12. link to original article PubMed
- FORT: Hoskin PJ, Kirkwood AA, Popova B, Smith P, Robinson M, Gallop-Evans E, Coltart S, Illidge T, Madhavan K, Brammer C, Diez P, Jack A, Syndikus I. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014 Apr;15(4):457-63. Epub 2014 Feb 24. link to original article PubMed NCT00310167
- TROG 99.03: MacManus M, Fisher R, Roos D, O'Brien P, Macann A, Davis S, Tsang R, Christie D, McClure B, Joseph D, Jayamohan J, Seymour JF. Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03. J Clin Oncol. 2018 Oct 10;36(29):2918-2925. Epub 2018 Jul 5. link to original article PubMed NCT00115700
Early disease, adjuvant therapy
Observation
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kelsey et al. 1994 | 1974-1981 | Randomized (C) | Chlorambucil | Did not meet primary endpoint of OS |
Yahalom et al. 1993 | 1980-1988 | Randomized (C) | CHOP x 6 | Seems to have inferior RFS |
MacManus et al. 2018 (TROG 99.03) | 2000-2012 | Randomized (C) | 1. CVP 2. R-CVP |
Seems to have inferior PFS |
No further treatment. Note that in TROG 99.03, patients enrolled after 2006 were randomized between this arm and R-CVP.
Preceding treatment
References
- Yahalom J, Varsos G, Fuks Z, Myers J, Clarkson BD, Straus DJ. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma: results of a prospective randomized study. Cancer. 1993 Apr 1;71(7):2342-50. link to original article PubMed
- Kelsey SM, Newland AC, Hudson GV, Jelliffe AM. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Med Oncol. 1994;11(1):19-25. link to original article PubMed
- TROG 99.03: MacManus M, Fisher R, Roos D, O'Brien P, Macann A, Davis S, Tsang R, Christie D, McClure B, Joseph D, Jayamohan J, Seymour JF. Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03. J Clin Oncol. 2018 Oct 10;36(29):2918-2925. Epub 2018 Jul 5. link to original article PubMed NCT00115700
Advanced disease, pre-phase
Rituximab monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Hainsworth et al. 2005a | 2000-2001 | Phase II |
Hainsworth et al. 2009 | NR in abstract | Phase II |
Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22
28-day course
Subsequent treatment
- Hainsworth et al. 2005a: R-CHOP x 3 or R-CVP x 3, then Rituximab consolidation
- Hainsworth et al. 2009: R-CHOP x 3, then Ibritumumab tiuxetan consolidation
References
- Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005 Mar 1;23(7):1500-6. Epub 2005 Jan 4. link to original article contains verified protocol PubMed
- Hainsworth JD, Spigel DR, Markus TM, Shipley D, Thompson D, Rotman R, Dannaher C, Greco FA. Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma. 2009 Jun;9(3):223-8. link to original article contains verified protocol PubMed
Advanced disease, first-line therapy, randomized data
Bendamustine & Obinutuzumab
back to top |
G-B: Gazyva (Obinutuzumab) & Bendamustine
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Marcus et al. 2017 (GALLIUM) | 2011-2014 | Phase 3 (E-RT-switch-ic) | See link | See link | See link |
Chemotherapy
- Bendamustine 90 mg/m2 IV once per day on days 1 & 2
Targeted therapy
- Obinutuzumab (Gazyva) as follows:
- Cycle 1: 1000 mg IV once per day on days 1, 8, 15
- Cycles 2 to 6: 1000 mg IV once on day 1
28-day cycle for 6 cycles
Subsequent treatment
References
- GALLIUM: Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331-1344. link to original article link to appendix contains verified protocol in appendix PubMed NCT01332968
- Update: Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018 Aug 10;36(23):2395-2404. Epub 2018 Jun 1. link to original article PubMed
Bendamustine & Rituximab (BR)
back to top |
BR: Bendamustine & Rituximab
R-B: Rituximab & Bendamustine
Regimen variant #1, 6 cycles
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Rummel et al. 2013 (StiL NHL1) | 2003-2008 | Phase 3 (E-de-esc) | R-CHOP | Superior PFS | |
Marcus et al. 2017 (GALLIUM) | 2011-2014 | Phase 3 (C) | See link | See link | See link |
Morschhauser et al. 2018 (RELEVANCE) | 2011-2014 | Phase 3 (C) | Lenalidomide & Rituximab | Did not meet primary endpoints of CR rate/PFS | Different toxicity |
Chemotherapy
- Bendamustine 90 mg/m2 IV once per day on days 1 & 2
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Supportive medications
- Antiemetics, antipyretics, and antibiotics according to local standard of care
- Prophylactic use of G-CSF allowed according ASCO guidelines (2006)
28-day cycle for up to 6 cycles
Subsequent treatment
- GALLIUM & RELEVANCE: Rituximab maintenance
Regimen variant #2, 6 cycles with rituximab extension
Study | Evidence |
---|---|
Rummel et al. 2014 (MAINTAIN) | Non-randomized portion of RCT |
Chemotherapy
- Bendamustine as follows:
- Cycles 1 to 6: 90 mg/m2 IV once per day on days 1 & 2
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
28-day cycle for 8 cycles
Subsequent treatment
- Rituximab maintenance x 2 y versus rituximab maintenance x 4 y
Regimen variant #3, 8 cycles
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Flinn et al. 2014 (BRIGHT) | 2009-2012 | Phase 3 (E-de-esc) | 1. R-CHOP 2. R-CVP |
Superior PFS1 Median PFS: NR vs NR (HR 0.61, 95% CI 0.45-0.85) |
1Reported efficacy in BRIGHT is based on the 2019 update.
Patients in BRIGHT were required to be treatment-naive with a need for treatment per any of the following: B symptoms, large tumor mass (lymphomas with a diameter greater than 3 cm in 3 or more regions or diameter greater than 7 cm in 1 region), presence of lymphoma-related complications, or hyperviscosity syndrome attributed to monoclonal gammopathy.
Chemotherapy
- Bendamustine 90 mg/m2 IV once per day on days 1 & 2
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Supportive medications
- Antiemetics, antipyretics, and antibiotics according to local standard of care
- Prophylactic use of G-CSF allowed according ASCO guidelines (2006)
28-day cycle for up to 8 cycles
References
- StiL NHL1: Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; StiL. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Apr 6;381(9873):1203-10. Epub 2013 Feb 20. Erratum in: Lancet. 2013 Apr 6;381(9873):1184. link to original article contains verified protocol PubMed NCT00991211
- Update: Abstract: Mathias J. Rummel, MD, Georg Maschmeyer, MD, Arnold Ganser, Andrea Heider, PhD, Ulrich von Grünhagen, MD, PhD5, Christoph Losem, Gerhard Heil, MD, Manfred Welslau, Christina Balser, MD, Ulrich Kaiser, MD, Eckhart Weidmann, Heinz Dürk, MD, Hans Peter Böck, Martina Beate Stauch, MD, Jürgen Barth, Wolfgang Blau, MD, Alexander Burchardt, MD, Frank Kauff, PhD, Axel Hinke, PhD and Wolfram Brugger, MD. Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 Study. Blood 2014 124:4407. link to abstract
- Update: Abstract: Mathias J. Rummel, Georg Maschmeyer, Arnold Ganser, Andrea Heider, Ulrich von Gruenhagen, Christoph Losem, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Eckhart Weidmann, Heinz Albert Dürk, Harald Ballo, Martina Stauch, Wolfgang Blau, Alexander Burchardt, Juergen Barth, Frank Kauff, and Wolfram Brugger. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study. Journal of Clinical Oncology 2017 35:15_suppl, 7501-7501 link to abstract
- BRIGHT: Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. link to original article contains verified protocol link to PMC article PubMed NCT00877006
- Update: Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, Trotman J, Hallman D, Chen L, Burke JM. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019 Apr 20;37(12):984-991. Epub 2019 Feb 27. link to original article link to PMC article PubMed
- Abstract: Mathias J. Rummel, MD, Andreas Viardot, Richard Greil, MD, Bernd Hertenstein, MD, Christian Lerchenmüller, MD, Arnold Ganser, Manfred Reeb, MD, Ulrich Kaiser, MD, Christina Balser, MD, Georg Maschmeyer, MD, Heinz Dürk, MD, Georg Schliesser, MD, Tobias Gaska, MD, Jan Dürig, MD, Axel C. Matzdorff, MD, Rudolf Weide, MD, Axel Hinke, PhD, Wolfgang Blau, MD, Alexander Burchardt, MD, Frank Kauff, PhD, Jürgen Barth and Wolfram Brugger, MD. Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214). Blood 2014 124:3052 link to abstract NCT00877214
- GALLIUM: Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331-1344. link to original article link to appendix contains verified protocol in appendix PubMed NCT01332968
- Update: Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018 Aug 10;36(23):2395-2404. Epub 2018 Jun 1. link to original article PubMed
- RELEVANCE: Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018 Sep 6;379(10):934-947. link to original article contains verified protocol in supplement PubMed NCT01650701
Chlorambucil monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Ardeshna et al. 2003 | 1981-1990 | Phase 3 (C) | Observation | Did not meet primary endpoint of OS |
This is the comparator arm to the "watch and wait" strategy, and is not commonly used.
Chemotherapy
- Chlorambucil (Leukeran) 10 mg PO once per day
Continued indefinitely
References
- Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, Marcus RE, Jelliffe A, Vaughan G, Hudson GV, Linch DC; British National Lymphoma Investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003 Aug 16;362(9383):516-22. link to original article contains verified protocol PubMed
Cyclophosphamide monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Peterson et al. 2003 (CALGB 7951) | 1980-1985 | Phase 3 (E-de-esc) | CHOP-B | Did not meet primary endpoint of OS |
Smith et al. 2009 (CALGB 8691) | 1986-1991 | Phase 3 (C) | Cyclophosphamide & Interferon alfa-2a | Did not meet primary endpoint of EFS |
Note: this is an experimental arm that did not meet its primary endpoint; included here because it was eventually used to establish this regimen as a standard comparator.
Chemotherapy
- Cyclophosphamide (Cytoxan) 100 mg/m2 PO once per day
- Dose modifications according to WBC and platelet count as listed in Table 1 of Peterson et al. 2003
Treatment continued in responders for 2 years beyond maximal response
References
- CALGB 7951: Peterson BA, Petroni GR, Frizzera G, Barcos M, Bloomfield CD, Nissen NI, Hurd DD, Henderson ES, Sartiano GP, Johnson JL, Holland JF, Gottlieb AJ. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2003 Jan 1;21(1):5-15. link to original article contains verified protocol PubMed
- CALGB 8691: Smith SM, Johnson J, Cheson BD, Canellos G, Petroni G, Oken M, Duggan D, Hurd D, Gockerman JP, Parker B, Prchal J, Peterson BA; CALGB; ECOG. Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. Leuk Lymphoma. 2009 Oct;50(10):1606-17. link to original article link to PMC article PubMed
G-CVP
back to top |
G-CVP: Gazyva (Obinutuzumab), Cyclophosphamide, Vincristine, Prednisone
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Marcus et al. 2017 (GALLIUM) | 2011-2014 | Phase 3 (E-RT-switch-ic) | See link | See link | See link |
Note: Patients received obinutuzumab only in cycles 7 & 8.
Targeted therapy
- Obinutuzumab (Gazyva) as follows:
- Cycle 1: 1000 mg IV once per day on days 1, 8, 15
- Cycles 2 to 8: 1000 mg IV once on day 1
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
21-day cycle for 8 cycles
Subsequent treatment
References
- GALLIUM: Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331-1344. link to original article link to appendix contains verified protocol in appendix PubMed NCT01332968
- Update: Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018 Aug 10;36(23):2395-2404. Epub 2018 Jun 1. link to original article PubMed
G-CHOP
back to top |
G-CHOP: Gazyva (Obinutuzumab), Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Predniso(lo)ne
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Marcus et al. 2017 (GALLIUM) | 2011-2014 | Phase 3 (E-RT-switch-ic) | See link | See link | See link |
Note: Patients received obinutuzumab only in cycles 7 & 8.
Targeted therapy
- Obinutuzumab (Gazyva) as follows:
- Cycle 1: 1000 mg IV once per day on days 1, 8, 15
- Cycles 2 to 8: 1000 mg IV once on day 1
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
21-day cycle for 8 cycles
Subsequent treatment
References
- GALLIUM: Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331-1344. link to original article link to appendix contains verified protocol in appendix PubMed NCT01332968
- Update: Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018 Aug 10;36(23):2395-2404. Epub 2018 Jun 1. link to original article PubMed
Lenalidomide & Rituximab (R2)
back to top |
R2: Rituximab & Revlimid (Lenalidomide)
Regimen variant #1
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Zucca et al. 2019 (SAKK 35/10) | 2011-2013 | Randomized Phase II (E-esc) | Rituximab | Might have superior CR/CRu rate |
Targeted therapy
- Lenalidomide (Revlimid) 15 mg PO once per day, starting 14 days prior to first rituximab infusion and continuing until 14 days past last rituximab infusion
- Rituximab (Rituxan) as follows:
- Cycles 1 & 3: 375 mg/m2 IV once per day on days 1, 8, 15, 22
28-day cycle for 4 cycles
Regimen variant #2
Study | Evidence |
---|---|
Fowler et al. 2014 (MDACC 2008-0042) | Phase II |
Targeted therapy
- Lenalidomide (Revlimid) 20 mg PO once per day on days 1 to 21
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
28-day cycle for up to 12 cycles
Regimen variant #3
Study | Evidence |
---|---|
Martin et al. 2017 (CALGB 50803) | Phase II |
Targeted therapy
- Lenalidomide (Revlimid) 20 mg PO once per day on days 1 to 21
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days 1, 8, 15, 22
- Cycles 4, 6, 8, 10: 375 mg/m2 IV once on day 1
28-day cycle for 12 cycles
Regimen variant #4
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Morschhauser et al. 2018 (RELEVANCE) | 2011-2014 | Phase 3 (E-switch-ooc) | 1. R-B 2. R-CHOP 3. R-CVP |
Did not meet primary endpoints of CR rate/PFS | Different toxicity |
Targeted therapy
- Lenalidomide (Revlimid) 20 mg PO once per day on days 2 to 22
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days 1, 8, 15, 22
- Cycles 2 to 6: 375 mg/m2 IV once on day 1
28-day cycle for 6 cycles
Subsequent treatment
- Responders: Lenalidomide & Rituximab maintenance
References
- MDACC 2008-0042: Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov;15(12):1311-8. Epub 2014 Oct 15. link to original article contains protocol link to PMC article PubMed NCT00695786
- SAKK 35/10: Zucca E, Rondeau S, Vanazzi A, Østenstad B, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson AS, de Nully Brown P, Hagberg H, Ferreri AJM, Lohri A, Novak U, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei SB, Ghielmini M, Kimby E; Swiss Group for Clinical Cancer Research; Nordic Lymphoma Group. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood. 2019 Jul 25;134(4):353-362. Epub 2019 May 17. link to original article PubMed NCT01307605
- CALGB 50803: Martin P, Jung SH, Pitcher B, Bartlett NL, Blum KA, Shea T, Hsi ED, Ruan J, Smith SE, Leonard JP, Cheson BD. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol. 2017 Nov 1;28(11):2806-2812. link to original article contains protocol link to PMC article PubMed NCT01145495
- RELEVANCE: Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018 Sep 6;379(10):934-947. link to original article contains verified protocol PubMed NCT01650701
Observation
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Horning & Rosenberg 1984 | 1963-1984 | Non-randomized | ||
Young et al. 1988 | NR in abstract | Phase 3 (E-de-esc) | ProMACE-MOPP, then TNI | |
Ardeshna et al. 2003 | 1981-1990 | Phase 3 (E-de-esc) | Chlorambucil | Did not meet primary endpoint of OS |
Brice et al. 1997 | 1986-1995 | Phase 3 (E-de-esc) | 1. Interferon alfa 2. Prednimustine |
Did not meet primary endpoint of OS |
Ardeshna et al. 2014 (CRUK-2004-001621-16) | 2004-2009 | Phase 3 (C) | 1. Rituximab induction | Inferior TTNT |
2. Rituximab induction, then Rituximab maintenance | Inferior TTNT |
Also known as "watchful waiting".
References
- Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984 Dec 6;311(23):1471-5. link to original article PubMed
- Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT Jr. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988 Apr;25(2 Suppl 2):11-6. PubMed
- Brice P, Bastion Y, Lepage E, Brousse N, Haïoun C, Moreau P, Straetmans N, Tilly H, Tabah I, Solal-Céligny P; Groupe d'Etude des Lymphomes de l'Adulte. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. J Clin Oncol. 1997 Mar;15(3):1110-7. link to original article PubMed
- Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, Marcus RE, Jelliffe A, Vaughan G, Hudson GV, Linch DC; British National Lymphoma Investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003 Aug 16;362(9383):516-22. link to original article PubMed
- CRUK-2004-001621-16: Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, Cunningham D, Davies J, Jack A, Stephens R, Walewski J, Ferhanoglu B, Bradstock K, Linch DC. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014 Apr;15(4):424-35. Epub 2014 Mar 4. link to original article PubMed NCT00112931
R-CHOP
back to top |
R-CHOP: Rituximab, Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Prednisone
Regimen variant #1, 3 cycles with prednisone 100 mg
Study | Years of enrollment | Evidence |
---|---|---|
Hainsworth et al. 2005a | 2000-2001 | Phase II |
Hainsworth et al. 2009 | NR in abstract | Phase II |
Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.
Preceding treatment
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
21-day cycle for 3 cycles
Subsequent treatment
- Hainsworth et al. 2005a: Rituximab consolidation
- Hainsworth et al. 2009: Ibritumumab tiuxetan consolidation, in 4 weeks
Regimen variant #2, 3 cycles with prednisone 100 mg/m2
Study | Evidence |
---|---|
Jacobs et al. 2008 (UPCI 03-005) | Phase II |
Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. R-CHOP given as per standard ECOG dosing, except that rituximab is given on day 1 of each cycle:
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
- Prednisone (Sterapred) 100 mg/m2 PO once per day on days 1 to 5
Supportive medications
- Filgrastim (Neupogen) "recommended according to guidelines"
21-day cycle for 3 cycles
Subsequent treatment
Regimen variant #3, prednisone 100 mg
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Salles et al. 2010 (PRIMAFL) | 2004-2007 | Non-randomized portion of RCT | |||
Flinn et al. 2014 (BRIGHT) | 2009-2012 | Phase 3 (C) | BR | Seems to have non-inferior CR rate | |
Marcus et al. 2017 (GALLIUM) | 2011-2014 | Phase 3 (C) | See link | See link | See link |
Morschhauser et al. 2018 (RELEVANCE) | 2011-2014 | Phase 3 (C) | Lenalidomide & Rituximab | Did not meet primary endpoints of CR rate/PFS | Different toxicity |
In PRIMA, initial therapy was investigator's choice. Patients in BRIGHT were required to be treatment-naive with a need for treatment per any of the following: B symptoms, large tumor mass (lymphomas with a diameter greater than 3 cm in 3 or more regions or diameter greater than 7 cm in 1 region), presence of lymphoma-related complications, or hyperviscosity syndrome attributed to monoclonal gammopathy. Patients in GALLIUM & RELEVANCE received rituximab only in cycles 7 & 8.
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
Supportive medications
- Antiemetics, antipyretics, and antibiotics per local standard of care
- G-CSF according to the American Society of Clinical Oncology guidelines
21-day cycle for 6 to 8 cycles (see note)
Subsequent treatment
- PRIMA, responders (PR or CR): Maintenance rituximab versus no further treatment
- GALLIUM & RELEVANCE: Maintenance rituximab
Regimen variant #4, prednisone 100 mg/m2
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Hiddemann et al. 2005 (GLSG '00) | 2000-2003 | Phase 3 (E-esc) | CHOP | Seems to have superior OS | Increased toxicity |
Federico et al. 2013 (FOLL05) | 2006-2010 | Phase 3 (E-esc) | 1. R-CVP | Seems to have superior PFS | |
2. R-FM | Did not meet primary endpoint of TTF |
In FOLL05, PFS was superior to R-CVP but equivalent to R-FM; risk/benefit ratio was better than R-FM. Patients in FOLL05 received a total of 8 doses of rituximab, regardless of the number of CHOP cycles.
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on either day 1 or day -1
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
- Prednisone (Sterapred) 100 mg/m2 PO once per day on days 1 to 5
21-day cycle for 6 to 8 cycles
Regimen variant #5, variant rituximab schedule
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Czuczman et al. 1999 | NR | Phase II | ||
Press et al. 2012 (SWOG S0016) | 2001-2008 | Phase 3 (C) | CHOP, then 131Iodine-Tositumomab | Inferior PFS1 |
1Reported efficacy for SWOG S0016 is based on the 2018 update.
In SWOG S0016, this regimen was intended for patients greater than 18 years with untreated bulky stage II or stage III-IV FL (all grades) expressing CD20.
Targeted therapy
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days -7 & -2
- Cycles 3 & 5: 375 mg/m2 IV once on day -2
- Cycle 6*: 375 mg/m2 IV once per day 8 days and 15 days after completion of cycle 6 (i.e., what would be cycle 7 days 8 & 15)
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
- Prednisone (Sterapred) 100 mg/m2 PO once per day on days 1 to 5
21-day cycle for 6 cycles
Regimen variant #6, 4 doses of rituximab
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Watanabe et al. 2011 (JCOG 0203) | 2002-2007 | Phase 3 (C) | R-CHOP-14 | Did not meet primary endpoint of PFS |
This regimen was intended for patients with previously untreated stage III to IV indolent B-cell NHL, including FL grade 3B.
Targeted therapy
- Rituximab (Rituxan) as follows:
- Cycles 1, 2, 4, 6: 375 mg/m2 IV once on day -2
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
Supportive medications
- G-CSF "according to the [2000] American Society of Clinical Oncology guidelines," i.e., generally no routine use except for patients at high risk (>40%) for febrile neutropenia due to special circumstances
21-day cycle for 6 cycles
References
- Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999 Jan;17(1):268-76. link to original article contains protocol PubMed
- Update: Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-López AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004 Dec 1;22(23):4711 to 6. Epub 2004 Oct 13. link to original article PubMed
- Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005 Mar 1;23(7):1500-6. Epub 2005 Jan 4. link to original article contains verified protocol PubMed
- GLSG '00: Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wörmann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trümper L, Aldaoud A, Parwaresch R, Unterhalt M. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005 Dec 1;106(12):3725-32. Epub 2005 Aug 25. link to original article contains protocol PubMed
- UPCI 03-005: Jacobs SA, Swerdlow SH, Kant J, Foon KA, Jankowitz R, Land SR, DeMonaco N, Joyce J, Osborn JL, Evans TL, Schaefer PM, Luong TM. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res. 2008 Nov 1;14(21):7088-94. link to original article contains verified protocol PubMed
- Hainsworth JD, Spigel DR, Markus TM, Shipley D, Thompson D, Rotman R, Dannaher C, Greco FA. Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma. 2009 Jun;9(3):223-8. link to original article contains verified protocol PubMed
- PRIMA: Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011 Jan 1;377(9759):42-51. Epub 2010 Dec 20. link to original article contains protocol PubMed NCT00140582
- QoL Analysis: Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;20(3):129-36. Epub 2014 Jul 16. link to original article PubMed
- Update: Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S, Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, Le Gouill S, Lister A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, Salles G. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. J Clin Oncol. 2019 Nov 1;37(31):2815-2824. link to original article link to PMC article PubMed
- JCOG 0203: Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Takeuchi K, Nawano S, Terauchi T, Hotta T. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. J Clin Oncol. 2011 Oct 20;29(30):3990-8. Epub 2011 Sep 19. link to original article contains verified protocol PubMed NCT00147121
- Update: Watanabe T, Tobinai K, Wakabayashi M, Morishima Y, Kobayashi H, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Yoshino T, Nawano S, Terauchi T, Hotta T, Nagai H, Tsukasaki K; JCOG0203 Collaborators. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. Lancet Haematol. 2018 Nov;5(11):e520-e531. link to original article PubMed
- SWOG S0016: Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131Iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. 2013 Jan 20;31(3):314-20. Epub 2012 Dec 10. link to original article link to PMC article PubMed NCT00006721
- Update: Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, Press OW. Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus (131)I-tositumomab: long-term follow-up of phase III randomized study SWOG-S0016. J Clin Oncol. 2018 Mar 1;36(7):697-703. Epub 2018 Jan 22. link to original article PubMed
- StiL NHL1: Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; StiL. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Apr 6;381(9873):1203-10. Epub 2013 Feb 20. Erratum in: Lancet. 2013 Apr 6;381(9873):1184. link to original article PubMed NCT00991211
- Update: Abstract: Mathias J. Rummel, MD, Georg Maschmeyer, MD, Arnold Ganser, Andrea Heider, PhD, Ulrich von Grünhagen, MD, PhD5, Christoph Losem, Gerhard Heil, MD, Manfred Welslau, Christina Balser, MD, Ulrich Kaiser, MD, Eckhart Weidmann, Heinz Dürk, MD, Hans Peter Böck, Martina Beate Stauch, MD, Jürgen Barth, Wolfgang Blau, MD, Alexander Burchardt, MD, Frank Kauff, PhD, Axel Hinke, PhD and Wolfram Brugger, MD. Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 Study. Blood 2014 124:4407. link to abstract
- Update: Abstract: Mathias J. Rummel, Georg Maschmeyer, Arnold Ganser, Andrea Heider, Ulrich von Gruenhagen, Christoph Losem, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Eckhart Weidmann, Heinz Albert Dürk, Harald Ballo, Martina Stauch, Wolfgang Blau, Alexander Burchardt, Juergen Barth, Frank Kauff, and Wolfram Brugger. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study. Journal of Clinical Oncology 2017 35:15_suppl, 7501-7501 link to abstract
- FOLL05: Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, Di Raimondo F, Carella AM, Pulsoni A, Merli F, Arcaini L, Angrilli F, Stelitano C, Gaidano G, Dell'olio M, Marcheselli L, Franco V, Galimberti S, Sacchi S, Brugiatelli M. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013 Apr 20;31(12):1506-13. Epub 2013 Mar 25. Erratum in: J Clin Oncol. 2014 Apr 1;32(10):1095. Dosage error in article text. link to original article contains verified protocol PubMed NCT00774826
- Update: Luminari S, Ferrari A, Manni M, Dondi A, Chiarenza A, Merli F, Rusconi C, Tarantino V, Tucci A, Vitolo U, Kovalchuk S, Angelucci E, Pulsoni A, Arcaini L, Angrilli F, Gaidano G, Stelitano C, Bertoldero G, Cascavilla N, Salvi F, Ferreri AJM, Vallisa D, Marcheselli L, Federico M. Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol. 2018 Mar 1;36(7):689-696. Epub 2017 Nov 2. link to original article PubMed
- Abstract: Armando Lopez-Guillermo, MD, PhD, Miguel A. Canales, MD, PhD, Ivan Dlouhy, Javier Briones, MD, Dolores Caballero, MD, PhD, Juan Manuel Sancho Sr., MD, Santiago Mercadal Vilchez, MD, Jose María Moraleda, MD, María José Terol, MD, PhD, Antonio Salar, MD, Luis Palomera, MD, Santiago Gardella, MD, Isidro Jarque, MD, Secundino Ferrer, Joan Bargay, MD, Andres Lopez, Carlos Panizo, Anna Muntanola, MD, Carlos Montalban, Eulogio Conde, MD, PhD, Miguel Hernandez, MD, Alfons Soler, Julian Marin, MD, Jose García Marco, Guillermo Deben and José Francisco Tomas, MD, PhD. A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization. Blood 2013 122:369. link to abstract
- BRIGHT: Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. link to original article contains verified protocol link to PMC article PubMed NCT00877006
- Update: Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, Trotman J, Hallman D, Chen L, Burke JM. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019 Apr 20;37(12):984-991. Epub 2019 Feb 27. link to original article link to PMC article PubMed
- GALLIUM: Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331-1344. link to original article link to appendix contains verified protocol in appendix PubMed NCT01332968
- Update: Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018 Aug 10;36(23):2395-2404. Epub 2018 Jun 1. link to original article PubMed
- RELEVANCE: Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018 Sep 6;379(10):934-947. link to original article contains verified protocol in supplement PubMed NCT01650701
R-CHVP+I
back to top |
R-CHVP+I: Rituximab, Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), VP-16 (Etoposide), Prednisolone, Interferon-a2a
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Salles et al. 2008 (FL2000) | 2000-2002 | Phase 3 (E-esc) | CHVP+I | Superior EFS |
Targeted therapy
- Rituximab (Rituxan) as follows:
- Cycles 3 & 4: 375 mg/m2 IV once per day on days 1 and 8
- Cycles 5 & 6: 375 mg/m2 IV once on day 1
Chemotherapy
- Cyclophosphamide (Cytoxan) 600 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 25 mg/m2 IV once on day 1
- Etoposide (Vepesid) 100 mg/m2 IV once on day 1
- Prednisolone (Millipred) 40 mg/m2 PO once per day on days 1 to 5
28-day cycle for 6 cycles
Subsequent treatment
References
- FL2000: Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF, Haioun C, Brice P, Mahé B, Bouabdallah R, Audhuy B, Ferme C, Dartigeas C, Feugier P, Sebban C, Xerri L, Foussard C. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008 Dec 15;112(13):4824-31. Epub 2008 Sep 17. link to original article contains verified protocol PubMed NCT00136552
- Update: Bachy E, Houot R, Morschhauser F, Sonet A, Brice P, Belhadj K, Cartron G, Audhuy B, Fermé C, Feugier P, Sebban C, Delwail V, Maisonneuve H, Le Gouill S, Lefort S, Brousse N, Foussard C, Salles G; Groupe d'Etude des Lymphomes de l'Adulte. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica. 2013 Jul;98(7):1107-14. Epub 2013 May 3. link to original article link to PMC article PubMed
R-CVP
back to top |
R-CVP: Rituximab, Cyclophosphamide, Vincristine, Prednisone
Regimen variant #1, prednisone 40 mg/m2
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Marcus et al. 2004 | 2000-2002 | Phase 3 (E-RT-esc) | CVP | Superior TTP | Similar toxicity |
Salles et al. 2010 (PRIMAFL) | 2004-2007 | Non-randomized portion of RCT | |||
Federico et al. 2013 (FOLL05) | 2006-2010 | Phase 3 (E-de-esc) | 1. R-CHOP | Seems to have inferior PFS | See paper |
2. R-FM | Inferior PFS1 | See paper | |||
Morschhauser et al. 2018 (RELEVANCE) | 2011-2014 | Phase 3 (C) | Lenalidomide & Rituximab | Did not meet primary endpoints of CR rate/PFS | Different toxicity |
1Reported efficacy for this arm of FOLL05 is based on the 2017 update.
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
- Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1 to 5
21-day cycle for up to 8 cycles
Subsequent treatment
- PRIMA, responders (PR or CR): Rituximab maintenance versus no further treatment
- RELEVANCE, responders: Rituximab maintenance
Regimen variant #2, prednisone 100 mg/day
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Flinn et al. 2014 (BRIGHT) | 2009-2012 | Phase 3 (C) | BR | Seems to have non-inferior CR rate | |
Marcus et al. 2017 (GALLIUM) | 2011-2014 | Phase 3 (C) | See link | See link | See link |
Patients in BRIGHT were required to be treatment-naive with a need for treatment per any of the following: B symptoms, large tumor mass (lymphomas with a diameter greater than 3 cm in 3 or more regions or diameter greater than 7 cm in 1 region), presence of lymphoma-related complications, or hyperviscosity syndrome attributed to monoclonal gammopathy. Patients in GALLIUM received rituximab only in cycles 7 & 8.
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- BRIGHT: patients could receive 1000 mg/m2 IV once on day 1, instead
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
Supportive medications
- Antiemetics, antipyretics, and antibiotics per local standard of care
- G-CSF "according to the American Society of Clinical Oncology guidelines"
21-day cycle for up to 8 cycles
Subsequent treatment
- GALLIUM: Rituximab maintenance
Regimen variant #3, 3 cycles
Study | Years of enrollment | Evidence |
---|---|---|
Hainsworth et al. 2005a | 2000-2001 | Phase II |
Preceding treatment
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Chemotherapy
- Cyclophosphamide (Cytoxan) 1000 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
21-day cycle for 3 cycles
Subsequent treatment
References
- Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005 Mar 1;23(7):1500-6. Epub 2005 Jan 4. link to original article contains verified protocol PubMed
- Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005 Feb 15;105(4):1417-23. Epub 2004 Oct 19.link to original article contains protocol PubMed
- Update: Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, Wassner-Fritsch E, Stein G. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008 Oct 1;26(28):4579-86. Epub 2008 Jul 28. link to original article PubMed
- PRIMA: Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011 Jan 1;377(9759):42-51. Epub 2010 Dec 20. link to original article contains protocol PubMed NCT00140582
- QoL Analysis: Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;20(3):129-36. Epub 2014 Jul 16. link to original article PubMed
- Update: Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S, Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, Le Gouill S, Lister A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, Salles G. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. J Clin Oncol. 2019 Nov 1;37(31):2815-2824. link to original article link to PMC article PubMed
- FOLL05: Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, Di Raimondo F, Carella AM, Pulsoni A, Merli F, Arcaini L, Angrilli F, Stelitano C, Gaidano G, Dell'olio M, Marcheselli L, Franco V, Galimberti S, Sacchi S, Brugiatelli M. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013 Apr 20;31(12):1506-13. Epub 2013 Mar 25. Erratum in: J Clin Oncol. 2014 Apr 1;32(10):1095. Dosage error in article text. link to original article contains verified protocol PubMed NCT00774826
- Update: Luminari S, Ferrari A, Manni M, Dondi A, Chiarenza A, Merli F, Rusconi C, Tarantino V, Tucci A, Vitolo U, Kovalchuk S, Angelucci E, Pulsoni A, Arcaini L, Angrilli F, Gaidano G, Stelitano C, Bertoldero G, Cascavilla N, Salvi F, Ferreri AJM, Vallisa D, Marcheselli L, Federico M. Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol. 2018 Mar 1;36(7):689-696. Epub 2017 Nov 2. link to original article PubMed
- BRIGHT: Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. link to original article contains verified protocol link to PMC article PubMed NCT00877006
- Update: Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, Trotman J, Hallman D, Chen L, Burke JM. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019 Apr 20;37(12):984-991. Epub 2019 Feb 27. link to original article link to PMC article PubMed
- GALLIUM: Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331-1344. link to original article link to appendix contains verified protocol in appendix PubMed NCT01332968
- Update: Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018 Aug 10;36(23):2395-2404. Epub 2018 Jun 1. link to original article PubMed
- RELEVANCE: Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018 Sep 6;379(10):934-947. link to original article contains verified protocol in supplement PubMed NCT01650701
R-FM
back to top |
R-FM: Rituximab, Fludarabine, Mitoxantrone
FMR: Fludarabine, Mitoxantrone, Rituximab
Regimen variant #1, 4 cycles
Study | Evidence |
---|---|
Zinzani et al. 2011 | Phase II |
Chemotherapy
- Fludarabine (Fludara) 25 mg/m2 IV once per day on days 2 to 4
- Mitoxantrone (Novantrone) 10 mg/m2 IV once on day 2
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Supportive medications
- G-CSF as follows:
- Prophylaxis: None
- Grade 3 or 4 neutropenia or delayed neutropenic fever: could be given with subsequent cycles at physician discretion
28-day cycle for 4 cycles
Subsequent treatment
- Patients were restaged 2 to 3 weeks after finishing cycle 4. People with at least a partial response (PR), ANC greater than 1500/uL, platelet count greater than 100 x 109/L, and less than 25% bone marrow involvement were eligible for consolidation therapy with ibritumomab tiuxetan, given within 12 weeks (paper does not specify "within 12 weeks" of what)
Regimen variant #2, 8 cycles
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Federico et al. 2013 (FOLL05) | 2006-2010 | Phase 3 (E-switch-ic) | 1. R-CHOP | Did not meet primary endpoint of TTF |
2. R-CVP | Superior PFS1 |
1Reported efficacy for this arm of FOLL05 is based on the 2017 update.
Note: risk/benefit ratio was worse than R-CHOP.
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Chemotherapy
- Fludarabine (Fludara) as follows:
- Cycles 1 to 6: 25 mg/m2 IV once per day on days 1 to 3
- Mitoxantrone (Novantrone) as follows:
- Cycles 1 to 6: 10 mg/m2 IV once on day 1
21-day cycle for 8 cycles
References
- Zinzani PL, Tani M, Pulsoni A, De Renzo A, Stefoni V, Broccoli A, Montini GC, Fina M, Pellegrini C, Gandolfi L, Cavalieri E, Torelli F, Scopinaro F, Argnani L, Quirini F, Derenzini E, Rossi M, Pileri S, Fanti S, Baccarani M. A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. Ann Oncol. 2012 Feb;23(2):415-20. Epub 2011 May 2. link to original article contains verified protocol PubMed
- FOLL05: Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, Di Raimondo F, Carella AM, Pulsoni A, Merli F, Arcaini L, Angrilli F, Stelitano C, Gaidano G, Dell'olio M, Marcheselli L, Franco V, Galimberti S, Sacchi S, Brugiatelli M. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013 Apr 20;31(12):1506-13. Epub 2013 Mar 25. Erratum in: J Clin Oncol. 2014 Apr 1;32(10):1095. Dosage error in article text. link to original article contains verified protocol PubMed NCT00774826
- Update: Luminari S, Ferrari A, Manni M, Dondi A, Chiarenza A, Merli F, Rusconi C, Tarantino V, Tucci A, Vitolo U, Kovalchuk S, Angelucci E, Pulsoni A, Arcaini L, Angrilli F, Gaidano G, Stelitano C, Bertoldero G, Cascavilla N, Salvi F, Ferreri AJM, Vallisa D, Marcheselli L, Federico M. Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol. 2018 Mar 1;36(7):689-696. Epub 2017 Nov 2. link to original article PubMed
R-FND
back to top |
R-FND: Rituximab, Fludarabine, Novantrone (mitoxantrone), Dexamethasone
Regimen
Study | Evidence |
---|---|
Vitolo et al. 2013 (ML17638) | Non-randomized portion of RCT |
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Chemotherapy
- Fludarabine (Fludara) 25 mg/m2 IV once per day on days 2 to 4
- Mitoxantrone (Novantrone) 10 mg/m2 IV once on day 2
- Dexamethasone (Decadron) 10 mg (route not specified) once per day on days 2 to 4
1-month cycle for 4 cycles
Subsequent treatment
- Non-progressors: Rituximab consolidation
- Responders: Rituximab maintenance versus observation
References
- ML17638: Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F, Tucci A, Botto B, Chiappella A, Chiarenza A, Pinto A, De Renzo A, Zaja F, Castellino C, Bari A, Alvarez De Celis I, Evangelista A, Parvis G, Gamba E, Lobetti-Bodoni C, Ciccone G, Rossi G. Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. J Clin Oncol. 2013 Sep 20;31(27):3351-9. Epub 2013 Aug 19. link to original article contains verified protocol PubMed NCT01144364
- Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: results of a randomized study. Br J Haematol. 2017 Apr;177(2):263-270. Epub 2017 Mar 24. link to original article link to PMC article PubMed
R-MCP
back to top |
R-MCP: Rituximab, Mitoxantrone, Chlorambucil, Prednisolone
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Herold et al. 2007 (OSHO-39) | 1998-2003 | Phase 3 (E-esc) | MCP | Superior OS |
Note: the chlorambucil dose is written in the reference as "3 x 3 mg/m2"; total dose per day is 9 mg/m2.
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Chemotherapy
- Mitoxantrone (Novantrone) 8 mg/m2 IV once per day on days 3 & 4
- Chlorambucil (Leukeran) 3 mg/m2 PO three times per day on days 3 to 7
- Prednisolone (Millipred) 25 mg/m2 PO once per day on days 3 to 7
28-day cycle for up to 8 cycles
Subsequent treatment
- Patients who achieved a PR or CR: Interferon alfa-2a maintenance within 4 to 8 weeks of completion of chemotherapy
References
- OSHO-39: Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, Dölken G, Naumann R, Knauf W, Freund M, Rohrberg R, Höffken K, Franke A, Ittel T, Kettner E, Haak U, Mey U, Klinkenstein C, Assmann M, von Grünhagen U; East German Study Group Hematology and Oncology. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007 May 20;25(15):1986-92. Epub 2007 Apr 9. link to original article contains verified protocol PubMed NCT00269113
- Update: Herold M, Scholz CW, Rothmann F, Hirt C, Lakner V, Naumann R. Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma. J Cancer Res Clin Oncol. 2015 Sep;141(9):1689-95. Epub 2015 Mar 25. link to original article PubMed
Rituximab monotherapy
back to top |
Regimen variant #1, 4 doses
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Colombat et al. 2001 | 1997-1998 | Phase II | ||
Hainsworth et al. 2000 | 1998-1999 | Phase II | ||
Hainsworth et al. 2002 | 1998-1999 | Phase II | ||
Ghielmini et al. 2004 (SAKK 35/98) | 1998-2001 | Non-randomized portion of RCT | ||
Kahl et al. 2014 (RESORT) | 2003-2008 | Non-randomized portion of RCT | ||
Taverna et al. 2015 (SAKK 35/03) | 2004-2007 | Non-randomized portion of RCT | ||
Ardeshna et al. 2014 (CRUK-2004-001621-16) | 2004-2009 | Phase 3 (E-esc) | 1. Observation | Superior TTNT |
2. Rituximab induction, then Rituximab maintenance | Did not meet primary endpoint of TTNT | |||
Ogura et al. 2018 (CT-P10 3.4) | 2015-2018 | Phase 3 (C) | CT-P10 | Equivalent ORR |
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22
Supportive medications
- Acetaminophen (Tylenol) 650 mg PO once per day on days 1, 8, 15, 22; 30 minutes prior to Rituximab (Rituxan)
- Diphenhydramine (Benadryl) 50 mg PO once per day on days 1, 8, 15, 22; 30 minutes prior to Rituximab (Rituxan)
4-week course
Subsequent treatment
- Hainsworth et al. 2002 & CT-P10 3.4, SD or better: Rituximab maintenance
- SAKK 35/98, SD or better: Rituximab maintenance versus no further treatment
- RESORT, PR or CR: Indefinite rituximab maintenance versus salvage rituximab at time of progression
- SAKK 35/03, PR or CR: Rituximab maintenance x 9 mo versus Rituximab maintenance x 5 y
Regimen variant #2, 8 doses
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kimby et al. 2015 (NLG ML16865) | 2002-2008 | Phase 3 (C) | Rituximab & IFN-α2a | Did not meet primary endpoint of TTF |
Zucca et al. 2019 (SAKK 35/10) | 2011-2013 | Randomized Phase II (C) | Lenalidomide & Rituximab | Might have inferior CR/CRu rate |
Note: only patients achieving some degree of measurable response in NLG ML16865 proceeded to the 2nd course of rituximab.
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22
12-week cycle for 2 cycles
References
- Hainsworth JD, Burris HA 3rd, Morrissey LH, Litchy S, Scullin DC Jr, Bearden JD 3rd, Richards P, Greco FA. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 2000 May 15;95(10):3052-6. link to original article PubMed
- Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haïoun C, Foussard C, Sebban C, Stamatoullas A, Milpied N, Boué F, Taillan B, Lederlin P, Najman A, Thièblemont C, Montestruc F, Mathieu-Boué A, Benzohra A, Solal-Céligny P. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001 Jan 1;97(1):101-6. link to original article contains protocol PubMed
- Update: Colombat P, Brousse N, Salles G, Morschhauser F, Brice P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Tilly H, Thieblemont C, Bergougnoux L, Lazreg F, Solal-Celigny P. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. Ann Oncol. 2012 Sep;23(9):2380-5. Epub 2012 Jul 10. link to original article PubMed
- Hainsworth JD, Litchy S, Burris HA 3rd, Scullin DC Jr, Corso SW, Yardley DA, Morrissey L, Greco FA. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol. 2002 Oct 15;20(20):4261-7. link to original article contains protocol PubMed
- SAKK 35/98: Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004 Jun 15;103(12):4416-23. Epub 2004 Feb 19. link to original article contains protocol PubMed
- Update: Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S, Okkinga E, Stupp R, Stahel R, Heizmann M, Vorobiof D, Lohri A, Dietrich PY, Zucca E, Ghielmini M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010 Oct 10;28(29):4480-4. Epub 2010 Aug 9. link to original article contains verified protocol PubMed
- Meta-analysis: Vidal L, Gafter-Gvili A, Leibovici L, Dreyling M, Ghielmini M, Hsu Schmitz SF, Cohen A, Shpilberg O. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2009 Feb 18;101(4):248-55. Epub 2009 Feb 10. PubMed
- CRUK-2004-001621-16: Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, Cunningham D, Davies J, Jack A, Stephens R, Walewski J, Ferhanoglu B, Bradstock K, Linch DC. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014 Apr;15(4):424-35. Epub 2014 Mar 4. link to original article contains verified protocol PubMed NCT00112931
- RESORT: Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402. J Clin Oncol. 2014 Oct 1;32(28):3096-102. Epub 2014 Aug 25. link to original article contains verified protocol link to PMC article PubMed NCT00075946
- SAKK 35/10: Zucca E, Rondeau S, Vanazzi A, Østenstad B, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson AS, de Nully Brown P, Hagberg H, Ferreri AJM, Lohri A, Novak U, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei SB, Ghielmini M, Kimby E; Swiss Group for Clinical Cancer Research; Nordic Lymphoma Group. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood. 2019 Jul 25;134(4):353-362. Epub 2019 May 17. link to original article PubMed NCT01307605
- NLG ML16865: Kimby E, Östenstad B, Brown P, Hagberg H, Erlanson M, Holte H, Linden O, Johansson AS, Ahlgren T, Wader K, Wahlin BE, Delabie J, Sundström C; Nordic Lymphoma Group. Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. Leuk Lymphoma. 2015;56(9):2598-607. link to original article contains verified protocol PubMed NCT01609010
- Pooled Update: Lockmer S, Østenstad B, Hagberg H, Holte H, Johansson AS, Wahlin BE, Wader KF, Steen CB, Meyer P, Maisenhølder M, Smedby KE, Brown P, Kimby E. Chemotherapy-free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: results from two Nordic Lymphoma Group trials with more than 10 years of follow-up. J Clin Oncol. 2018 Nov 20;36(33):3315-23. Epub 2018 Oct 4. link to original article PubMed
- SAKK 35/03: Taverna C, Martinelli G, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Vanazzi A, Laszlo D, Raats J, Rauch D, Vorobiof DA, Lohri A, Biaggi Rudolf C, Rondeau S, Rusterholz C, Heijnen IA, Zucca E, Ghielmini M. Rituximab maintenance for a maximum of 5 years after single-agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III trial SAKK 35/03. J Clin Oncol. 2016 Feb 10;34(5):495-500. Epub 2015 Dec 28. link to original article contains verified protocol link to PMC article PubMed NCT00227695
- Update: Moccia AA, Taverna C, Schär S, Vanazzi A, Rondeau S, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Raats J, Rauch D, Vorobiof DA, Lohri A, Ruegsegger C, Biaggi Rudolf C, Rusterholz C, Hayoz S, Ghielmini M, Zucca E. Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. Blood Adv. 2020 Dec 8;4(23):5951-5957. link to original article link to PMC article PubMed
- CT-P10 3.4: Ogura M, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Tumyan G, Kim JS, Lennard A, Mariz J, Ilyin N, Jurczak W, Lopez Martinez A, Samoilova O, Zhavrid E, Yañez Ruiz E, Trneny M, Popplewell L, Coiffier B, Buske C, Kim WS, Lee SJ, Lee SY, Bae YJ, Kwak LW. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. Lancet Haematol. 2018 Nov;5(11):e543-e553. link to original article contains protocol PubMed NCT02260804
Advanced disease, first-line therapy, non-randomized or retrospective data
Bendamustine & Ofatumumab
back to top |
Regimen
Study | Evidence |
---|---|
Czuczman et al. 2015 (C18083-2048) | Phase II |
The subtypes of indolent lymphoma that this regimen was used for are not specified in the abstract. Given that follicular lymphoma is the most common indolent lymphoma, the regimen is included here.
Chemotherapy
- Bendamustine 90 mg/m2 IV once per day on days 1 & 2
Targeted therapy
- Ofatumumab (Arzerra) as follows:
- Cycle 1: 300 mg IV once on day 1, then 1000 mg IV once on day 8
- Cycle 2 onwards: 1000 mg IV once on day 1
28-day cycle for 6 cycles
References
- C18083-2048: Czuczman MS, Kahanic S, Forero A, Davis G, Munteanu M, Van Den Neste E, Offner F, Bron D, Quick D, Fowler N. Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma. Ann Hematol. 2015 Apr;94(4):633-41. Epub 2015 Jan 30. link to original article contains protocol PubMed NCT01108341
FR
back to top |
FR: Fludarabine & Rituximab
Regimen
Study | Evidence | Efficacy |
---|---|---|
Czuczman et al. 2005 | Phase II | ORR: 90% |
Chemotherapy
- Fludarabine (Fludara) as follows:
- Weeks 2, 6, 10, 14, 18, 22: 25 mg/m2 IV once per day on days 1 to 5
Targeted therapy
- Rituximab (Rituxan) as follows:
- Weeks 1 & 26: 375 mg/m2 IV once per day on days 1 & 4
- Weeks 6, 14, 22: 375 mg/m2 IV once 72 hours before day 1
26-week course
References
- Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005 Feb 1;23(4):694-704. link to original article contains verified protocol PubMed
Ibritumomab tiuxetan protocol
back to top |
Regimen variant #1
Study | Evidence |
---|---|
Scholz et al. 2013 | Phase II |
Ibatici et al. 2013 | Phase II |
Recruitment in Scholz et al. was limited to patients at least 50 years old due to radiation safety concerns; Ibatici et al. was open to all adult patients greater than 18 years old. Treatment regimen is identical.
Targeted therapy
- Rituximab (Rituxan) 250 mg/m2 IV once per day on days 1 & either day 8 or 9, given first on day 8 or 9
Radioconjugate therapy
- Ibritumomab tiuxetan & Yttrium-90 (Zevalin) 15 MBq/kg (maximum dose of 1200 MBq) IV once on day 8 or 9, given second
8- to 9-day course
Regimen variant #2, fractionated
Study | Evidence |
---|---|
Illidge et al. 2013 (FIZZ) | Phase II |
This regimen was for patients with less than or equal to 20% bone marrow involvement; others received induction rituximab, first. See paper for details.
Radioconjugate therapy
- Rituximab (Rituxan) 250 mg/m2 IV once per day on day 1 & either day 8 or 9, given first on day 8 or 9
- Ibritumomab tiuxetan & Yttrium-90 (Zevalin) 11.1 MBq/kg (maximum dose of 888 MBq) IV once on either day 8 or 9, given second
8- to 12-week cycle for 2 cycles
References
- Scholz CW, Pinto A, Linkesch W, Lindén O, Viardot A, Keller U, Hess G, Lastoria S, Lerch K, Frigeri F, Arcamone M, Stroux A, Frericks B, Pott C, Pezzutto A. 90Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol. 2013 Jan 20;31(3):308-13. Epub 2012 Dec 10. link to original article contains verified protocol PubMed NCT00772655
- FIZZ: Illidge TM, Mayes S, Pettengell R, Bates AT, Bayne M, Radford JA, Ryder WD, Le Gouill S, Jardin F, Tipping J, Zivanovic M, Kraeber-Bodere F, Bardies M, Bodet-Milin C, Malek E, Huglo D, Morschhauser F. Fractionated 90Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria. J Clin Oncol. 2014 Jan 20;32(3):212-8. Epub 2013 Dec 2. link to original article contains verified protocol PubMed NCT01493479
- Ibatici A, Pica GM, Nati S, Vitolo U, Botto B, Ciochetto C, Petrini M, Galimberti S, Ciabatti E, Orciuolo E, Zinzani PL, Cascavilla N, Guolo F, Fraternali Orcioni G, Carella AM. Safety and efficacy of (90) Yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients: an Italian cooperative study. Br J Haematol. 2014 Mar;164(5):710-6. Epub 2013 Dec 17. link to original article contains verified protocol PubMed
O-CHOP
back to top |
O-CHOP: Ofatumumab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone
Regimen
Study | Evidence |
---|---|
Czuczman et al. 2012 (MUNIN) | Phase II |
Note: both 500 mg and 1000 mg doses of ofatumumab were tested, but since there was no increase in toxicity in patients receiving the 1000 mg dose, the 1000 mg dose was chosen for future ofatumumab trials "to avoid underdosing patients"
Targeted therapy
- Ofatumumab (Arzerra) as follows:
- Cycle 1: 300 mg IV once on day 1
- Cycles 2 to 6: 1000 mg IV once on day 1
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 3
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 3
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 3
- Prednisone (Sterapred) 100 mg PO once per day on days 3 to 7
Supportive medications
- Acetaminophen (Tylenol) 1000 mg (no route specified) before each dose of Ofatumumab (Arzerra)
- Cetirizine (Zyrtec) 10 mg (or equivalent) PO before each dose of Ofatumumab (Arzerra)
- Prednisolone (Millipred) (or equivalent) 100 mg before dose 1 and 2 of Ofatumumab (Arzerra)
21-day cycle for 6 cycles
References
- MUNIN: Czuczman MS, Hess G, Gadeberg OV, Pedersen LM, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Strange C, Windfeld K, Viardot A; 409 Study Investigators. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Br J Haematol. 2012 May;157(4):438-45. Epub 2012 Mar 13. link to original article contains verified protocol PubMed NCT00494780
PCR
back to top |
PCR: Pentostatin, Cyclophosphamide, Rituximab
Regimen
Study | Evidence |
---|---|
Samaniego et al. 2015 (MDACC 2004-0818) | Phase II |
Chemotherapy
- Pentostatin (Nipent) 4 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 600 mg/m2 IV once on day 1
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Supportive medications
- Ondansetron (Zofran) 8 mg (route not specified) prior to chemo
- Diphenhydramine (Benadryl) 25 mg (route not specified) prior to chemo
- 500 ml of 5% dextrose/one-half normal saline before and after each pentostatin dose
- Filgrastim (Neupogen) at the discretion of the treating physician
- Cycle 1: Allopurinol (Zyloprim) 300 mg PO once per day on days 1 to 15
- Trimethoprim-Sulfamethoxazole (Bactrim DS) once per day three days per week during and for 1 month following therapy
- Acyclovir (Zovirax) 400 mg PO twice per day during and for 1 month following therapy
21-day cycle for 6 cycles
References
- MDACC 2004-0818: Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol. 2015 Jun;169(6):814-23. Epub 2015 Mar 31. link to original article contains verified protocol link to PMC article PubMed NCT00496873
- Update: Khashab T, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Vega F, Kwak LW, Samaniego F. Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. Br J Haematol. 2019 May;185(4):670-678. Epub 2019 Feb 28. link to original article PubMed
R-CMD
back to top |
R-CMD: Rituximab, Cladribine, Mitoxantrone, Dexamethasone
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Sakai et al. 2015 | 2008-2011 | Phase II |
Note: the dose of dexamethasone in the manuscript text as well as the accompanying table is listed as 8 mg/body. It is unclear to us what this means.
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Chemotherapy
- Cladribine (Leustatin) 0.10 mg/kg IV once per day on days 1 to 3
- Mitoxantrone (Novantrone) 8 mg/m2 IV once on day 1
- Dexamethasone (Decadron) 8 mg/body (route not specified) on days 1 to 3
21-day cycle for 4 cycles
Subsequent treatment
References
- Sakai T, Masaki Y, Otsuki N, Sakamaki I, Kishi S, Miyazono T, Urasaki Y, Murakami J, Satoh T, Nakamura T, Iwao H, Nakajima A, Kawanami T, Miki M, Fujita Y, Tanaka M, Fukushima T, Okazaki T, Ueda T; Hokuriku Hematology Oncology Study Group. Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group. Med Oncol. 2015 Sep;32(9):232. link to original article contains verified protocol link to PMC article PubMed
R-FCM
back to top |
R-FCM: Rituximab, Fludarabine, Cyclophosphamide, Mitoxantrone
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Salles et al. 2010 (PRIMAFL) | 2004-2007 | Non-randomized portion of RCT |
Targeted therapy
- Rituximab (Rituxan) as follows:
- Cycles 1, 3, 5, 6: 375 mg/m2 IV once on day 1
- Cycles 2 & 4: 375 mg/m2 IV once per day on days 1 & 15
Chemotherapy
- Fludarabine (Fludara) 25 mg/m2 IV once per day on days 1 to 3
- Cyclophosphamide (Cytoxan) 200 mg/m2 PO once per day on days 1 to 3
- Mitoxantrone (Novantrone) 6 mg/m2 IV once on day 1
28-day cycle for 6 cycles
Subsequent treatment
- Responders (PR or CR): Rituximab maintenance versus no further treatment
References
- PRIMA: Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011 Jan 1;377(9759):42-51. Epub 2010 Dec 20. link to original article contains protocol PubMed NCT00140582
- QoL Analysis: Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;20(3):129-36. Epub 2014 Jul 16. link to original article PubMed
- Update: Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S, Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, Le Gouill S, Lister A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, Salles G. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. J Clin Oncol. 2019 Nov 1;37(31):2815-2824. link to original article link to PMC article PubMed
VR
back to top |
VR: Velcade (Bortezomib) & Rituximab
Regimen
Study | Evidence |
---|---|
Evens et al. 2014 (NU 06H1) | Phase II |
Targeted therapy
- Bortezomib (Velcade) 1.6 mg/m2 IV once per day on days 1, 8, 15, 22
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days 1, 8, 15, 22
- Cycles 2 & 3: 375 mg/m2 IV once on day 1
35-day cycle for 3 cycles
Subsequent treatment
References
- NU 06H1: Evens AM, Smith MR, Lossos IS, Helenowski I, Millenson M, Winter JN, Rosen ST, Gordon LI. Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-hodgkin lymphoma: a multicentre phase II study. Br J Haematol. 2014 Aug;166(4):514-20. Epub 2014 Apr 25. link to original article contains verified protocol PubMed NCT00369707
VR-CHOP
back to top |
VR-CHOP: Velcade (Bortezomib) Rituximab, Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Predniso(lo)ne
Regimen
Study | Evidence |
---|---|
Cohen et al. 2015 (X05215) | Phase II |
The largest group of patients studied in this trial had follicular lymphoma. Note the decreased cap on vincristine.
Targeted therapy
- Bortezomib (Velcade) 1.6 mg/m2 IV once per day on days 1 & 8
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 1.5 mg) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
21-day cycle for up to 8 cycles
Subsequent treatment
- Patients with CR: Rituximab maintenance
- Patients with SD/PR: VR maintenance
References
- X05215: Cohen JB, Switchenko JM, Koff JL, Sinha R, Kaufman JL, Khoury HJ, Bumpers N, Colbert A, Hutchison-Rzepka A, Nastoupil LJ, Heffner LT, Langston AA, Lechowicz MJ, Lonial S, Flowers CR. A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. Br J Haematol. 2015 Nov;171(4):539-46. Epub 2015 Aug 7. link to original article contains protocol link to PMC article PubMed NCT00634179
Consolidation after first-line therapy
Note: consolidation here is defined as any regimen with an intended length of treatment of 12 months or less.
Ibritumomab tiuxetan protocol
back to top |
An abstract presented at ASH 2013 from the ZAR2007 trial has preliminary results that R-CHOP followed by Zevalin is inferior to R-CHOP followed by rituximab maintenance; detailed results are not yet available and therefore only the reference is provided, here.
Regimen variant #1
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Morschhauser et al. 2008 (FIT) | 2001-2005 | Phase 3 (E-RT-esc) | Observation | Superior PFS |
Preceding treatment
- First-line therapy (most received CHOP or CVP; some received "CHOP-like", "rituximab combination", "fludarabine combination", or chlorambucil), with PR/CR
Targeted therapy
- Rituximab (Rituxan) 250 mg/m2 IV once per day on days 1 & 8, given first on day 8
Radioconjugate therapy
- Ibritumomab tiuxetan & Yttrium-90 (Zevalin) 14.8 MBq/kg (maximum dose of 1184 MBq) IV over 10 minutes once on day 8, given second
8-day course
Regimen variant #2
Study | Evidence | Efficacy |
---|---|---|
Zinzani et al. 2011 | Phase II | ORR: 89% |
Preceding treatment
Radioconjugate therapy
- Rituximab (Rituxan) 250 mg/m2 IV once per day on days 1 & 8 +/- 1 day (total dose: 500 mg/m2)
- Ibritumomab tiuxetan & Yttrium-90 (Zevalin) given immediately following second dose of rituximab, as follows:
- Platelet count greater than 150 x 109/L: 14.8 MBq/kg (maximum dose of 1184 MBq) IV over 10 minutes once on day 8
- Platelet count of 100 to 149 x 109/L: 11.1 MBq/kg (maximum dose of 1184 MBq) IV over 10 minutes once on day 8
8-day course
Regimen variant #3
Study | Years of enrollment | Evidence |
---|---|---|
Hainsworth et al. 2009 | NR in abstract | Phase II |
See text for further information about Zevalin eligbility criteria. If patient did not meet criteria within 7 weeks after final R-CHOP, Zevalin was omitted.
Preceding treatment
- R-CHOP x 3
Radioconjugate therapy
- Ibritumomab tiuxetan & Yttrium-90 (Zevalin) 0.4 mCi/kg
- Dose reduced to 0.3 mCi/kg if platelet count 100 to 149 x 109/L)
8-day course
Regimen variant #4
Study | Evidence | Efficacy |
---|---|---|
Zinzani et al. 2008 (FLUMIZ) | Phase II | ORR: 98% |
Preceding treatment
Radioconjugate therapy
- Rituximab (Rituxan) 250 mg/m2 IV once per day on days 1 & 8 +/- 1 day (total dose: 500 mg/m2)
- Ibritumomab tiuxetan & Yttrium-90 (Zevalin) given immediately following second dose of rituximab, as follows:
- Platelet count greater than 150 x 109/L: 14.8 MBq/kg (maximum dose of 1184 MBq) IV over 10 minutes once on day 8
- Platelet count of 100 to 149 x 109/L: 11.1 MBq/kg (maximum dose of 1184 MBq) IV over 10 minutes once on day 8
8-day course
Regimen variant #5
Study | Years of enrollment | Evidence | Efficacy |
---|---|---|---|
Jacobs et al. 2008 (UPCI 03-005) | 2004-2007 | Phase II | ORR: 89% |
Preceding treatment
- R-CHOP x 3
Radioconjugate therapy
- Rituximab (Rituxan) 250 mg/m2 IV once per day on days 1 & 8
- Ibritumomab tiuxetan & Yttrium-90 (Zevalin) 0.4 mCi/kg (15 MBq/kg) (maximum dose of 32 mCi/1.2 GBq) IV over 10 minutes once on day 8, given immediately following rituximab
8-day course, followed in 1 to 2 weeks by:
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22
28-day course
Regimen variant #6
Study | Evidence | Efficacy |
---|---|---|
Provencio et al. 2013 | Phase II | ORR: 93% |
To be completed; further details are not available in the abstract.
Preceding treatment
Radioconjugate therapy
References
- FLUMIZ: Zinzani PL, Tani M, Pulsoni A, Gobbi M, Perotti A, De Luca S, Fabbri A, Zaccaria A, Voso MT, Fattori P, Guardigni L, Ronconi S, Cabras MG, Rigacci L, De Renzo A, Marchi E, Stefoni V, Fina M, Pellegrini C, Musuraca G, Derenzini E, Pileri S, Fanti S, Piccaluga PP, Baccarani M. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol. 2008 Apr;9(4):352-8. Epub 2008 Mar 14. link to original article contains verified protocol PubMed EudraCT 2004-002211-92
- FIT: Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008 Nov 10;26(32):5156-64. Epub 2008 Oct 14. link to original article contains protocol PubMed NCT00185393
- Update: Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, Soubeyran P, Tilly H, Bischof-Delaloye A, van Putten WL, Kylstra JW, Hagenbeek A. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III First-Line Indolent Trial. J Clin Oncol. 2013 Jun 1;31(16):1977-83. Epub 2013 Apr 1. link to original article contains protocol PubMed
- UPCI 03-005: Jacobs SA, Swerdlow SH, Kant J, Foon KA, Jankowitz R, Land SR, DeMonaco N, Joyce J, Osborn JL, Evans TL, Schaefer PM, Luong TM. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res. 2008 Nov 1;14(21):7088-94. link to original article contains verified protocol PubMed NCT00177554
- Hainsworth JD, Spigel DR, Markus TM, Shipley D, Thompson D, Rotman R, Dannaher C, Greco FA. Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma. 2009 Jun;9(3):223-8. link to original article contains verified protocol PubMed
- Zinzani PL, Tani M, Pulsoni A, De Renzo A, Stefoni V, Broccoli A, Montini GC, Fina M, Pellegrini C, Gandolfi L, Cavalieri E, Torelli F, Scopinaro F, Argnani L, Quirini F, Derenzini E, Rossi M, Pileri S, Fanti S, Baccarani M. A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. Ann Oncol. 2012 Feb;23(2):415-20. Epub 2011 May 2. link to original article contains verified protocol PubMed
- Provencio M, Cruz Mora MÁ, Gómez-Codina J, Quero Blanco C, Llanos M, García-Arroyo FR, de la Cruz L, Gumá Padró J, Delgado Pérez JR, Sánchez A, Alvarez Cabellos R, Rueda A; GOTEL. Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group. Leuk Lymphoma. 2014 Jan;55(1):51-5. Epub 2013 Jun 12. link to original article PubMed
- Abstract: Armando Lopez-Guillermo, MD, PhD, Miguel A. Canales, MD, PhD, Ivan Dlouhy, Javier Briones, MD, Dolores Caballero, MD, PhD, Juan Manuel Sancho Sr., MD, Santiago Mercadal Vilchez, MD, Jose María Moraleda, MD, María José Terol, MD, PhD, Antonio Salar, MD, Luis Palomera, MD, Santiago Gardella, MD, Isidro Jarque, MD, Secundino Ferrer, Joan Bargay, MD, Andres Lopez, Carlos Panizo, Anna Muntanola, MD, Carlos Montalban, Eulogio Conde, MD, PhD, Miguel Hernandez, MD, Alfons Soler, Julian Marin, MD, Jose García Marco, Guillermo Deben and José Francisco Tomas, MD, PhD. A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization. Blood 2013 122:369. link to abstract NCT00662948
Observation
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hagenbeek et al. 1998 | 1985-1992 | Phase 3 (C) | Interferon alfa | Might have inferior TTP |
Fisher et al. 2000 (SWOG S8809) | 1988-1994 | Phase 3 (C) | Interferon alfa | Did not meet primary endpoints of PFS/OS |
Ghielmini et al. 2004 (SAKK 35/98) | 1998-2001 | Phase 3 (C) | Rituximab | Seems to have inferior EFS |
Morschhauser et al. 2008 (FIT) | 2001-2005 | Phase 3 (C) | Ibritumomab tiuxetan | Inferior PFS |
Hochster et al. 2009 (ECOG E1496) | NR | Phase 3 (C) | Rituximab | Inferior PFS |
Salles et al. 2010 (PRIMAFL) | 2004-2007 | Phase 3 (C) | Rituximab | Inferior PFS |
Vitolo et al. 2013 (ML17638) | 2004-2007 | Phase 3 (C) | Rituximab | Did not meet primary endpoint of PFS |
No further treatment after induction therapy.
Preceding treatment
- SAKK 35/98: R x 4
- FIT: First-line therapy (most received CHOP or CVP; some received "CHOP-like", "rituximab combination", "fludarabine combination", or chlorambucil), with PR/CR
- ECOG E1496: CVP x 6 to 8
- PRIMAFL: R-CHOP or R-CVP or R-FCM
- ML17638: R-FND x 4
References
- Hagenbeek A, Carde P, Meerwaldt JH, Somers R, Thomas J, De Bock R, Raemaekers JM, van Hoof A, De Wolf-Peeters C, van Glabbeke M; EORTC Lymphoma Cooperative Group. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol. 1998 Jan;16(1):41-7. link to original article PubMed
- SWOG S8809: Fisher RI, Dana BW, LeBlanc M, Kjeldsberg C, Forman JD, Unger JM, Balcerzak SP, Gaynor ER, Roy V, Miller T. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol. 2000 May;18(10):2010-6. link to original article PubMed
- SAKK 35/98: Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004 Jun 15;103(12):4416-23. Epub 2004 Feb 19. link to original article contains protocol PubMed
- Update: Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S, Okkinga E, Stupp R, Stahel R, Heizmann M, Vorobiof D, Lohri A, Dietrich PY, Zucca E, Ghielmini M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010 Oct 10;28(29):4480-4. Epub 2010 Aug 9. link to original article contains verified protocol PubMed
- FIT: Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008 Nov 10;26(32):5156-64. Epub 2008 Oct 14. link to original article contains protocol PubMed NCT00185393
- Update: Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, Soubeyran P, Tilly H, Bischof-Delaloye A, van Putten WL, Kylstra JW, Hagenbeek A. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III First-Line Indolent Trial. J Clin Oncol. 2013 Jun 1;31(16):1977-83. Epub 2013 Apr 1. link to original article contains protocol PubMed
- ECOG E1496: Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, Zhang L, Colocci N, Frankel S, Horning SJ. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009 Apr 1;27(10):1607-14. Epub 2009 Mar 2. link to original article contains verified protocol link to PMC article PubMed NCT00003204
- Update: Barta SK, Li H, Hochster HS, Hong F, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Colocci N, Bengtson EM, Horning SJ, Kahl BS. Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer. 2016 Oct;122(19):2996-3004. Epub 2016 Jun 28. link to original article link to PMC article PubMed
- PRIMA: Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011 Jan 1;377(9759):42-51. Epub 2010 Dec 20. link to original article contains protocol PubMed NCT00140582
- QoL Analysis: Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;20(3):129-36. Epub 2014 Jul 16. link to original article PubMed
- Update: Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S, Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, Le Gouill S, Lister A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, Salles G. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. J Clin Oncol. 2019 Nov 1;37(31):2815-2824. link to original article link to PMC article PubMed
- ML17638: Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F, Tucci A, Botto B, Chiappella A, Chiarenza A, Pinto A, De Renzo A, Zaja F, Castellino C, Bari A, Alvarez De Celis I, Evangelista A, Parvis G, Gamba E, Lobetti-Bodoni C, Ciccone G, Rossi G. Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. J Clin Oncol. 2013 Sep 20;31(27):3351-9. Epub 2013 Aug 19. link to original article contains verified protocol PubMed NCT01144364
Rituximab monotherapy, abbreviated course
back to top |
Consolidation or maintenance regimens of less than one year duration or less than 12 total doses.
Regimen variant #1, 2 doses in 2 weeks
Study | Years of enrollment | Evidence |
---|---|---|
Hainsworth et al. 2005a | 2000-2001 | Phase II |
Counting from the beginning, this is given in weeks 14 & 15.
Preceding treatment
- Rituximab pre-phase x 4, then R-CHOP x 3
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1 & 8
14-day course
Regimen variant #2, 4 doses in 4 weeks
Study | Years of enrollment | Evidence |
---|---|---|
Rambaldi et al. 2002 | NR | Phase II |
Hainsworth et al. 2002 | 1998-1999 | Phase II |
Ladetto et al. 2008 (GITMO 3320) | 2000-2005 | Non-randomized portion of RCT |
Preceding treatment
- Rambaldi et al. 2002 & GITMO 3320: CHOP x 6
- Hainsworth et al. 2002: Rituximab
- Zinzani et al. 2004: CHOP x 6 versus FM x 6
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22
Supportive medications
- Acetaminophen (Tylenol) 650 mg PO once per day on days 1, 8, 15, 22; 30 minutes prior to Rituximab (Rituxan)
- Diphenhydramine (Benadryl) 50 mg PO once per day on days 1, 8, 15, 22; 30 minutes prior to Rituximab (Rituxan)
4-week course
Regimen variant #3, 4 doses in 4 months
Study | Years of enrollment | Evidence |
---|---|---|
Sakai et al. 2015 | 2008-2011 | Phase II |
Preceding treatment
- R-CMD x 4
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
28-day cycle for 4 cycles
Regimen variant #4, 8 doses in 8 months
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Vitolo et al. 2013 (ML17638) | 2004-2007 | Phase 3 (E-esc) | Observation | Did not meet primary endpoint of PFS |
Preceding treatment
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
2-month cycle for 4 cycles
Regimen variant #5, 8 doses in 9 months
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Ghielmini et al. 2004 (SAKK 35/98) | 1998-2001 | Phase 3 (E-esc) | Observation | Seems to have superior EFS |
Taverna et al. 2015 (SAKK 35/03) | 2004-2007 | Phase 3 (C) | Rituximab x 5 y | Did not meet primary endpoint of EFS |
Note: maintenance treatment begins in week 12.
Preceding treatment
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
2-month cycle for 4 cycles
References
- Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, Barbui T, Bernasconi C, Dastoli G, Fuga G, Gamba E, Gargantini L, Gattei V, Lauria F, Lazzarino M, Mandelli F, Morra E, Pulsoni A, Ribersani M, Rossi-Ferrini PL, Rupolo M, Tura S, Zagonel V, Zaja F, Zinzani P, Reato G, Foa R. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood. 2002 Feb 1;99(3):856-62. link to original article contains verified protocol PubMed
- Hainsworth JD, Litchy S, Burris HA 3rd, Scullin DC Jr, Corso SW, Yardley DA, Morrissey L, Greco FA. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol. 2002 Oct 15;20(20):4261-7. link to original article contains protocol PubMed
- SAKK 35/98: Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004 Jun 15;103(12):4416-23. Epub 2004 Feb 19. link to original article contains protocol PubMed
- Update: Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S, Okkinga E, Stupp R, Stahel R, Heizmann M, Vorobiof D, Lohri A, Dietrich PY, Zucca E, Ghielmini M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010 Oct 10;28(29):4480-4. Epub 2010 Aug 9. link to original article contains verified protocol PubMed
- Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005 Mar 1;23(7):1500-6. Epub 2005 Jan 4. link to original article contains verified protocol PubMed
- GITMO 3320: Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C; GITMO; Intergruppo Italiano Linfomi. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008 Apr 15;111(8):4004-13. Epub 2008 Jan 31. link to original article contains protocol PubMed NCT00435955
- ML17638: Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F, Tucci A, Botto B, Chiappella A, Chiarenza A, Pinto A, De Renzo A, Zaja F, Castellino C, Bari A, Alvarez De Celis I, Evangelista A, Parvis G, Gamba E, Lobetti-Bodoni C, Ciccone G, Rossi G. Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. J Clin Oncol. 2013 Sep 20;31(27):3351-9. Epub 2013 Aug 19. link to original article contains verified protocol PubMed NCT01144364
- Sakai T, Masaki Y, Otsuki N, Sakamaki I, Kishi S, Miyazono T, Urasaki Y, Murakami J, Satoh T, Nakamura T, Iwao H, Nakajima A, Kawanami T, Miki M, Fujita Y, Tanaka M, Fukushima T, Okazaki T, Ueda T; Hokuriku Hematology Oncology Study Group. Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group. Med Oncol. 2015 Sep;32(9):232. link to original article contains verified protocol link to PMC article PubMed
- SAKK 35/03: Taverna C, Martinelli G, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Vanazzi A, Laszlo D, Raats J, Rauch D, Vorobiof DA, Lohri A, Biaggi Rudolf C, Rondeau S, Rusterholz C, Heijnen IA, Zucca E, Ghielmini M. Rituximab maintenance for a maximum of 5 years after single-agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III trial SAKK 35/03. J Clin Oncol. 2016 Feb 10;34(5):495-500. Epub 2015 Dec 28. link to original article contains verified protocol link to PMC article PubMed NCT00227695
- Update: Moccia AA, Taverna C, Schär S, Vanazzi A, Rondeau S, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Raats J, Rauch D, Vorobiof DA, Lohri A, Ruegsegger C, Biaggi Rudolf C, Rusterholz C, Hayoz S, Ghielmini M, Zucca E. Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. Blood Adv. 2020 Dec 8;4(23):5951-5957. link to original article link to PMC article PubMed
VR
back to top |
VR: Velcade (Bortezomib) & Rituximab
Regimen
Study | Evidence |
---|---|
Evens et al. 2014 (NU 06H1) | Phase II |
Preceding treatment
Targeted therapy
- Bortezomib (Velcade) 1.6 mg/m2 IV once on day 1
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
2-month cycle for 4 cycles
References
- NU 06H1: Evens AM, Smith MR, Lossos IS, Helenowski I, Millenson M, Winter JN, Rosen ST, Gordon LI. Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-hodgkin lymphoma: a multicentre phase II study. Br J Haematol. 2014 Aug;166(4):514-20. Epub 2014 Apr 25. link to original article contains verified protocol PubMed NCT00369707
Maintenance after first-line therapy
Lenalidomide & Rituximab (R2)
back to top |
R2: Rituximab & Revlimid (Lenalidomide)
Regimen
Study | Evidence |
---|---|
Morschhauser et al. 2018 (RELEVANCE) | Non-randomized portion of RCT |
Preceding treatment
Targeted therapy
- Lenalidomide (Revlimid) 10 mg PO once per day
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
8-week cycle for 12 cycles
References
- RELEVANCE: Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018 Sep 6;379(10):934-947. link to original article contains verified protocol PubMed NCT01650701
Obinutuzumab monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Marcus et al. 2017 (GALLIUM) | 2011-2014 | Phase 3 (E-RT-switch-ic) | See link | See link | See link |
Preceding treatment
Targeted therapy
- Obinutuzumab (Gazyva) 1000 mg IV once on day 1
2-month cycle for 12 cycles
References
- GALLIUM: Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331-1344. link to original article link to appendix contains verified protocol in appendix PubMed NCT01332968
- Update: Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018 Aug 10;36(23):2395-2404. Epub 2018 Jun 1. link to original article PubMed
Placebo
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Freedman et al. 2009 | 2004-2006 | Phase 3 (C) | Mitumprotimut-T & GM-CSF | Seems to have superior TTP |
No active antineoplastic treatment.
Preceding treatment
- Rituximab x 4
References
- Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol. 2009 Jun 20;27(18):3036-43. Epub 2009 May 4. link to original article link to PMC article PubMed
Rituximab monotherapy, extended course
back to top |
Maintenance regimens of one to two years duration or 12 to 16 total doses.
Regimen variant #1, q8wk cycles
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Salles et al. 2010 (PRIMAFL) | 2004-2007 | Phase 3 (E-RT-esc) | Observation | Superior PFS |
Davies et al. 2017 (SABRINA) | 2011-2013 | Phase 3 (C) | SC Rituximab | Similar efficacy |
Starts 8 weeks after the last induction treatment.
Preceding treatment
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
8-week cycle for 12 cycles
Regimen variant #2, q6mo cycles
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hochster et al. 2009 (ECOG E1496) | NR | Phase 3 (E-RT-esc) | Observation | Superior PFS |
Preceding treatment
- CVP x 6 to 8 cycles
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22
6-month cycle for 4 cycles (2 years)
Regimen variant #3
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Ardeshna et al. 2014 (CRUK-2004-001621-16) | 2004-2009 | Phase 3 (E-esc) | 1. Observation | Superior TTNT |
2. Rituximab induction, no maintenance | Did not meet primary endpoint of TTNT |
Preceding treatment
Targeted therapy
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days 1, 8, 15, 22
- Cycles 2 to 13: 375 mg/m2 IV once on day 1
28-day cycle for 1 cycle, then 2-month cycle for 12 cycles
Regimen variant #4
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Rummel et al. 2014 (MAINTAIN) | 2009-2012 | Phase 3 (C) | Rituximab x 4y | TBD | |
Witzens-Harig et al. 2014 (MAXIMA) | 2006-NR | Non-randomized | |||
Marcus et al. 2017 (GALLIUM) | 2011-2014 | Phase 3 (C) | See link | See link | See link |
Preceding treatment
- MAINTAIN: BR x 6 and 2 doses of rituximab
- MAXIMA: Rituximab monotherapy or rituximab and chemotherapy (Most patients, 62%, received an anthracycline-based regimen)
- GALLIUM: BR x 6 or R-CHOP x 8 or R-CVP x 8
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
2-month cycle for 12 cycles (2 years)
References
- Meta-analysis: Vidal L, Gafter-Gvili A, Leibovici L, Dreyling M, Ghielmini M, Hsu Schmitz SF, Cohen A, Shpilberg O. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2009 Feb 18;101(4):248-55. Epub 2009 Feb 10. PubMed
- ECOG E1496: Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, Zhang L, Colocci N, Frankel S, Horning SJ. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009 Apr 1;27(10):1607-14. Epub 2009 Mar 2. link to original article contains verified protocol link to PMC article PubMed NCT00003204
- Update: Barta SK, Li H, Hochster HS, Hong F, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Colocci N, Bengtson EM, Horning SJ, Kahl BS. Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer. 2016 Oct;122(19):2996-3004. Epub 2016 Jun 28. link to original article link to PMC article PubMed
- PRIMA: Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011 Jan 1;377(9759):42-51. Epub 2010 Dec 20. link to original article contains protocol PubMed NCT00140582
- QoL Analysis: Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;20(3):129-36. Epub 2014 Jul 16. link to original article PubMed
- Update: Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S, Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, Le Gouill S, Lister A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, Salles G. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. J Clin Oncol. 2019 Nov 1;37(31):2815-2824. link to original article link to PMC article PubMed
- CRUK-2004-001621-16: Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, Cunningham D, Davies J, Jack A, Stephens R, Walewski J, Ferhanoglu B, Bradstock K, Linch DC. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014 Apr;15(4):424-35. Epub 2014 Mar 4. link to original article contains verified protocol PubMed NCT00112931
- MAXIMA: Witzens-Harig M, Foá R, Di Rocco A, van Hazel G, Chamone DF, Rowe JM, Arcaini L, Poddubnaya I, Ho AD, Ivanova V, Vranovsky A, Thurley D, Oertel S. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study. Ann Hematol. 2014 Oct;93(10):1717-24. Epub 2014 May 14. Erratum in: Ann Hematol. 2014 Oct;93(10):1807. link to original article contains verified protocol PubMed NCT00430352
- Abstract: Mathias J. Rummel, MD, Andreas Viardot, Richard Greil, MD, Bernd Hertenstein, MD, Christian Lerchenmüller, MD, Arnold Ganser, Manfred Reeb, MD, Ulrich Kaiser, MD, Christina Balser, MD, Georg Maschmeyer, MD, Heinz Dürk, MD, Georg Schliesser, MD, Tobias Gaska, MD, Jan Dürig, MD, Axel C. Matzdorff, MD, Rudolf Weide, MD, Axel Hinke, PhD, Wolfgang Blau, MD, Alexander Burchardt, MD, Frank Kauff, PhD, Jürgen Barth and Wolfram Brugger, MD. Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214). Blood 2014 124:3052. link to abstract NCT00877214
- SABRINA: Davies A, Merli F, Mihaljević B, Mercadal S, Siritanaratkul N, Solal-Céligny P, Boehnke A, Berge C, Genevray M, Zharkov A, Dixon M, Brewster M, Barrett M, MacDonald D. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017 Jun;4(6):e272-e282. Epub 2017 May 2. link to original article does not contain protocol PubMed NCT01200758
- GALLIUM: Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331-1344. link to original article link to appendix contains verified protocol in appendix PubMed NCT01332968
- Update: Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018 Aug 10;36(23):2395-2404. Epub 2018 Jun 1. link to original article PubMed
Rituximab monotherapy, very extended course
back to top |
Maintenance regimens of more than two years duration.
Regimen variant #1, 4 years
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Rummel et al. 2014 (MAINTAIN) | 2009-2012 | Phase 3 (E-esc) | Rituximab x 2 y | TBD |
Preceding treatment
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
2-month cycle for 24 cycles (4 years)
Regimen variant #2, 5 years
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Taverna et al. 2015 (SAKK 35/03) | 2004-2007 | Phase 3 (E-esc) | Rituximab x 9 mo | Did not meet primary endpoint of EFS |
Preceding treatment
Targeted therapy
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days 1, 8, 15, 22
- Cycles 2 to 30: 375 mg/m2 IV once on day 1
2-month cycle for up to 30 cycles (5 years)
Regimen variant #3, indefinite
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kahl et al. 2014 (RESORT) | 2003-2008 | Phase 3 (E-esc) | Rituximab; salvage | Did not meet primary endpoint of TTF |
Preceding treatment
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
13-week cycles
References
- Abstract: Mathias J. Rummel, MD, Andreas Viardot, Richard Greil, MD, Bernd Hertenstein, MD, Christian Lerchenmüller, MD, Arnold Ganser, Manfred Reeb, MD, Ulrich Kaiser, MD, Christina Balser, MD, Georg Maschmeyer, MD, Heinz Dürk, MD, Georg Schliesser, MD, Tobias Gaska, MD, Jan Dürig, MD, Axel C. Matzdorff, MD, Rudolf Weide, MD, Axel Hinke, PhD, Wolfgang Blau, MD, Alexander Burchardt, MD, Frank Kauff, PhD, Jürgen Barth and Wolfram Brugger, MD. Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214). Blood 2014 124:3052. link to abstract NCT00877214
- RESORT: Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402. J Clin Oncol. 2014 Oct 1;32(28):3096-102. Epub 2014 Aug 25. link to original article contains verified protocol link to PMC article PubMed NCT00075946
- SAKK 35/03: Taverna C, Martinelli G, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Vanazzi A, Laszlo D, Raats J, Rauch D, Vorobiof DA, Lohri A, Biaggi Rudolf C, Rondeau S, Rusterholz C, Heijnen IA, Zucca E, Ghielmini M. Rituximab maintenance for a maximum of 5 years after single-agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III trial SAKK 35/03. J Clin Oncol. 2016 Feb 10;34(5):495-500. Epub 2015 Dec 28. link to original article contains verified protocol link to PMC article PubMed NCT00227695
- Update: Moccia AA, Taverna C, Schär S, Vanazzi A, Rondeau S, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Raats J, Rauch D, Vorobiof DA, Lohri A, Ruegsegger C, Biaggi Rudolf C, Rusterholz C, Hayoz S, Ghielmini M, Zucca E. Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. Blood Adv. 2020 Dec 8;4(23):5951-5957. link to original article link to PMC article PubMed
Rituximab and hyaluronidase monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Davies et al. 2017 (SABRINA) | 2011-2013 | Phase 3 (E-RT-switch-ic) | IV Rituximab | Similar efficacy |
Starts 8 weeks after the last induction treatment.
Preceding treatment
Targeted therapy
- Rituximab and hyaluronidase human (Rituxan Hycela) 1400 mg SC once on day 1
8-week cycle for 12 cycles
References
- SABRINA: Davies A, Merli F, Mihaljević B, Mercadal S, Siritanaratkul N, Solal-Céligny P, Boehnke A, Berge C, Genevray M, Zharkov A, Dixon M, Brewster M, Barrett M, MacDonald D. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017 Jun;4(6):e272-e282. Epub 2017 May 2. link to original article does not contain protocol PubMed NCT01200758
VR
back to top |
VR: Velcade (Bortezomib) & Rituximab
Regimen
Study | Evidence |
---|---|
Cohen et al. 2015 (X05215) | Phase II |
Preceding treatment
- VR-CHOP x 6 to 8
Targeted therapy
- Bortezomib (Velcade) 1.6 mg/m2 IV once per day on days 1, 8, 15, 22
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22
6-month cycle for up to 4 cycles (2 years)
References
- X05215: Cohen JB, Switchenko JM, Koff JL, Sinha R, Kaufman JL, Khoury HJ, Bumpers N, Colbert A, Hutchison-Rzepka A, Nastoupil LJ, Heffner LT, Langston AA, Lechowicz MJ, Lonial S, Flowers CR. A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. Br J Haematol. 2015 Nov;171(4):539-46. Epub 2015 Aug 7. link to original article contains verified protocol link to PMC article PubMed NCT00634179
Relapsed or refractory, randomized data
Bendamustine monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Friedberg et al. 2008 | 2003-2005 | Phase II | ||
Kahl et al. 2010 | 2005-2007 | Phase II (RT) | ||
Sehn et al. 2016 (GADOLIN) | 2010-2014 | Phase 3 (C) | Bendamustine & Obinutuzumab | Seems to have inferior OS1 |
Rummel et al. 2021 (COMPLEMENT A + B) | 2010-2016 | Phase 3 (C) | Bendamustine & Ofatumumab | Did not meet primary endpoint of PFS |
1Reported efficacy in GADOLIN is based on the 2018 update.
Chemotherapy
- Bendamustine 120 mg/m2 IV once per day on days 1 & 2
21- to 28-day cycle for 6 to 8 cycles (up to 12 in Friedberg et al. 2008)
References
- Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008 Jan 10;26(2):204-10. Erratum in: J Clin Oncol. 2008 Apr 10;26(11) 1911. link to original article contains verified protocol PubMed
- Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010 Jan 1;116(1):106-14. link to original article contains verified protocol link to PMC article PubMed
- GADOLIN: Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016 Aug;17(8):1081-93. Epub 2016 Jun 23. link to original article contains protocol PubMed NCT01059630
- Update: Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018 Aug 1;36(22):2259-2266. Epub 2018 Mar 27. link to original article PubMed
- COMPLEMENT A + B: Rummel MJ, Janssens A, MacDonald D, Keating MM, Zaucha JM, Davis J, Lasher J, Babanrao Pisal C, Izquierdo M, Friedberg JW. A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study). Br J Haematol. 2021 Jun;193(6):1123-1133. Epub 2021 May 10. link to original article contains verified protocol PubMed NCT01077518
Bendamustine & Obinutuzumab
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Sehn et al. 2016 (GADOLIN) | 2010-2014 | Phase 3 (E-RT-esc) | Bendamustine | Seems to have superior OS |
Note: Reported efficacy is based on the 2018 update.
Chemotherapy
- Bendamustine 90 mg/m2 IV once per day on days 1 & 2
Targeted therapy
- Obinutuzumab (Gazyva) as follows:
- Cycle 1: 1000 mg IV once per day on days 1, 8, 15
- Cycles 2 to 6: 1000 mg IV once on day 1
28-day cycle for 6 cycles
Subsequent treatment
References
- GADOLIN: Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016 Aug;17(8):1081-93. Epub 2016 Jun 23. link to original article contains protocol PubMed NCT01059630
- Update: Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018 Aug 1;36(22):2259-2266. Epub 2018 Mar 27. link to original article PubMed
Bendamustine & Rituximab (BR)
back to top |
BR: Bendamustine, Rituximab
Regimen variant #1, 4 cycles
Study | Evidence |
---|---|
Matsumoto et al. 2015 (BRB) | Phase II |
Note: rituximab could be given on day 0, 1, 2, or 3 "according to the clinical convenience of each institution."
Chemotherapy
- Bendamustine 90 mg/m2 IV once per day on days 1 & 2
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
28-day cycle for 4 cycles
Regimen variant #2, 4 cycles with rituximab lead-in
Study | Evidence |
---|---|
Rummel et al. 2005 | Phase II |
Robinson et al. 2008 (SDX-105-01) | Phase II |
Note: Robinson et al. 2008 said that patients "could receive up to six cycles if disease regression was evident between the second and fourth cycles".
Chemotherapy
- Bendamustine 90 mg/m2 IV once per day on days 2 & 3
Targeted therapy
- Rituximab (Rituxan) as follows:
- One week prior to start of cycle 1: 375 mg/m2 IV once
- Cycles 1 to 4: 375 mg/m2 IV once on day 1
- 4 weeks after cycle 4: 375 mg/m2 IV once
28-day cycle for 4 cycles (see note)
Regimen variant #3, 6 cycles
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Rummel et al. 2015 (StiL NHL 2-2003) | 2003-2010 | Phase 3 (E-switch-ic) | FR | Superior PFS |
Chemotherapy
- Bendamustine 90 mg/m2 IV once per day on days 1 & 2
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
28-day cycle for up to 6 cycles
References
- Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Dürk H, Rost A, Neise M, von Grünhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005 May 20;23(15):3383-9. link to original article contains verified protocol PubMed
- SDX-105-01: Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, Schwartzberg LS, Lemieux B, Cheson BD. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008 Sep 20;26(27):4473-9. Epub 2008 Jul 14. link to original article contains verified protocol PubMed NCT00069758
- BRB: Matsumoto K, Takayama N, Aisa Y, Ueno H, Hagihara M, Watanabe K, Nakaya A, Chen K, Shimizu T, Tsukada Y, Yamada Y, Nakazato T, Ishida A, Miyakawa Y, Yokoyama K, Nakajima H, Masuda Y, Yano T, Okamoto S; Keio BRB Study Group. A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study. Int J Hematol. 2015 Jun;101(6):554-62. Epub 2015 Mar 19. link to original article contains verified protocol PubMed
- StiL NHL 2-2003: Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; StiL. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016 Jan;17(1):57-66. Epub 2015 Dec 5. link to original article contains protocol PubMed NCT01456351
Bevacizumab & Rituximab
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hainsworth et al. 2014 | 2005-2012 | Randomized (E-esc) | Rituximab | Seems to have superior PFS |
Targeted therapy
- Bevacizumab (Avastin) as follows:
- Cycle 1: 10 mg/kg IV once per day on days 3 & 15
- Cycles 2 to 5: 10 mg/kg IV once per day on days 1, 15, 29, 43
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days 1, 8, 15, 22
- Cycles 2 to 5: 375 mg/m2 IV once on day 1
12-week cycle for 1 cycle, then 2-month cycle for 4 cycles
References
- Hainsworth JD, Greco FA, Raefsky EL, Thompson DS, Lunin S, Reeves J Jr, White L, Quinn R, DeBusk LM, Flinn IW. Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):277-83. Epub 2014 Feb 28. link to original article contains verified protocol PubMed
Copanlisib & Rituximab
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Matasar et al. 2021 (CHRONOS-3) | 2015-2019 | Randomized (E-esc) | Rituximab | Superior PFS Median PFS: 21.5 vs 13.8 mo (HR 0.52, 95% CI 0.39-0.69) |
Targeted therapy
- Copanlisib (Aliqopa) 60 mg IV over 60 minutes once per day on days 1, 8, 15, given first
- Rituximab (Rituxan) given second as follows:
- Cycle 1: 375 mg/m2 IV once per day on days 1, 8, 15, 22
- Cycles 3, 5, 7, 9: 375 mg/m2 IV once on day 1
28-day cycles
References
- CHRONOS-3: Matasar MJ, Capra M, Özcan M, Lv F, Li W, Yañez E, Sapunarova K, Lin T, Jin J, Jurczak W, Hamed A, Wang MC, Baker R, Bondarenko I, Zhang Q, Feng J, Geissler K, Lazaroiu M, Saydam G, Szomor Á, Bouabdallah K, Galiulin R, Uchida T, Mongay Soler L, Cao A, Hiemeyer F, Mehra A, Childs BH, Shi Y, Zinzani PL. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 May;22(5):678-689. Epub 2021 Apr 10. link to original article contains verified protocol PubMed NCT02367040
Ibritumomab tiuxetan protocol
back to top |
Regimen variant #1, 0.3 mCi/kg
Study | Years of enrollment | Evidence |
---|---|---|
Wiseman et al. 2002 | 1998-1999 | Phase II (RT) |
Note: this dosing was intended for patients with mild thrombocytopenia.
Targeted therapy
- Rituximab (Rituxan) 250 mg/m2 IV once per day on days 1 & 8
Radioconjugate therapy
- Ibritumomab tiuxetan 1.6 mg & Indium-111 5 mCi IV over 10 minutes once on day 1
- Ibritumomab tiuxetan & Yttrium-90 (Zevalin) 0.3 mCi/kg (11 MBq/kg) (maximum dose of 32 mCi/1.2 GBq) IV over 10 minutes once on day 8, given immediately following rituximab
8-day course
Regimen variant #2, 0.4 mCi/kg
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Witzig et al. 1999 | NR | Phase I/II | ||
Witzig et al. 2002a | NR | Phase 3 (E-RT-switch-ic) | Rituximab | Superior ORR |
Witzig et al. 2002b | 1998-1999 | Phase II (RT) |
Note: Witzig et al. 2002b was intended for patients with rituximab-refractory disease.
Radioconjugate therapy
- Rituximab (Rituxan) 250 mg/m2 IV once per day on days 1 & 8
- Ibritumomab tiuxetan 1.6 mg & Indium-111 5 mCi IV over 10 minutes once on day 1
- Ibritumomab tiuxetan & Yttrium-90 (Zevalin) 0.4 mCi/kg (15 MBq/kg) (maximum dose of 32 mCi/1.2 GBq) IV over 10 minutes once on day 8, given immediately following rituximab
8-day course
References
- Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E, Grillo-López AJ. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999 Dec;17(12):3793-803. link to original article contains verified protocol PubMed
- Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002 May 15;20(10):2453-63. link to original article contains verified protocol PubMed
- Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-López AJ, White CA. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002 Jun 15;99(12):4336-42. link to original article PubMed
- Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002 Aug 1;20(15):3262-9. link to original article contains verified protocol PubMed
Lenalidomide monotherapy
back to top |
Regimen variant #1, up to 12 cycles
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Leonard et al. 2015 (CALGB 50401) | 2006-2011 | Randomized Phase II (E-de-esc) | Lenalidomide & Rituximab | Inferior TTP |
Targeted therapy
- Lenalidomide (Revlimid) as follows:
- Cycle 1: 15 mg PO once per day on days 1 to 21
- Cycles 2 (if prior dose tolerated): 20 mg PO once per day on days 1 to 21
- Cycles 3 to 12 (if prior dose tolerated): 25 mg PO once per day on days 1 to 21
Supportive medications
28-day cycle for 12 cycles
Regimen variant #2, indefinite
Study | Evidence |
---|---|
Witzig et al. 2009 (CC-5013-NHL-001) | Phase II |
Targeted therapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
28-day cycles
References
- CC-5013-NHL-001: Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Vose JM. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol. 2009 Nov 10;27(32):5404-9. Epub 2009 Oct 5. link to original article contains verified protocol PubMed NCT00179673
- CALGB 50401: Leonard JP, Jung SH, Johnson J, Pitcher BN, Bartlett NL, Blum KA, Czuczman M, Giguere JK, Cheson BD. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015 Nov 1;33(31):3635-40. Epub 2015 Aug 24. link to full article contains verified protocol link to PMC article PubMed NCT00238238
Lenalidomide & Rituximab (R2)
back to top |
Regimen variant #1, len 10
Study | Years of enrollment | Evidence |
---|---|---|
Chong et al. 2015 (UPCC 02408) | 2008-2012 | Phase II |
Targeted therapy
- Lenalidomide (Revlimid) 10 mg PO once per day
- Rituximab (Rituxan) as follows:
- Cycle 3: 375 mg/m2 IV once per day on days 1, 8, 15, 22
28-day cycles
Regimen variant #2, len dose escalation 15 -> 25 x 12
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Leonard et al. 2015 (CALGB 50401) | 2006-2011 | Randomized Phase II (E-esc) | Lenalidomide | Superior TTP |
Targeted therapy
- Lenalidomide (Revlimid) as follows:
- Cycle 1: 15 mg PO once per day on days 1 to 21
- Cycles 2 (if prior dose tolerated): 20 mg PO once per day on days 1 to 21
- Cycles 3 to 12 (if prior dose tolerated): 25 mg PO once per day on days 1 to 21
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days 8, 15, 22, 29
Supportive medications
28-day cycle for 12 cycles
Regimen variant #3, len 20 x 2
Study | Years of enrollment | Evidence |
---|---|---|
Tuscano et al. 2014 (RV-PI-NHL-0488) | 2010-NR | Phase II |
Targeted therapy
- Lenalidomide (Revlimid) 20 mg PO once per day on days 1 to 21
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once on day 15
- Cycle 2: 375 mg/m2 IV once per day on days 1, 8, 15, 22
Supportive medications
- Allopurinol (Zyloprim) as follows:
- Cycle 1: 300 mg PO once per day
- Aspirin 81 mg PO once per day
28-day cycle for 2 cycles
Subsequent treatment
- Responders: Lenalidomide maintenance
- Patients with less than a CR after induction: more rituximab could be given at the discretion of the treating physician. Dosing details not provided in the reference
Regimen variant #4, len 20 x 12
FDA-recommended dose |
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Leonard et al. 2019 (AUGMENT) | 2014-2017 | Phase 3 (E-RT-esc) | Rituximab | Superior PFS Median PFS: 39.4 mo vs 14.1 mo (HR 0.46, 95% CI 0.34-0.62) |
Targeted therapy
- Lenalidomide (Revlimid) 20 mg PO once per day on days 1 to 21
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days 1, 8, 15, 22
- Cycles 2 to 5: 375 mg/m2 IV once on day 1
28-day cycle for 12 cycles
Regimen variant #5, len 20 x 12, staggered rituximab
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Awaiting publication (MAGNIFY) | 2014-NR | Phase 3b (C-RT) | R2, then Lenalidomide | Not reported |
Note: this trial has not been published to our knowledge, but is cited in the package insert. Dosing information is from CT.gov.
Targeted therapy
- Lenalidomide (Revlimid) 20 mg PO once per day on days 1 to 21
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days 1, 8, 15, 22
- Cycles 3, 5, 7, 9, 11: 375 mg/m2 IV once on day 1
28-day cycle for 12 cycles
Subsequent treatment
References
- RV-PI-NHL-0488: Tuscano JM, Dutia M, Chee K, Brunson A, Reed-Pease C, Abedi M, Welborn J, O'Donnell RT. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014 May;165(3):375-81. Epub 2014 Mar 7. link to original article contains verified protocol PubMed NCT01316523
- UPCC 02408: Chong EA, Ahmadi T, Aqui NA, Svoboda J, Nasta SD, Mato AR, Walsh KM, Schuster SJ. Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent B-cell and mantle cell lymphomas. Clin Cancer Res. 2015 Apr 15;21(8):1835-42. Epub 2015 Jan 28. link to original article contains verified protocol PubMed NCT00783367
- CALGB 50401: Leonard JP, Jung SH, Johnson J, Pitcher BN, Bartlett NL, Blum KA, Czuczman M, Giguere JK, Cheson BD. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015 Nov 1;33(31):3635-40. Epub 2015 Aug 24. link to full article contains verified protocol link to PMC article PubMed NCT00238238
- AUGMENT: Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabeçadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG; AUGMENT Trial Investigators. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019 May 10;37(14):1188-1199. Epub 2019 Mar 21. link to original article link to PMC article PubMed NCT01938001
- EZH-302: NCT04224493
- MAGNIFY: NCT01996865
Obinutuzumab monotherapy
back to top |
Regimen variant #1
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Sehn et al. 2015 (GAUSS) | 2009-2010 | Randomized Phase II (E-switch-ic) | Rituximab | Might have superior ORR |
Targeted therapy
- Obinutuzumab (Gazyva) 1000 mg IV once per day on days 1, 8, 15, 22
28-day course
Subsequent treatment
- Patients with SD or better: Optional maintenance obinutuzumab
Regimen variant #2
Study | Evidence |
---|---|
Salles et al. 2012 (GAUGUIN) | Phase I/II |
Note: Dose here is that recommended by Salles et al. 2013 as having "encouraging activity with an acceptable safety profile"
Targeted therapy
- Obinutuzumab (Gazyva) as follows:
- Cycle 1: 1600 mg (diluted to 10 mg/mL) IV once per day on days 1 & 7
- Cycles 2 to 8: 800 mg IV once on day 1
- Initial infusion rate is 50 mg/hour. In the absence of infusion-related reactions (IRRs), the rate is then increased by 50 mg/hour every 30 minutes, up to a maximum of 400 mg/hour.
Supportive medications
- Acetaminophen (Tylenol) (no dose specified) PO once per infusion; 30 minutes prior to Obinutuzumab (Gazyva)
- Antihistamine (no drug or dose specified) PO once per infusion; 30 minutes prior to Obinutuzumab (Gazyva)
- Corticosteroids before Obinutuzumab (Gazyva) for patients at "high risk" of infusion reaction
21-day cycle for 8 cycles
References
- GAUGUIN: Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, Bieska G, Asikanius E, Carlile D, Birkett J, Pisa P, Cartron G. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012 May 31;119(22):5126-32. Epub 2012 Mar 19. link to original article PubMed NCT00517530
- Subgroup analysis: Morschhauser FA, Cartron G, Thieblemont C, Solal-Céligny P, Haioun C, Bouabdallah R, Feugier P, Bouabdallah K, Asikanius E, Lei G, Wenger M, Wassner-Fritsch E, Salles GA. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013 Aug 10;31(23):2912-9. Epub 2013 Jul 8. link to original article contains verified protocol PubMed
- Subgroup analysis: Salles GA, Morschhauser F, Solal-Céligny P, Thieblemont C, Lamy T, Tilly H, Gyan E, Lei G, Wenger M, Wassner-Fritsch E, Cartron G. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013 Aug 10;31(23):2920-6. Epub 2013 Jul 8. link to original article contains verified protocol PubMed
- Subgroup analysis: Cartron G, de Guibert S, Dilhuydy MS, Morschhauser F, Leblond V, Dupuis J, Mahe B, Bouabdallah R, Lei G, Wenger M, Wassner-Fritsch E, Hallek M. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014 Oct 2;124(14):2196-202. Epub 2014 Aug 20. link to original article contains verified protocol PubMed
- GAUSS: Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE, Buckstein R, Friedberg JW, Crump M, Jaksic B, Zinzani PL, Padmanabhan Iyer S, Sahin D, Chai A, Fingerle-Rowson G, Press OW. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol. 2015 Oct 20;33(30):3467-74. Epub 2015 Aug 17. link to original article] contains verified protocol link to PMC article PubMed NCT00576758
R-CHOP
back to top |
R-CHOP: Rituximab, Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Prednisone
Regimen variant #1, 3 cycles
Study | Evidence |
---|---|
Illidge et al. 2016 (SCHRIFT) | Phase II |
Dosing details for R-CHOP were not available in the abstract; this is a typical R-CHOP regimen.
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
21-day cycle for 3 cycles
Subsequent treatment
Regimen variant #2, 6 cycles with prednisone 100 mg
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Van Oers et al. 2006 (EORTC 20981) | 1998-2004 | Phase 3 (E-esc) | CHOP | Superior PFS |
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
21-day cycle for 6 cycles
Subsequent treatment
- Responders (PR or CR): Rituximab maintenance versus no further treatment
Regimen variant #3, 6 cycles with prednisone 100 mg/m2
Study | Evidence |
---|---|
Czuczman et al. 1999 | Phase II |
Targeted therapy
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days -6 & -1 (7 and 2 days before cycle 1 day 1)
- Cycles 3 & 5: 375 mg/m2 IV once on day -2
- Cycle 6*: 375 mg/m2 IV once per day on days 29 & 36 (i.e., what would be cycle 7 days 8 & 15)
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
- Prednisone (Sterapred) 100 mg/m2 PO once per day on days 1 to 5
21-day cycle for 6 cycles
References
- Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999 Jan;17(1):268-76. link to original article contains protocol PubMed
- Update: Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-López AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004 Dec 1;22(23):4711 to 6. Epub 2004 Oct 13. link to original article PubMed
- EORTC 20981: van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van 't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006 Nov 15;108(10):3295-301. Epub 2006 Jul 27. link to original article contains verified protocol PubMed NCT00004179
- Update: van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010 Jun 10;28(17):2853-8. Epub 2010 May 3. link to original article contains verified protocol link to PMC article PubMed
- SCHRIFT: Illidge TM, McKenzie HS, Mayes S, Bates A, Davies AJ, Pettengell R, Stanton L, Cozens K, Hampson G, Dive C, Zivanovic M, Tipping J, Gallop-Evans E, Radford JA, Johnson PW; UK National Cancer Research Institute Lymphoma Group. Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. Br J Haematol. 2016 Apr;173(2):274-82. Epub 2016 Feb 5. link to original article contains protocol PubMed NCT00637832
R-FCM
back to top |
R-FCM: Rituximab, Fludarabine, Cyclophosphamide, Mitoxantrone
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Forstpointner et al. 2004 | 1998-2001 | Phase 3 (E-esc) | FCM | Seems to have superior PFS |
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day -1 (the day before FCM)
Chemotherapy
- Fludarabine (Fludara) 25 mg/m2 IV over 30 minutes once per day on days 1 to 3
- Cyclophosphamide (Cytoxan) 200 mg/m2 IV over 4 hours once per day on days 1 to 3
- Mitoxantrone (Novantrone) 8 mg/m2 IV over 30 minutes once on day 1
28-day cycle for 4 cycles
Subsequent treatment
- PR or CR: Rituximab maintenance versus no further treatment
References
- Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Böck HP, Wandt H, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004 Nov 15;104(10):3064-71. Epub 2004 Jul 29. link to original article contains verified protocol PubMed
- Update: Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hänel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W; German Low Grade Lymphoma Study Group. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006 Dec 15;108(13):4003-8. Epub 2006 Aug 31. link to original article contains verified protocol PubMed
Rituximab monotherapy
back to top |
Regimen variant #1, induction then consolidation
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hainsworth et al. 2014 | 2005-2012 | Randomized (C) | Bevacizumab & Rituximab | Seems to have inferior PFS |
Maloney et al. 2020 (HOMER) | 2010-2016 | Phase 3 (C) | Ofatumumab | Did not meet primary endpoint of PFS |
Targeted therapy
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days 1, 8, 15, 22
- Cycles 2 to 5: 375 mg/m2 IV once on day 1
12-week cycle for 1 cycle, then 2-month cycle for 4 cycles
Regimen variant #2, induction only
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Maloney et al. 1994 | NR | Phase 1, <20 pts | ||
Maloney et al. 1997a | NR | Phase II (RT) | ||
Maloney et al. 1997b | NR | Phase 1, <20 pts | ||
McLaughlin et al. 1998 | 1995-1996 | Phase II (RT) | ||
Witzig et al. 2002a | NR | Phase 3 (C) | Ibritumomab tiuxetan | Inferior ORR |
Ghielmini et al. 2004 (SAKK 35/98) | 1998-2001 | Non-randomized portion of RCT | ||
Hainsworth et al. 2005b | 1998-2002 | Non-randomized portion of RCT | ||
Sehn et al. 2015 (GAUSS) | 2009-2010 | Randomized Phase II (C) | Obinutuzumab | Might have inferior ORR |
Note: the phase 1 described by Maloney et al. 1994 did not actually employ this dosing level, but is included here for reference purposes.
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22
Supportive medications
- (not explicitly mentioned in all references)
- Acetaminophen (Tylenol) 650 mg PO once per day on days 1, 8, 15, 22; 30 minutes prior to Rituximab (Rituxan)
- Diphenhydramine (Benadryl) 50 mg PO once per day on days 1, 8, 15, 22; 30 minutes prior to Rituximab (Rituxan)
4-week course
Subsequent treatment
- SAKK 35/98, patients with SD or better at 12 weeks: Rituximab maintenance versus no further treatment
- Hainsworth et al. 2005b, patients with SD or better: Rituximab maintenance versus re-treatment with rituximab at time of progression
- GAUSS, SD or better: Optional rituximab maintenance
Regimen variant #3
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Coiffier et al. 2011 (LYM-3001) | 2006-2008 | Phase 3 (C) | VR | Seems to have inferior PFS |
Targeted therapy
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days 1, 8, 15, 22
- Cycles 2 to 6: 375 mg/m2 IV once on day 1
Supportive medications
- Acetaminophen (Tylenol) 650 mg PO once per infusion; 30 minutes prior to Rituximab (Rituxan)
- Diphenhydramine (Benadryl) 50 mg PO once per infusion; 30 minutes prior to Rituximab (Rituxan)
35-day cycle for 6 cycles
Regimen variant #4
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kahl et al. 2014 (RESORT) | 2003-2008 | Phase 3 (C) | Rituximab; indefinite | Did not meet primary endpoint of TTF |
Preceding treatment
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22
4-week course, repeated every progression until treatment failure
References
- Phase 1: Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994 Oct 15;84(8):2457-66. link to original article PubMed
- Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997 Sep 15;90(6):2188-95. link to original article contains protocol PubMed
- Phase 1: Maloney DG, Grillo-López AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997 Oct;15(10):3266-74. link to original article PubMed
- McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33. link to original article contains verified protocol PubMed
- Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002 May 15;20(10):2453-63. link to original article contains verified protocol PubMed
- SAKK 35/98: Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004 Jun 15;103(12):4416-23. Epub 2004 Feb 19. link to original article contains protocol PubMed
- Update: Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S, Okkinga E, Stupp R, Stahel R, Heizmann M, Vorobiof D, Lohri A, Dietrich PY, Zucca E, Ghielmini M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010 Oct 10;28(29):4480-4. Epub 2010 Aug 9. link to original article contains verified protocol PubMed
- Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005 Feb 20;23(6):1088-95. Epub 2005 Jan 18. link to original article contains protocol PubMed
- LYM-3001: Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theocharous P, van de Velde H, Elsayed YA, Zinzani PL; LYM-3001 study investigators. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol. 2011 Aug;12(8):773-84. Epub 2011 Jul 1. link to original article contains verified protocol PubMed NCT00312845
- Subgroup analysis: Zinzani PL, Khuageva NK, Wang H, Garicochea B, Walewski J, Van Hoof A, Soubeyran P, Caballero D, Buckstein R, Esseltine DL, Theocharous P, Enny C, Zhu E, Elsayed YA, Coiffier B. Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. J Hematol Oncol. 2012 Oct 22;5:67. link to original article link to PMC article PubMed
- RESORT: Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402. J Clin Oncol. 2014 Oct 1;32(28):3096-102. Epub 2014 Aug 25. link to original article contains verified protocol link to PMC article PubMed NCT00075946
- Hainsworth JD, Greco FA, Raefsky EL, Thompson DS, Lunin S, Reeves J Jr, White L, Quinn R, DeBusk LM, Flinn IW. Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):277-83. Epub 2014 Feb 28. link to original article contains verified protocol PubMed
- GAUSS: Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE, Buckstein R, Friedberg JW, Crump M, Jaksic B, Zinzani PL, Padmanabhan Iyer S, Sahin D, Chai A, Fingerle-Rowson G, Press OW. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol. 2015 Oct 20;33(30):3467-74. Epub 2015 Aug 17. link to original article] contains verified protocol link to PMC article PubMed NCT00576758
- HOMER: Maloney DG, Ogura M, Fukuhara N, Davis J, Lasher J, Izquierdo M, Banerjee H, Tobinai K. A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy. Blood Adv. 2020 Aug 25;4(16):3886-3893. link to original article link to PMC article PubMed NCT01200589
- CHRONOS-3: Matasar MJ, Capra M, Özcan M, Lv F, Li W, Yañez E, Sapunarova K, Lin T, Jin J, Jurczak W, Hamed A, Wang MC, Baker R, Bondarenko I, Zhang Q, Feng J, Geissler K, Lazaroiu M, Saydam G, Szomor Á, Bouabdallah K, Galiulin R, Uchida T, Mongay Soler L, Cao A, Hiemeyer F, Mehra A, Childs BH, Shi Y, Zinzani PL. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 May;22(5):678-689. Epub 2021 Apr 10. link to original article contains verified protocol PubMed NCT02367040
VR
back to top |
VR: Velcade (Bortezomib), Rituximab
Regimen variant #1
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Coiffier et al. 2011 (LYM-3001) | 2006-2008 | Phase 3 (E-esc) | Rituximab | Seems to have superior PFS |
Targeted therapy
- Bortezomib (Velcade) 1.6 mg/m2 IV over 3 to 5 seconds once per day on days 1, 8, 15, 22
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days 1, 8, 15, 22
- Cycles 2 to 5: 375 mg/m2 IV once on day 1
Supportive medications
- No routine antiviral prophylaxis was mandated
35-day cycle for 5 cycles
Regimen variant #2
Study | Evidence |
---|---|
Agathocleous et al. 2010 | Phase II |
Targeted therapy
- Bortezomib (Velcade) 1.6 mg/m2 IV once per day on days 1, 8, 15, 22
- Rituximab (Rituxan) as follows:
- Cycles 1 & 4: 375 mg/m2 IV once per day on days 1, 8, 15, 22
35-day cycle for up to 6 cycles
Regimen variant #3
Study | Evidence |
---|---|
de Vos et al. 2009 (M34103-061) | Phase II |
Targeted therapy
- Bortezomib (Velcade) 1.6 mg/m2 IV once per day on days 1, 8, 15, 22
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days 1, 8, 15, 22
35-day cycle for 3 cycles
Regimen variant #4
Study | Years of enrollment | Evidence |
---|---|---|
Baiocchi et al. 2011 (OSU-0430) | 2005-2009 | Phase II, <20 patients reported |
Bortezomib dose was initially 1.5 mg/m2 but was reduced due to excess grade 3 neurotoxicity.
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 IV once per day on days 1, 4, 8, 11
- Rituximab (Rituxan) as follows:
- Cycle 2 onwards: 375 mg/m2 IV once per day on days 1 & 8
21-day cycle for up to 5 cycles.
Subsequent treatment
- SD or better: optional VR maintenance
References
- M34103-061: de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory SA, Holladay C, Zhang T, Boral AL. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol. 2009 Oct 20;27(30):5023-30. Epub 2009 Sep 21. link to original article contains verified protocol PubMed NCT00085696
- Agathocleous A, Rohatiner A, Rule S, Hunter H, Kerr JP, Neeson SM, Matthews J, Strauss S, Montoto S, Johnson P, Radford J, Lister A. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. Br J Haematol. 2010 Nov;151(4):346-53. Epub 2010 Sep 29. link to original article contains verified protocol PubMed
- OSU-0430: Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd JC, Blum KA. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer. 2011 Jun 1;117(11):2442-51. Epub 2010 Dec 14. link to original article contains verified protocol link to PMC article PubMed NCT00201877
- LYM-3001: Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theocharous P, van de Velde H, Elsayed YA, Zinzani PL; LYM-3001 study investigators. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol. 2011 Aug;12(8):773-84. Epub 2011 Jul 1. link to original article contains verified protocol PubMed NCT00312845
- Subgroup analysis: Zinzani PL, Khuageva NK, Wang H, Garicochea B, Walewski J, Van Hoof A, Soubeyran P, Caballero D, Buckstein R, Esseltine DL, Theocharous P, Enny C, Zhu E, Elsayed YA, Coiffier B. Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. J Hematol Oncol. 2012 Oct 22;5:67. link to original article link to PMC article PubMed
Relapsed or refractory, non-randomized or retrospective data
Axicabtagene ciloleucel monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
ZUMA-5 | Phase II (RT) |
No peer-reviewed publication or dosing details are yet available.
Immunotherapy
References
- ZUMA-5: NCT03105336
Bortezomib monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
O'Connor et al. 2005 | Phase II, <20 patients reported |
Targeted therapy
- Bortezomib (Velcade) 1.5 mg/m2 IV once per day on days 1, 4, 8, 11
Supportive medications
- "Use of antiemetics, erythropoietin, and Filgrastim (Neupogen) was allowed if deemed necessary by the treating physician."
21-day cycles
References
- O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005 Feb 1;23(4):676-84. Epub 2004 Dec 21. link to original article contains verified protocol PubMed
BVR
back to top |
BVR: Bendamustine, Velcade (Bortezomib), Rituximab
VBR: Velcade (Bortezomib), Bendamustine, Rituximab
Regimen variant #1, 1.3/90/375
Study | Years of enrollment | Evidence |
---|---|---|
Friedberg et al. 2011 (ULYM07054) | 2007-2009 | Phase II, <20 patients in this subgroup |
Chemotherapy
- Bendamustine 90 mg/m2 IV once per day on days 1 & 4, given third
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 IV once per day on days 1, 4, 8, 11, given first
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1, given second
Supportive medications
- Premedications, antiemetic therapy, and growth factor support per institutional guidelines
- No routine antibiotic or antiviral prophylaxis was given
28-day cycle for 6 cycles
Regimen variant #2, 1.6/90/375
Study | Years of enrollment | Evidence |
---|---|---|
Fowler et al. 2011 (VERTICAL) | 2008-2009 | Phase II |
Note: Bendamustine was dose-escalated in the first phase of the trial and the 90 mg/m2 dose is the MTD.
Chemotherapy
- Bendamustine 90 mg/m2 IV once per day on days 1 & 2, given second
Targeted therapy
- Bortezomib (Velcade) 1.6 mg/m2 IV once per day on days 1, 8, 15, 22, given first
- Rituximab (Rituxan) as follows, given third:
- Cycle 1: 375 mg/m2 IV once per day on days 1, 8, 15, 22
- Cycles 2 to 5: 375 mg/m2 IV once on day 1
Supportive medications
- Antiviral prophylaxis at physician discretion
35-day cycle for 5 cycles
References
- ULYM07054: Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011 Mar 10;117(10):2807-12. Epub 2011 Jan 14. link to original article contains verified protocol link to PMC article PubMed NCT00547534
- VERTICAL: Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, Letzer J, Amin B, Williams ME, Smith S, Saleh A, Rosen P, Shi H, Parasuraman S, Cheson BD. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol. 2011 Sep 1;29(25):3389-95. Epub 2011 Aug 1. link to original article contains verified protocol PubMed NCT00636792
Copanlisib monotherapy
back to top |
Regimen variant #1, flat dose
FDA-recommended dose |
Study | Years of enrollment | Evidence | Efficacy |
---|---|---|---|
Dreyling et al. 2017 (CHRONOS-1) | 2012-NR | Phase II (RT) | ORR: 59% (95% CI, 49-68) |
Note: this is the FDA-recommended dose and the dose used for most of the patients enrolled in this trial; however, the 2017 publication only details the weight-based dosing (see below).
Targeted therapy
- Copanlisib (Aliqopa) 60 mg IV over 60 minutes once per day on days 1, 8, 15
28-day cycles
Regimen variant #2, weight-based
Study | Years of enrollment | Evidence | Efficacy |
---|---|---|---|
Dreyling et al. 2017 (CHRONOS-1) | 2012-NR | Phase II (RT) | ORR: 59% (95% CI, 49-68) |
Targeted therapy
- Copanlisib (Aliqopa) 0.8 mg/kg IV over 60 minutes once per day on days 1, 8, 15
28-day cycles
References
- CHRONOS-1: Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, Verhoef G, Linton K, Thieblemont C, Vitolo U, Hiemeyer F, Giurescu M, Garcia-Vargas J, Gorbatchevsky I, Liu L, Koechert K, Peña C, Neves M, Childs BH, Zinzani PL. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017 Sep 1;28(9):2169-2178. link to original article link to PMC article contains verified protocol PubMed NCT01660451
Duvelisib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Flinn et al. 2019 (DYNAMO) | 2013-2015 | Phase II (RT) |
Targeted therapy
- Duvelisib (Copiktra) 25 mg PO twice per day
28-day cycles
References
- DYNAMO: Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, Merli M, Lunin SD, Pettitt AR, Nagy Z, Tournilhac O, Abou-Nassar KE, Crump M, Jacobsen ED, de Vos S, Kelly VM, Shi W, Steelman L, Le N, Weaver DT, Lustgarten S, Wagner-Johnston ND, Zinzani PL. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. J Clin Oncol. 2019 Apr 10;37(11):912-922. Epub 2019 Feb 11. link to original article contains verified protocol PubMed NCT01882803
FR
back to top |
FR: Fludarabine & Rituximab
Regimen
Study | Evidence | Efficacy |
---|---|---|
Czuczman et al. 2005 | Phase II | ORR: 90% |
Chemotherapy
- Fludarabine (Fludara) as follows:
- Weeks 2, 6, 10, 14, 18, 22: 25 mg/m2 IV once per day on days 1 to 5
Targeted therapy
- Rituximab (Rituxan) as follows:
- Weeks 1 & 26: 375 mg/m2 IV once per day on days 1 & 4
- Weeks 6, 14, 22: 375 mg/m2 IV once 72 hours before day 1
26-week course
References
- Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005 Feb 1;23(4):694-704. link to original article contains verified protocol PubMed
Ibrutinib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Efficacy |
---|---|---|---|
Bartlett et al. 2017 (MC1282) | 2013-2014 | Phase II | ORR: 37.5% (95% CI, 23-54) |
Gopal et al. 2018 (DAWN) | 2013-2016 | Phase II | ORR: 21% (95% CI, 14-30) |
Targeted therapy
- Ibrutinib (Imbruvica) 560 mg PO once per day
28-day cycles
References
- MC1282: Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, Thye LS, Anderson DM, Krysiak K, Ramirez C, Qi J, Siegel BA, Griffith M, Griffith OL, Gomez F, Fehniger TA. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood. 2018 Jan 11;131(2):182-190. Epub 2017 Oct 26. link to original article contains verified protocol link to PMC article PubMed NCT01849263
- DAWN: Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, Yacoub A, Lill M, Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Caballero D, Deshpande S, Gartenberg GJ, Wang SS, Damle RN, Schaffer M, Balasubramanian S, Vermeulen J, Cheson BD, Salles G. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study. J Clin Oncol. 2018 Aug 10;36(23):2405-2412. Epub 2018 May 31. link to original article contains protocol PubMed NCT01779791
Idelalisib monotherapy
back to top |
On 3/21/2016 Gilead announced that they were stopping seven clinical trials of idelalisib in patients with CLL, SLL, and iNHL due to excess deaths and increased rates of SAEs. A REMS program has also been announced.
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Gopal et al. 2014 (DELTA) | 2011-2012 | Phase II (RT) |
Targeted therapy
- Idelalisib (Zydelig) 150 mg PO twice per day
Continued indefinitely
References
- DELTA: Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014 Mar 13;370(11):1008-18. Epub 2014 Jan 22. link to original article contains verified protocol link to PMC article PubMed NCT01282424
- Update: Abstract: Ajay K. Gopal, MD, Brad S. Kahl, MD, Sven de Vos, MD, PhD, Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Wojciech Jurczak, MD, PhD, Ian W. Flinn, MD, PhD, Christopher R. Flowers, MD, Peter Martin, MD, Andreas Viardot, MD, Kristie A. Blum, MD, Andre Goy, MD, Andrew Davies, BM PhD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD, PhD, Leanne M. Holes, Bess Sorensen, PhD, Wayne R. Godfrey, MD and Gilles Andre Salles, MD, PhD. Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). Blood 2014 124:1708. link to abstract
Inotuzumab ozogamicin monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Goy et al. 2016 (B1931007) | Phase II |
Antibody-drug conjugate therapy
- Inotuzumab ozogamicin (Besponsa) 1.8 mg/m2 IV once on day 1
28-day cycle for 4 to 8 cycles
References
- B1931007: Goy A, Forero A, Wagner-Johnston N, Christopher Ehmann W, Tsai M, Hatake K, Ananthakrishnan R, Volkert A, Vandendries E, Ogura M. A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. Br J Haematol. 2016 Aug;174(4):571-81. Epub 2016 Apr 22. link to original article PubMed NCT00868608
Lenalidomide, Dexamethasone, Rituximab
back to top |
Regimen
Study | Evidence |
---|---|
Ahmadi et al. 2013 (UPCC 02408) | Phase II, <20 pts in subgroup |
Targeted therapy
- Lenalidomide (Revlimid) 10 mg PO once per day
- Rituximab (Rituxan) as follows:
- Cycle 3: 375 mg/m2 IV once per day on days 1, 8, 15, 22
Chemotherapy
- Dexamethasone (Decadron) 8 mg (route not specified) once per day on days 1, 8, 15, 22
28-day cycles
References
- UPCC 02408: Ahmadi T, Chong EA, Gordon A, Aqui NA, Nasta SD, Svoboda J, Mato AR, Schuster SJ. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. Cancer. 2014 Jan 15;120(2):222-8. Epub 2013 Oct 7. link to original article contains verified protocol PubMed NCT00783367
PEP-C
back to top |
PEP-C: Prednisone, Etoposide, Procarbazine, Cyclophosphamide
Protocol
Study | Evidence |
---|---|
Coleman et al. 2008 | Retrospective |
Chemotherapy, induction phase
- Prednisone (Sterapred) 20 mg PO once per day after breakfast
- Etoposide (Vepesid) 50 mg PO once per day after dinner
- Procarbazine (Matulane) 50 mg PO once per day at bedtime
- Cyclophosphamide (Cytoxan) 50 mg PO once per day after lunch
Supportive medications
- Ondansetron (Zofran) (dose not specified, presumably PO) with each Procarbazine (Matulane) dose
Continue until WBC count less than 3 x 109/L, hold until WBC count recovery, then titrate in maintenance phase per paper (see publication for details)
Chemotherapy, maintenance phase
- Same medications and doses given per day as used in the induction phase, but the number of days per week they are used is titrated to maintain a WBC count of at least 3 x 109/L; for example, 5 out of 7 days, every other day, once per week, etc.
References
- Retrospective: Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, George P, Kaufman TP, Leonard JP. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 2008 May 15;112(10):2228-32. link to original article contains verified protocol PubMed
R-CVP
back to top |
R-CVP: Rituximab, Cyclophosphamide, Vincristine, Prednisone
Regimen
Study | Evidence |
---|---|
Illidge et al. 2016 (SCHRIFT) | Phase II |
Dosing details for R-CVP were not available in the abstract; this is a typical R-CVP regimen.
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
21-day cycle for 3 cycles
Subsequent treatment
References
- SCHRIFT: Illidge TM, McKenzie HS, Mayes S, Bates A, Davies AJ, Pettengell R, Stanton L, Cozens K, Hampson G, Dive C, Zivanovic M, Tipping J, Gallop-Evans E, Radford JA, Johnson PW; UK National Cancer Research Institute Lymphoma Group. Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. Br J Haematol. 2016 Apr;173(2):274-82. Epub 2016 Feb 5. link to original article contains protocol PubMed NCT00637832
R-DexaBEAM
back to top |
R-DexaBEAM: Rituximab, Dexamethasone, BiCNU (Carmustine), Etoposide, Ara-C (Cytarabine), Melphalan
Regimen
Study | Evidence |
---|---|
Kirschey et al. 2014 (Mz-135) | Phase II |
Note: the dosing in the manuscript is different than below. The below are the correct doses as verified by the authors.
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1 & 8
Chemotherapy
- Dexamethasone (Decadron) 8 mg PO three times per day on days 1 to 10
- Carmustine (BCNU) 60 mg/m2 IV once on day 3
- Etoposide (Vepesid) 75 mg/m2 IV once per day on days 4 to 7
- Cytarabine (Ara-C) 100 mg/m2 IV twice per day on days 4 to 7
- Melphalan (Alkeran) 20 mg/m2 IV once on day 2
3- to 4-week cycle for 2 cycles
Subsequent treatment
- R-BEAM with autologous hematopoietic stem cell transplant or R-TBI/Cy with autologous hematopoietic stem cell transplant
References
- Mz-135: Kirschey S, Flohr T, Wolf HH, Frickhofen N, Gramatzki M, Link H, Basara N, Peter N, Meyer RG, Schmitz N, Weidmann E, Banat A, Schulz A, Kolbe K, Derigs G, Theobald M, Hess G. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. Br J Haematol. 2015 Mar;168(6):824-34. Epub 2014 Dec 28. link to original article contains verified protocol PubMed NCT02099292
R-FND
back to top |
R-FND: Rituximab, Fludarabine, Novantrone, Dexamethasone
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Nastoupil et al. 2017 | 1997-2002 | Randomized (E-switch-ic) | FND, then R | Did not meet primary endpoint of CR rate |
Note: although this is the experimental arm of a negative study, the concurrent approach is the standard approach now.
Targeted therapy
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days 1 & 8
- Cycles 2 to 5: 375 mg/m2 IV once on day 1
Chemotherapy
- Fludarabine (Fludara) 25 mg/m2 IV once per day on days 2 to 4
- Mitoxantrone (Novantrone) 10 mg/m2 IV once on day 2
- Dexamethasone (Decadron) 20 mg IV or PO once per day on days 1 to 5
28-day cycle for up to 8 cycles
Subsequent treatment
References
- Review: Hagemeister F, Cabanillas F, Coleman M, Gregory SA, Zinzani PL. The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist. 2005 Feb;10(2):150-9. link to original article PubMed content property of HemOnc.org
- Retrospective: Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee MS, Ayala A, McLaughlin P. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006 Apr 1;24(10):1582-9. link to original article PubMed
- Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: results of a randomized study. Br J Haematol. 2017 Apr;177(2):263-270. Epub 2017 Mar 24. link to original article link to PMC article contains verified protocol PubMed
R-INO
back to top |
R-INO: Rituximab, INOtuzumab ozogamicin
Regimen
Study | Evidence | Efficacy |
---|---|---|
Fayad et al. 2013 (B1931004) | Phase I/II | ORR: 87% |
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Antibody-drug conjugate therapy
- Inotuzumab ozogamicin (Besponsa) 1.8 mg/m2 IV once on day 2
28-day cycle for up to 8 cycles
References
- B1931004: Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, Rohatiner A, Advani A, Foran J, Hess G, Coiffier B, Czuczman M, Giné E, Durrant S, Kneissl M, Luu KT, Hua SY, Boni J, Vandendries E, Dang NH. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013 Feb 10;31(5):573-83. Epub 2013 Jan 7. link to original article link to PMC article contains verified protocol PubMed NCT00299494
Tazemetostat monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Years of enrollment | Evidence |
---|---|---|
Morschhauser et al. 2020 (E7438-G000-101) | 2015-2019 | Phase II (RT) |
Targeted therapy
- Tazemetostat (Tazverik) 800 mg PO twice per day
Continued indefinitely
References
- E7438-G000-101: Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, Batlevi CL, Campbell P, Ribrag V, Damaj GL, Dickinson M, Jurczak W, Kazmierczak M, Opat S, Radford J, Schmitt A, Yang J, Whalen J, Agarwal S, Adib D, Salles G. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020 Oct 6:S1470-2045(20)30441-1. link to original article contains protocol PubMed NCT01897571
Temsirolimus monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Smith et al. 2010 (NCI-6199) | Phase II |
Targeted therapy
- Temsirolimus (Torisel) 25 mg IV over 30 minutes once per day on days 1, 8, 15, 22
28-day cycle for at least 2 cycles
References
- NCI-6199: Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, Doyle LA, Vokes EE, Pro B. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 1;28(31):4740-6. Epub 2010 Sep 13. link to original article contains verified protocol link to PMC article PubMed NCT00290472
Umbralisib monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Evidence |
---|---|
Fowler et al. 2019 (UNITY-NHL) | Phase II (RT) |
Targeted therapy
- Umbralisib (Ukoniq) 800 mg PO once per day
Continued indefinitely
References
- Abstract: Nathan Hale Fowler, Felipe Samaniego, Wojciech Jurczak, Ewa Lech-Maranda, Nilanjan Ghosh, Piers Patten, James Andrew Reeves, Lori Ann Leslie, Julio C. Chavez, Paolo Ghia, Corrado Tarella, John M. Burke, Jeff Porter Sharman, Kathryn Kolibaba, Owen A. O'Connor, Chan Cheah, Hari P. Miskin, Peter Sportelli, Michael S. Weiss, and Pier Luigi Zinzani. Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study. Journal of Clinical Oncology 2019 37:15_suppl, 7506-7506 link to abstract NCT02793583
Vorinostat monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Kirschbaum et al. 2011 (PHII-63) | Phase II, <20 pts in subgroup |
Ogura et al. 2014 | Phase II |
Targeted therapy
- Vorinostat (Zolinza) 200 mg PO twice per day on days 1 to 14
21-day cycles
References
- PHII-63: Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, Matsuoka D, Pulone B, Rotter AJ, Espinoza-Delgado I, Nademanee A, Forman SJ, Gandara D, Newman E. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011 Mar 20;29(9):1198-203. Epub 2011 Feb 7. link to original article contains verified protocol link to PMC article PubMed NCT00253630
- Ogura M, Ando K, Suzuki T, Ishizawa K, Oh SY, Itoh K, Yamamoto K, Au WY, Tien HF, Matsuno Y, Terauchi T, Yamamoto K, Mori M, Tanaka Y, Shimamoto T, Tobinai K, Kim WS. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2014 Jun;165(6):768-776. Epub 2014 Mar 12. link to original article contains verified protocol link to PMC article PubMed
Vorinostat & Rituximab
back to top |
Regimen
Study | Evidence |
---|---|
Chen et al. 2015 (CoH 07195) | Phase II, <20 patients in this subgroup |
Targeted therapy
- Vorinostat (Zolinza) 200 mg PO twice per day on days 1 to 14
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
21-day cycles until progression or two cycles past documented CR
References
- CoH 07195: Chen R, Frankel P, Popplewell L, Siddiqi T, Ruel N, Rotter A, Thomas SH, Mott M, Nathwani N, Htut M, Nademanee A, Forman SJ, Kirschbaum M. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica. 2015 Mar;100(3):357-62. Epub 2015 Jan 16. link to original article contains verified protocol link to PMC article PubMed NCT00720876
VR-CP
back to top |
VR-CP: Velcade (Bortezomib), Rituximab, Cyclophosphamide, Prednisone
Regimen
Study | Evidence |
---|---|
Craig et al. 2014 (C05012) | Phase II |
Targeted therapy
- Bortezomib (Velcade) 1.6 mg/m2 IV once per day on days 1 & 8
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Chemotherapy
- Cyclophosphamide (Cytoxan) 1000 mg/m2 IV once on day 1
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
Supportive medications
- Antiviral prophylaxis against VZV recommended for all patients
21-day cycle for 6 cycles
References
- C05012: Craig M, Hanna WT, Cabanillas F, Chen CS, Esseltine DL, Neuwirth R, O'Connor OA. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2014 Sep;166(6):920-8. Epub 2014 Jul 9. link to original article contains verified protocol PubMed NCT00715208
Consolidation after subsequent lines of therapy
FCR, then allo HSCT
back to top |
FCR: Fludarabine, Cyclophosphamide, Rituximab
Regimen
Study | Evidence |
---|---|
Khouri et al. 2001 (MDACC ID01-233) | Non-randomized |
Details are best described in the 2008 update.
Chemotherapy
- Fludarabine (Fludara) 30 mg/m2 IV once per day on days -5 to -3
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once per day on days -5 to -3
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day -13, then 1000 mg/m2 IV once per day on days -6, +1, +8
Immunotherapy
- Allogeneic stem cells transfused on day 0
GVHD prophylaxis
- Antithymocyte globulin, horse ATG (Atgam) by the following donor-based criteria:
- Matched unrelated donor: 15 mg/kg IV once per day on days -5 to -3
- Tacrolimus (Prograf) adjusted to level of 5 to 10 ng/mL for 6 months in patients in remission
- Methotrexate (MTX) by the following donor-based criteria:
- Related donors: 5 mg/m2 IV once per day on days +1, +3, +6
- Unrelated donors: 5 mg/m2 IV once per day on days +1, +3, +6, +11
One course
Immunotherapy
Stem cells transfused on day 0
References
- MDACC ID01-233: Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001 Dec 15;98(13):3595-9. link to original article PubMed NCT00048737
- Update: Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008 Jun 15;111(12):5530-6. Epub 2008 Apr 14. Erratum in: Blood. 2009 Feb 12;113(7):1613. link to original article contains verified protocol link to PMC article PubMed
- Update: Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. 2012 Jun 28;119(26):6373-8. Epub 2012 May 14. link to original article contains verified protocol link to PMC article PubMed
Ibritumomab tiuxetan protocol
back to top |
Regimen
Study | Evidence |
---|---|
Illidge et al. 2016 (SCHRIFT) | Phase II |
Preceding treatment
Targeted therapy
- Rituximab (Rituxan) 250 mg/m2 IV once per day on days 1 & 8, given first on day 8
Radioconjugate therapy
- Ibritumomab tiuxetan & Yttrium-90 (Zevalin) 15 MBq/kg (maximum dose of 1200 MBq) IV once on day 8, given immediately after rituximab
8-day course
References
- SCHRIFT: Illidge TM, McKenzie HS, Mayes S, Bates A, Davies AJ, Pettengell R, Stanton L, Cozens K, Hampson G, Dive C, Zivanovic M, Tipping J, Gallop-Evans E, Radford JA, Johnson PW; UK National Cancer Research Institute Lymphoma Group. Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. Br J Haematol. 2016 Apr;173(2):274-82. Epub 2016 Feb 5. link to original article contains protocol PubMed NCT00637832
Observation
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Ghielmini et al. 2004 (SAKK 35/98) | 1998-2001 | Phase 3 (C) | Rituximab | Seems to have inferior EFS |
Forstpointner et al. 2004 | 1998-2001 | Phase 3 (C) | Rituximab | Seems to have inferior PFS |
Van Oers et al. 2006 (EORTC 20981) | 1998-2004 | Phase 3 (C) | Rituximab | Seems to have inferior OS |
Pettengell et al. 2013 (EBMT Lym-1) | 1999-2006 | Phase 3 (C) | Rituximab | Seems to have inferior PFS |
No further treatment after second-line therapy.
Preceding treatment
- SAKK 35/98: R x 4
- Forstpointner et al. 2004: R-FCM x 4 versus FCM x 4
- EORTC 20981: CHOP versus R-CHOP
- EBMT Lym-1: BEAM with auto HSCT
References
- SAKK 35/98: Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004 Jun 15;103(12):4416-23. Epub 2004 Feb 19. link to original article contains protocol PubMed
- Update: Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S, Okkinga E, Stupp R, Stahel R, Heizmann M, Vorobiof D, Lohri A, Dietrich PY, Zucca E, Ghielmini M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010 Oct 10;28(29):4480-4. Epub 2010 Aug 9. link to original article contains verified protocol PubMed
- Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Böck HP, Wandt H, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004 Nov 15;104(10):3064-71. Epub 2004 Jul 29. link to original article contains verified protocol PubMed
- Update: Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hänel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W; German Low Grade Lymphoma Study Group. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006 Dec 15;108(13):4003-8. Epub 2006 Aug 31. link to original article contains verified protocol PubMed
- EORTC 20981: van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van 't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006 Nov 15;108(10):3295-301. Epub 2006 Jul 27. link to original article contains verified protocol PubMed NCT00004179
- Update: van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010 Jun 10;28(17):2853-8. Epub 2010 May 3. link to original article contains verified protocol link to PMC article PubMed
- EBMT Lym-1: Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, Caballero D, Tilly H, Walewski JA, Bence-Bruckler I, To B, Geisler CH, Schots R, Kimby E, Taverna CJ, Kozák T, Dreger P, Uddin R, Ruiz de Elvira C, Goldstone AH. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013 May 1;31(13):1624-30. Epub 2013 Apr 1. link to original article PubMed NCT00005589
Rituximab monotherapy, abbreviated course
back to top |
Maintenance regimens of less than one year duration or less than 12 total doses.
Regimen variant #1, 4 doses
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Ghielmini et al. 2004 (SAKK 35/98) | 1998-2001 | Phase 3 (E-esc) | Observation | Seems to have superior EFS |
Pettengell et al. 2013 (EBMT Lym-1) | 1999-2006 | Phase 3 (E-esc) | Observation | Seems to have superior EFS |
Note: SAKK 35/98 specifies that treatment is to be given at week 12, month 5, 7, 9. Pettengell et al. 2013 does not specify when the maintenance rituximab is to begin post-auto HSCT.
Preceding treatment
- SAKK 35/98: Rituximab re-induction
- EBMT Lym-1: BEAM with auto HSCT
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
2-month cycle for 4 cycles
Regimen variant #2, 8 doses
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Forstpointner et al. 2004 | 1998-2001 | Phase 3 (E-esc) | Observation | Seems to have superior PFS |
Note: first cycle begins 3 months after completion of salvage therapy.
Preceding treatment
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22
6-month cycle for 2 cycles
References
- SAKK 35/98: Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004 Jun 15;103(12):4416-23. Epub 2004 Feb 19. link to original article contains protocol PubMed
- Update: Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S, Okkinga E, Stupp R, Stahel R, Heizmann M, Vorobiof D, Lohri A, Dietrich PY, Zucca E, Ghielmini M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010 Oct 10;28(29):4480-4. Epub 2010 Aug 9. link to original article contains verified protocol PubMed
- Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Böck HP, Wandt H, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004 Nov 15;104(10):3064-71. Epub 2004 Jul 29. link to original article contains verified protocol PubMed
- Update: Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hänel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W; German Low Grade Lymphoma Study Group. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006 Dec 15;108(13):4003-8. Epub 2006 Aug 31. link to original article contains verified protocol PubMed
- EBMT Lym-1: Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, Caballero D, Tilly H, Walewski JA, Bence-Bruckler I, To B, Geisler CH, Schots R, Kimby E, Taverna CJ, Kozák T, Dreger P, Uddin R, Ruiz de Elvira C, Goldstone AH. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013 May 1;31(13):1624-30. Epub 2013 Apr 1. link to original article PubMed NCT00005589
R-BEAM, then auto HSCT
back to top |
R-BEAM: Rituximab, BiCNU (Carmustine), Etoposide, Ara-C (Cytarabine), Melphalan
Regimen
Study | Evidence |
---|---|
Kirschey et al. 2014 (Mz-135) | Phase II |
A minimum number of 2 × 106/kg bw CD34-positive cells were required to proceed.
Preceding treatment
- R-DexaBEAM x 2
Autologous HSCT conditioning regimens
References
- Mz-135: Kirschey S, Flohr T, Wolf HH, Frickhofen N, Gramatzki M, Link H, Basara N, Peter N, Meyer RG, Schmitz N, Weidmann E, Banat A, Schulz A, Kolbe K, Derigs G, Theobald M, Hess G. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. Br J Haematol. 2015 Mar;168(6):824-34. Epub 2014 Dec 28. link to original article contains verified protocol PubMed NCT02099292
R-TBI/Cy, then auto HSCT
back to top |
R-TBI/Cy: Rituximab, Total, Body, Irradiation, Cyclophosphamide
Regimen
Study | Evidence |
---|---|
Kirschey et al. 2014 (Mz-135) | Phase II |
Preceding treatment
- R-DexaBEAM x 2
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days -8 & -2
Chemotherapy
- Cyclophosphamide (Cytoxan) 60 mg/kg IV once per day on days -3 & -2
Radiotherapy
- Total body irradiation (TBI) with a total dose of 1200 cGy over 3 days (days -6 to -4) in fractions
Supportive therapy
- Autologous stem cells re-infused on day 0
One course
Stem cells reinfused on day 0
References
- Mz-135: Kirschey S, Flohr T, Wolf HH, Frickhofen N, Gramatzki M, Link H, Basara N, Peter N, Meyer RG, Schmitz N, Weidmann E, Banat A, Schulz A, Kolbe K, Derigs G, Theobald M, Hess G. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. Br J Haematol. 2015 Mar;168(6):824-34. Epub 2014 Dec 28. link to original article contains verified protocol PubMed NCT02099292
Cyclophosphamide & TBI, then auto HSCT
back to top |
Cy/TBI: Cyclophosphamide & Total Body Irradiation
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Schouten et al. 2003 (CUP) | 1993-1997 | Phase 3 (E-esc) | CHOP x 3 | Might have superior OS |
Chemotherapy
- Cyclophosphamide (Cytoxan) 60 mg/kg IV once per day on days -3 & -2
Radiotherapy
- Total body irradiation (TBI) 1200 cGy in fractions on days –6 to –4 (pulmonary dosage was limited to 800 cGy)
Supportive therapy
- Autologous stem cells re-infused on day 0
One course
References
- CUP: Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE, Doorduijn JK, Sydes MR, Kvalheim G. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003 Nov 1;21(21):3918-27. Epub 2003 Sep 29. link to original article PubMed
(90)YFC, then allo HSCT
back to top |
(90)YFC: Ibritumomab tiuxetan, Fludarabine, Cyclophosphamide
Regimen
Study | Evidence |
---|---|
Khouri et al. 2001 (MDACC ID01-233) | Non-randomized |
Targeted therapy
- Rituximab (Rituxan) 250 mg/m2 IV once per day on days -14 & -7
Radioconjugate therapy
- Ibritumomab tiuxetan & Indium-111 5 mCi IV once on day -14 for dosimetry
- Ibritumomab tiuxetan & Yttrium-90 (Zevalin) 0.4 mCi/kg (15 MBq/kg) (maximum dose of 32 mCi/1.2 GBq) IV once on day -7
Chemotherapy
- Fludarabine (Fludara) 30 mg/m2 IV once per day on days -5 to -3
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once per day on days -5 to -3
Immunotherapy
- Allogeneic stem cells transfused on day 0
GVHD prophylaxis
- Antithymocyte globulin, rabbit ATG (Thymoglobulin) by the following donor-based criteria:
- Matched unrelated or mismatched donors: 1 mg/kg IV once per day on days -2 & -1
- Tacrolimus (Prograf)
- Methotrexate (MTX)
One course
Immunotherapy
Stem cells transfused on day 0
References
- MDACC ID01-233: Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001 Dec 15;98(13):3595-9. link to original article PubMed NCT00048737
- Update: Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008 Jun 15;111(12):5530-6. Epub 2008 Apr 14. Erratum in: Blood. 2009 Feb 12;113(7):1613. link to original article contains verified protocol link to PMC article PubMed
- Update: Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. 2012 Jun 28;119(26):6373-8. Epub 2012 May 14. link to original article contains verified protocol link to PMC article PubMed
Maintenance after subsequent lines of therapy
Lenalidomide monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Tuscano et al. 2014 (RV-PI-NHL-0488) | Phase II |
Preceding treatment
Targeted therapy
- Lenalidomide (Revlimid) 20 mg PO once per day on days 1 to 21
Supportive medications
- Aspirin 81 mg PO once per day
28-day cycles
References
- RV-PI-NHL-0488: Tuscano JM, Dutia M, Chee K, Brunson A, Reed-Pease C, Abedi M, Welborn J, O'Donnell RT. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014 May;165(3):375-81. Epub 2014 Mar 7. link to original article contains verified protocol PubMed NCT01316523
Obinutuzumab monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Sehn et al. 2015 (GAUSS) | 2009-2010 | Non-randomized portion of RCT |
Sehn et al. 2016 (GADOLIN) | 2010-2014 | Non-randomized portion of RCT |
Preceding treatment
- GAUSS: Obinutuzumab induction
- GADOLIN: Bendamustine & Obinutuzumab x 6
Targeted therapy
- Obinutuzumab (Gazyva) 1000 mg IV once on day 1
2-month cycle for 12 cycles
References
- GAUSS: Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE, Buckstein R, Friedberg JW, Crump M, Jaksic B, Zinzani PL, Padmanabhan Iyer S, Sahin D, Chai A, Fingerle-Rowson G, Press OW. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol. 2015 Oct 20;33(30):3467-74. Epub 2015 Aug 17. link to original article] contains verified protocol link to PMC article PubMed NCT00576758
- GADOLIN: Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016 Aug;17(8):1081-93. Epub 2016 Jun 23. link to original article contains protocol PubMed NCT01059630
- Update: Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018 Aug 1;36(22):2259-2266. Epub 2018 Mar 27. link to original article PubMed
Rituximab monotherapy, extended course
back to top |
Maintenance regimens of one to two years duration or 12 to 16 total doses.
Regimen variant #1, 3-month cycles
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Van Oers et al. 2006 (EORTC 20981) | 1998-2004 | Phase 3 (E-esc) | Observation | Seems to have superior OS |
Preceding treatment
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
3-month cycle for up to 8 cycles (2 years)
Regimen variant #2, 2-month cycles
Study | Years of enrollment | Evidence |
---|---|---|
Witzens-Harig et al. 2014 (MAXIMA) | 2006-NR | Non-randomized |
Sehn et al. 2015 (GAUSS) | 2009-2010 | Non-randomized portion of RCT |
Preceding treatment
- MAXIMA: Rituximab monotherapy or rituximab and chemotherapy (Most patients, 62%, received an anthracycline-based regimen)
- GAUSS: Rituximab
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
2-month cycle for up to 12 cycles (2 years)
References
- EORTC 20981: van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van 't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006 Nov 15;108(10):3295-301. Epub 2006 Jul 27. link to original article contains verified protocol PubMed NCT00004179
- Update: van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010 Jun 10;28(17):2853-8. Epub 2010 May 3. link to original article contains verified protocol link to PMC article PubMed
- MAXIMA: Witzens-Harig M, Foá R, Di Rocco A, van Hazel G, Chamone DF, Rowe JM, Arcaini L, Poddubnaya I, Ho AD, Ivanova V, Vranovsky A, Thurley D, Oertel S. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study. Ann Hematol. 2014 Oct;93(10):1717-24. Epub 2014 May 14. Erratum in: Ann Hematol. 2014 Oct;93(10):1807. link to original article contains verified protocol PubMed NCT00430352
- GAUSS: Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE, Buckstein R, Friedberg JW, Crump M, Jaksic B, Zinzani PL, Padmanabhan Iyer S, Sahin D, Chai A, Fingerle-Rowson G, Press OW. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol. 2015 Oct 20;33(30):3467-74. Epub 2015 Aug 17. link to original article] contains verified protocol link to PMC article PubMed NCT00576758
VR
back to top |
VR: Velcade (Bortezomib), Rituximab
Regimen
Study | Evidence |
---|---|
Baiocchi et al. 2011 (OSU-0430) | Phase II, <20 patients reported |
Preceding treatment
Targeted therapy
- Bortezomib (Velcade) 1.3 mg/m2 IV once per day on days 1 & 8
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1 & 8
6-month cycle for up to 4 cycles (2 years)
References
- OSU-0430: Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd JC, Blum KA. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer. 2011 Jun 1;117(11):2442-51. Epub 2010 Dec 14. link to original article contains verified protocol link to PMC article PubMed NCT00201877
Prognosis
Follicular lymphoma international prognostic index (FLIPI - 1)
back to top |
Each category is assigned 0 or 1 points:
- Age
- Less than 60 years (0 points)
- Greater than or equal to 60 years (1 point)
- Ann Arbor stage
- I or II (0 points)
- III or IV (1 point)
- Hemoglobin level
- Less than 12 g/dL (1 point)
- Greater than or equal to 12 g/dL (0 points)
- Serum LDH level (note that reference ranges can vary widely!)
- Less than or equal to upper limit of normal (0 points)
- Greater than upper limit of normal (1 point)
- Number of nodal sites
- Less than 5 (0 points)
- Greater than or equal to 5 (1 point)
Risk stratification:
- 0 or 1 points: Low risk
- 2 points: Intermediate risk
- Greater than or equal to 3 points: High risk
References
- Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haïoun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E. Follicular lymphoma international prognostic index. Blood. 2004 Sep 1;104(5):1258-65. Epub 2004 May 4. link to original article PubMed
Follicular lymphoma international prognostic index (FLIPI - 2)
back to top |
Each category is assigned 0 or 1 points:
- Age
- Less than 60 years (0 points)
- Greater than or equal to 60 years (1 point)
- Hemoglobin level
- Less than 12 g/dL (1 point)
- Greater than or equal to 12 g/dL (0 points)
- β2-microglobulin level (note that reference ranges can vary)
- Less than or equal to upper limit of normal (0 points)
- Greater than upper limit of normal (1 point)
- Longest diameter of the largest involved node
- Less than or equal to 6 cm (0 points)
- Greater than 6 cm (1 point)
- Bone marrow involvement
- No (0 points)
- Yes (1 point)
Risk stratification:
- 0 points: Low risk
- 1 or 2 points: Intermediate risk
- Greater than or equal to 3 points: High risk
References
- Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Céligny P. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009 Sep 20;27(27):4555-62. Epub 2009 Aug 3. link to original article PubMed
Response criteria
NCI Sponsored International Working Group Criteria (1999)
- Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999 Apr;17(4):1244. Review. Erratum in: J Clin Oncol 2000 Jun;18(11):2351. link to original article PubMed
Investigational agents
These are drugs under study with at least some promising results for this disease.